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PREFACE
This dissertation deals with proteasomes (from 'protease' and Greek 'soma' = protein-
chopping body) and their role in the regulation of immune responses. Proteasomes are
barrel-shaped molecular machines (enzymes) that are found in every cell of the body.
Their job is to chop up proteins, much like a garden shredder that cuts twigs and branches
into small pieces. The small protein pieces can be transported to the cell surface to be
presented to T-cells, immune cells that constitute a part of the white blood cells. If a body
cell is 'sick' (i.e. it has turned into a tumor cell or is infected by pathogens such as viruses
or bacteria), the protein fragments on the cell surface look different. They therefore can
activate T-cells to kill the diseased cell for the good of the whole organism. During the
research for my Diploma thesis (April-Dec. 1997) and my Ph.D. thesis (Jan. 1998-Dec.
2000) I tried to find out more about how exactly proteins are cleaved by proteasomes. I
was lucky and could determine some of the rules that proteasomes follow to chop up
proteins. These rules were used as a basis for the prediction of proteasome cleavages.
My results have important implications for vaccine development and the prediction of
immune responses.
The dissertation is divided into 4 main parts: Introduction, Results, Summary and
References.
The Introduction provides an extensive, state-of-the-art synopsis on proteasomes and
their function within the immune system. My own published and unpublished results,
described in detail in the Results part, are briefly mentioned in the Introduction. Specific
background information on the single projects of the Results part are given in the
introductions to the five Results sections.
The Results part is also divided into sections (2.1-2.5), which represent the main
accomplishments of my Ph.D. thesis project and are based on publications (2.1-2.3) and
submitted manuscripts (2.4 and 2.5) that resulted from my research. They are presented
here in chronological order and, as they are thematically linked and interdependent, were
chosen to make up the main body of my thesis. Each section of the Results part is
subdivided into parts specific for each sub-section: Summary, Introduction, Materials &
Methods, Results, Discussion, References, Abbreviations and Participating researchers.
Therefore, no separate sections for Materials & Methods and Discussion exist. Please
note that the five sections of the Results part reflect the state-of-the-art of the respective
VI
publishing date, i.e. late 1998 for sections 2.1 and 2.2, and early 2000 for 2.3. Sections
2.4 and 2.5 have only been submitted for publication recently and therefore reflect current
state of the art. - I chose this format for the Results section because it adequately mirrors
the chronological course and rationale of the entire thesis project. Besides, it corresponds
to a common, international format for the presentation of scientific results and thus
guarantees this work to be comprehensible for international readers.
The Summary at the end of this dissertation combines the results of the five parts of the
Result section and puts them into perspective of future developments. Moreover, projects
that are still ongoing or were not mentioned for space limitations are briefly outlined here.
References are given at the end of this thesis for the Introduction and the Summary.
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1 Introduction
1.1 The Immune System
1.1.1 Function
Every organism has to protect itself against continuous attack by foreign organisms, such
as parasites, fungi, bacteria or viruses. In the case of prions, even foreign proteins seem
to be able to act as pathogens. The immune system was evolved for the defense against
these pathogenic organisms. Its two essential characteristics are the recognition of the
pathogen and its removal.
1.1.2 Overview
The immune system can be divided into the innate immune system and the adaptive (or
specific) immune system. The former contains anatomical barriers such as the skin and
mucosae, physiological barriers such as lysozyme, interferons and complement, endocytic
and phagocytic cells and natural killer cells. Besides, inflammatory responses -
vasodilatation, extravasation of inflammatory cells, acute phase proteins and chemical
messengers such as histamine and bradykinin – belong to the innate immune response.
The adaptive immune response is characterized by four main features: specificity,
diversity, memory and the recognition of self, altered self and non-self. The cells of the
adaptive immune system which guarantee these attributes are, on the one hand,
professional antigen-presenting cells (APC) and, on the other hand, lymphocytes.
The B-lymphocytes, together with the antibodies they secrete, constitute the main
effectors of the humoral immune response, whereas T-lymphocytes represent the
main effectors of cellular defense mechanisms. Cytotoxic T-lymphocytes (CTL) kill
foreign cells, mutated cells or virus-infected cells, whereas T-helper (Th) cells mainly
activate and regulate B-cells, CTL and APC through chemical messengers (cytokines).
1.1.3 Cellular components and the role of peptides
Cells of the adaptive immune system, especially T-cells, screen host cells for two
properties: First, is it a host (self) cell or a foreign (non-self) cell? Second, in case the T
cell is looking at self: Is the host cell healthy or is it threatened by virus-infection or
transformation? Malignant transformation of a cell can be the result of mutations that will
lead to changes in the characteristics of the host cell (altered self).
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All the decisions about self, foreign and disturbed self are made with the help of the
major histocompatibility system (MHC). The peptide-binding and –presenting MHC-cell
surface molecules can be viewed as passports for host cells. MHC class I (MHC I)
molecules can be found on the surface of most nucleated cells, whereas MHC class II
(MHC II) molecules are mainly found on the surface of APC (dendritic cells, B-cells,
macrophages), but also on inflamed and thymus epithelial cells. Self and non-self are
distinguished by characteristics of both the MHC molecules and the peptides presented by
them; the distinction between healthy self and altered self depends on the nature of the
peptides presented in the MHC binding groove and on the presence of signals activating
APC.
1.1.3.1 MHC-molecules
MHC II molecules consist of two chains (α, β) whose C-termini are fixed in the cell
membrane and whose N-terminal domains form the peptide binding groove. MHC I
molecules are comprised of a heavy α-chain which is non-covalently linked to β2-
microglobulin (β2m). Here, the peptide binding groove is only made up of the α-chain.
One of the main differences between MHC I and MHC II molecules, besides their different
cellular distribution (see 1.1.3) and peptide-loading (see 1.2), is the structure of the
peptide binding groove. In both cases, the groove is made of a “floor” of β-sheet structure
and two lining “walls” of α-helices. However, whereas the groove is open to both sides for
MHC II molecules, it is closed for MHC I molecules (Bjorkman et al., 1987; Brown et al.,
1993). As a result, MHC I can only accommodate peptides of 8-10 aa in length (Falk et al.,
1991; Madden et al., 1991), whereas MHC II can hold peptides of up to 15-20 aa. In both
cases, however, the ligand interacts with the surface of the binding groove only over a
stretch of about 9 aa. Non-covalent (hydrophobic) interactions and electrostatic forces
(hydrogen bonds) fix the peptide to the MHC molecule. This is achieved by means of
particular aa of the peptide, the so-called anchor-residues, that fit snugly into
complementary pockets of the MHC binding groove (Rammensee et al., 1993). A
peculiarity of MHC molecules is their enormous polymorphism (Parham et al., 1995).
This polymorphism entails that different MHC alleles vary in their pockets and therefore
require different binding motifs, i.e. combinations of anchor residues, for binding of their
peptide ligands. Most MHC I binding motifs require hydrophobic (aromatic and branched-
chain) aa in P9, i.e. at the C-terminus of the peptide. Ligands of the human MHC I
molecules HLA-A*0201, for example, need the aa L or V in P2 (position 2) and V or L in
P9. HLA-A3 and HLA-A11 require L, V or M in P2 and K in P9 of the presented peptide
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(Rammensee et al., 1999). Thus, the binding motifs clearly represent a strict selection
criterion for peptide sequences to be presented by MHC molecules (see also 1.2.2 and
Figure 1.2-1).
1.1.3.2 Antigen recognition by T-lymphocytes
T-lymphocytes are selected according to two criteria during their maturation in the thymus:
They have to be able to recognize self-MHC (positive selection) and they must not be
activated by MHC-bound self-peptides (negative selection). The former requirement
guarantees that T cells "see" presented peptides only in the context of self-MHC, named
restriction for self-MHC or self-restriction (Zinkernagel and Doherty, 1974).
Autoreactive T cells specific for self-MHC and self-peptide are thus eliminated, leading to
self-tolerance. The selection of a self-restricted, self-tolerant T cell repertoire (i.e. pool
of available T cells) guarantees that the cellular immune response only hits foreign
organisms, virus-infected or tumor cells.
MHC/peptide-complexes are recognized by the T cell receptor (TCR), the antigen
receptor of T cells. It consists of two chains, α and β, which are linked via a disulfide
bridge. Both chains are made up of two immunoglobulin (Ig) domains. The two outer Ig
domains of each TCR chain (Vα + Vβ) build the antigen recognition site which interacts
with and recognizes the MHC/peptide-complex (see Figure 1.1-1). The actual MHC ligand
(peptide) that is recognized by T cells and activates them is called T cell epitope.
The variability of the TCR (1016) is so large that there should exist T cells recognizing all
non-self or altered self MHC ligands. However, stochastic processes in T cell maturation
and clonal T cell expansion lead to diverse T cell repertoires in individual members of a
population.
The role of the MHC molecule as a "passport" was already hinted at earlier. However,
eventually it is the nature of the peptide that decides whether T cells will be activated or
inactivated (anergized), i.e. whether an MHC-bound peptide functions as a T cell epitope
or just as an MHC ligand, respectively. Thus the peptide plays a crucial role in the
recognition of self and non-self and the regulation of immune responses.
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Figure 1.1-1: Crystal structures of TCR recognizing a MHC/peptide-complex
Front (A) and side (B) view of the human MHC molecule HLA-A2; side view (C) of the mouse MHC
molecule H-2Kb. MHC and TCR are drawn as ribbon models; the MHC-bound peptide (yellow) is
drawn as stick-model. The peptide-binding groove of MHC molecules is made up of the α1 and α2
domains of the MHC I heavy α-chain. [The pictures are taken from Garboczi et al. (1996) for (A), (B)
and from Garcia et al. (1996) for (C).]
1.2 Antigen Processing
1.2.1 MHC class II pathway
The antigen processing pathway leading to the loading of MHC II molecules is also called
endosomal pathway. Here, membrane proteins are endocytosed or extracellular
antigens are taken up either in an unspecific (phagocytosis, pinocytosis; e.g. by
macrophages) or specific fashion (receptor-mediated endocytosis; e.g. via membrane-
bound antibodies on B cells). The internalized phagosomes or clathrin-coated vesicles
then fuse with lysosomes, whose proteolytic enzymes (cathepsins and probably some
aminopeptidases) and low pH will start the degradation of the antigens. So-called MHC II-
loading compartments (MIIC), formed by fusion of lysosomal vesicles with MHC II-
containing trans-Golgi vesicles, represent the sites where the actual loading of MHC II
molecules with peptides takes place. The final, trimolecular complex of MHC II α- and β-
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chains and the peptide is then transported to the cell surface (Cresswell, 1994; Watts,
1997).
1.2.2 MHC class I pathway
The class I pathway of antigen processing, also called the cytosolic pathway, leads to
the loading of MHC I molecules by peptides mainly derived from cytosolic proteins (Pamer
and Cresswell, 1998; Früh and Yang, 1999; van Endert, 1999). In healthy cells, these
peptides stem solely from intracellular host (self) proteins. On the contrary, in transformed
(mutated) or virus-infected cells, mutated (=altered self) or viral (=non-self) peptides,
respectively, can make it onto MHC I and to the cell surface. The first step in this pathway
is the degradation of proteins by the barrel-shaped, multicatalytic proteasome complex.
The proteasome chops up proteins into small protein pieces, some of which will make
their way - probably assisted by chaperones - to the transporter associated with
antigen processing (TAP) in the ER membrane.
Figure 1.2-1: Schematic overview over antigen processing in the class I pathway.
A cytosolic protein is targeted for degradation by the proteasome (1). The nature of the resulting
peptide fragments is not completely understood (?). Some proteasomal cleavage products are
translocated by TAP (2) into the endoplasmic reticulum (ER) and loaded onto MHC class I molecules
(3). MHC/peptide-complexes on the cell surface are screened by CTL for foreign or mutated peptides
(not shown).
TAP preferentially translocates peptides of 8-16 aa with hydrophobic or basic C-termini
into the ER lumen (Schumacher et al., 1994; Momburg et al., 1994; van Endert, 1999;
Uebel and Tampe, 1999). It was only recently determined that the major substrates for
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TAP in vivo are derived from newly synthesized proteins (Reits et al., 2000). An
intricate army of ER-resident chaperones (calreticulin, calnexin, tapasin and perhaps PDI
and gp96) will then help to load fitting peptides into the binding groove of MHC I
molecules (Lammert et al., 1997a, Lammert et al., 1997b; Sadasivan et al., 1996). The
fate of peptides that do not bind to MHC is not completely understood (Falk et al., 1990),
but they are probably removed from the ER by retrograde transport into the cytosol, which
is most likely mediated by the Sec61p channel (Koopmann et al., 2000). An overview over
MHC I processing pathway is shown in Figure 1.2-1.
1.3 The Proteasome
1.3.1 Cellular roles of proteasomes
Proteasomes are the key proteases for non-lysosomal proteolysis in eukaryotic cells. Most
(short-lived1) proteins, in order to be recognized and degraded by proteasomes, have to
be tagged by ubiquitin (Hershko and Ciechanover, 1998; Hershko et al., 2000). Signals for
ubiquitination are manifold (reviewed in Ciechanover, 1998): They comprise primary
(substrate-inherent, structural) motifs or secondary (post-translational) modifications.
Examples for primary motifs include the N-end rule pathway (i.e. protein stability is
influenced by its N-terminal aa residue; Bachmair et al., 1986; reviewed in Varshavsky,
1996; Varshavsky et al., 2000) and the destruction box, a nine-amino-acid motif found in
mitotic cyclins and certain other cell-cycle regulators. A secondary modification that can
trigger ubiquitin-dependent degradation is phosphorylation (e.g. in IκBα; Yaron et al.,
1997), for example at Pro(P)-, Glu(E)-, Ser(S) and Thr(T)-rich (PEST-) sequences.
Proteins can also be targeted for degradation by association with an ancillary protein (e.g.
p53 is degraded after binding to the human papilloma virus oncoprotein E6; Scheffner et
al., 1993). It was shown recently that a large fraction of the substrates for ubiquitin-
dependent proteasomal degradation are newly synthesized proteins, so-called DRiPs (for
Defective Ribosomal initiation Products) (Schubert et al., 2000). Proteasomes degrade
some proteins devoid of ubiquitination-tags, for example ODC (Murakami et al., 1992),
damaged calmodulin (Tarcsa et al., 2000) and p21Clp1 (Sheaff et al., 2000). This is
speculated to reflect a more ancient mode of substrate recognition by proteasomes,
                                               
1 It must be noted that to this date, it is still disputed whether ubiquitin conjugation is essential in
the degradation of long-lived proteins (Rock and Goldberg, 1999).
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mediated by sequence signals ("class I degrons") inherent in the substrate sequence
itself (Verma and Deshaies, 2000). Although some examples for this hypothesis have
lately been identified (see above), it still must be assumed that by far the main part of
protein turnover in eucaryotic cells is ubiquitin-dependent.
Proteasomes are not limited to purely metabolic functions. Proteasomal protein
degradation also takes over regulatory roles such as periodic cyclin degradation (Glotzer
et al., 1991; Seufert et al., 1995), the removal of misfolded proteins (Seufert and Jentsch,
1990) or the activation of the transcription factor NF-κB (Palombella et al., 1994).
Proteasomes are mainly localized within the cytosol and the nucleus of cells, but they are
also found in association with the endoplasmic reticulum (ER) (Rivett et al., 1992;
Newman et al., 1996; Enenkel et al., 1998; Brooks et al., 2000) and the cytoskeleton
(Scherrer and Bey, 1994).
The importance of ubiquitin-dependent protein degradation in MHC I antigen presentation
was suggested by the fact that enhanced protein degradation rescued the defective
presentation of viral epitopes in vaccinia-infected cells (Townsend et al., 1988) and was
elegantly demonstrated by the use of mutant cell lines with defects in the ubiquitin-
dependent degradation pathway (Michalek et al., 1993; Grant et al., 1995). The
fundamental role of proteasomes themselves for the supply of MHC I ligands was
confirmed by the use of proteasome inhibitors: In living cells, peptide aldehyde inhibitors
and the very proteasome-specific Streptomyces compound lactacystin-β-lactone
completely blocked the presentation of peptides from several different proteins, including
ovalbumin, β-galactosidase, and influenza viral antigens (Rock et al., 1994; Harding et al.,
1995; Grant et al., 1995; Cerundolo et al., 1997).
1.3.2 Proteasome species: Structure and function
Proteasomes exist more or less in two ways: As the free catalytic (i.e. proteolytically
active) core of all proteasome species, the barrel-shaped 20S proteasome (named after
its  sedimentation coefficient), and as associations of 20S proteasomes with regulatory
protein complexes. 20S proteasomes exist in a constitutive form and as so-called
immuno-proteasomes, in which the active site subunits have been exchanged for IFN-γ-
inducible immuno-subunits. 20S proteasomes can be capped on both ends of their
cylindrical structure by regulatory protein complexes, the 19S regulatory particle (19S
cap, PA700) or the IFN-γ-inducible activator PA28 (11S regulator). 20S proteasomes that
are singly or doubly capped by the 19S regulatory particle are called 26S proteasomes
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(Figure 1.3-1). The 19S particle consists of a 20S-proximal 'base', which contains all six
proteasomal ATPases and can activate the degradation of peptides and non-ubiquitinated
proteins, and of a 'lid', which is required for ubiquitin-dependent proteolysis (Glickman et
al., 1998). As the 19S cap confers recognition of ubiquitin (Deveraux et al., 1994; Ferrell
et al., 1996), 26S proteasomes are thought to be responsible for the main part of protein
degradation in vivo (DeMartino and Slaughter, 1999; Ferrell et al., 2000). However, 20S
proteasomes might execute parts of the ubiquitin-independent protein turnover (1.3.1).
Additionally, there exist hybrid proteasomes that are capped, on the one end, by 19S
and, on the other end, by PA28 (Hendil et al., 1998; Tanahashi et al., 2000). These hybrid
proteasomes might play an important role in vivo as they possibly link protein degradation
to immune responses (see 1.3.8).
Figure 1.3-1: The different proteasome species within cells.
Relative distributions of proteasomes and their regulators, PA28 and PA700 (= 19S), in HeLa cells.
Immuno-proteasomes are missing from the figure; they can be a part of any proteasome complex
containing 20S proteasomes. [The graph was taken from Tanahashi et al. (2000).)
The two most abundant proteasome species in cells are 20S and 26S proteasomes. Two
recent reports show that free 20S is more abundant than 26S (Tanahashi et al., 2000;
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Brooks et al., 2000). Experimental artifacts from cell fractionation methods
(centrifugation, gel filtration, Western blotting) might lead to overestimation of the amount
of free 20S, by counting molecules dissociated from larger proteasome complexes due to
the purification conditions. However, the same results were obtained by
immunofluorescent labeling of cells, confirming that free 20S really exist. Nevertheless, it
is still unclear whether 20S proteasomes are functional in vivo or whether they merely
represent assembly/disassembly intermediates on the way to/from 26S proteasomes.
Brooks and colleagues (2000) propose that the existence of free 20S proteasomes
permits the formation of PA28-20S complexes after IFN-γ-induced synthesis of PA28.
Only recently, an inhibitor of proteasomes, PI31, has been identified and described to
compete for binding to 20S proteasomes with PA28 (Zaiss et al., 1999).
1.3.3 Three-dimensional structure and catalytic mechanism of the 20S
proteasome
20S proteasomes have been found in all eucaryotes from yeast to man, in archaebacteria
and in some eubacteria (Tamura et al., 1995). The quarternary structure of 28 subunits,
which are subdivided into the homologous α- and β-subunits, is highly conserved in all
cases. However, the differentiation of the 20S subunits has increased during evolution:
Archaebacteria (Thermoplasma) only possess one kind of α- and β-subunits, some
eubacteria have two kinds whereas yeast already has 7 kinds each. Mammalian genomes
encode 3 additional, IFN-γ-inducible β-subunits, giving rise to altogether 7 α- and 10 β-
subunits for mammalian proteasomes. The number of proteolytically active β-subunits,
however, has decreased in evolution: All β-subunits of Thermoplasma proteasomes are
active (i.e. 2x7 = 14 active sites per 20S particle), whereas only 3 different active β-
subunits exist in eucaryotic proteasomes (i.e. 2x3 =6 active sites per 20S particle).
The proteolytic centers (active sites) are located on the inside of the 20S cylinder and are
embodied by three different β-subunits in eucaryotic proteasomes. The two identical
halves (α7β7) of 20S proteasomes are joined head-to-head with rotational symmetry (C2-
axis along the β7β'7-contact area) (Figure 1.3-2).
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Figure 1.3-2: X-ray structure of yeast 20S proteasome
The picture shows the back half of the 20S cylinder. The given dimensions of the complex were are
for Thermoplasma proteasomes, whose quarternary structure is very similar to that of yeast
proteasomes (taken from Baumeister et al., 1998). The locations of the active sites are marked by
the binding of inhibitor molecules (yellow). *The opening in the α-rings of yeast proteasomes is only
formed upon activation by SDS or binding of the regulators 19S or PA28 (Whitby, 2000; Groll, 2000).
See Figure 1.3-4 for a more schematic view. [The x-ray picture is taken from Groll et al. (1997).]
Proteasomes belong to the small group of threonine-proteases within the family of N-
terminal nucleophile (Ntn) hydrolases (Seemüller et al., 1995). The nucleophile for
peptide-bond hydrolysis is the γ-O-atom of the N-terminal threonine in the active β-
subunits. This threonine residue is only liberated after autocatalytic processing of
propeptides (Seemüller et al., 1996), a mechanism that guarantees proteasome halves
not to become active before their assembly into complete proteasome cylinders. The N-
terminal amino group acts as proton-acceptor-donor when the substrate peptide bond is
attacked. As for other Ntn-hydrolases, a long-lived acyl-enzyme intermediate is postulated
(Löwe et al., 1995). The proposed catalytic mechanism is depicted in Figure 1.3-3. The
cleavage product with the newly made N-terminus should then diffuse away from the
active site, thus rendering it less likely to be cleaved again by the same active site. This
assumption is in line with the results of kinetic modeling which suggest that the C-termini
of internal protein fragments are generated before the N-termini (Holzhütter and Kloetzel,
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2000).
Figure 1.3-3: Catalytic mechanism of proteasomes
The chemical cleavage reactions are shown for a substrate peptide bond (top), a vinyl sulfone
inhibitor (center) and lactacystin, a β-lactone inhibitor (bottom). [The figure is taken from Kisselev et
al. (2000).]
1.3.4 Topology of the active sites
The three-dimensional structure of a eucaryotic 20S proteasome (yeast) was only solved
recently by X-ray crystallography (Groll et al., 1997; Figure 1.3-2). The X-ray image made
it possible to determine the precise positioning of the single subunits in relation to each
other (schematic pictures in Figure 1.3-4). The subunit topology of human 20S
proteasomes was first reported to slightly differ (Kopp et al., 1997), but was later
confirmed by the same group to be identical to that of yeast (Dahlmann et al., 2000).
Therefore, the subunit arrangement found for yeast proteasomes seems to be valid for all
eucaryots.
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Figure 1.3-4: Topology of α- and β-subunits in yeast 20S proteasomes
(Top) 3-D picture of subunit topology; nomenclature: systematic/yeast. (Bottom) Rolled-open 20S
cylinder revealing the relative positions of the subunits; nomenclature: systematic, yeast, human,
IFN-γ-inducible (from top to bottom). C2: symmetry axis through the cylinder. [The picture on the top
was taken from Groll et al. (1999).]
For reference and to avoid confusion early on, an overview on the nomenclature and the
cleavage specificities of the β-subunits that harbor active sites is shown in Table 1.3-1.
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Table 1.3-1: Nomenclature and cleavage specificity of the active site β-subunits in yeast







(only const.) (for const. subunits)
β1 β1i δ/Y LMP2 Pre3 post-acidic
β2 β2i Z MECL-1 Pup1 T-like
β5 β5i X LMP7 Pre2 ChT-like
* The cleavage specificities relate to the constitutive subunits. Check section 1.3.7.2 for more detail.
1.3.5 Cleavage specificity
As proteasomal degradation products are the main source for MHC I ligands, the most
interesting aspect for immunologists in the investigation of eucaryotic proteasomes is their
cleavage specificity. Characterization of proteasomal cleavage specificity has been and is
still looked at using artificial tri- or tetrapeptides including a fluorogenic leaving group (see
Figure 1.3-5).
Several distinct proteolytic specificities have been described: the chymotrypsin (ChT) -like
activity (cleaving after hydrophobic - both branched chain and aromatic - aa residues), the
trypsin (T) –like activity (cleaving after the basic aa Arg, Lys and His) and the
peptidylglutamyl-peptide hydrolyzing (PGPH) or post-acidic or caspase-like activity
(cleaving after the acidic aa Asp and Glu). In addition, two more activities have been
postulated: SNAAP (small neutral amino acid peptidase) and BrAAP (branched-chain
amino acid peptidase) (Orlowski et al., 1993). The differential influence of inhibitors on
some of these activities led to the assumption that they must origin from distinct active
sites (Orlowski, 1990; Rivett, 1989; Orlowski et al., 1993). However, the crystallographic
structure showed and it is today accepted that only three different active sites exist.
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Figure 1.3-5: Fluorogenic model substrates used for characterization of proteasomal cleavage
specificities.
(A) The peptide is cleaved between the most C-terminal aa (P1) and the fluorogenic leaving group
(LG). The cleavage specificity can only be determined by P-residues. (B) A normal peptide contains
aa C-terminal of the cleavage site (P'-aa) which influence cleavage site selection. PG: protective
group; P4-P4': aa-string (nomenclature according to Schechter and Berger, 19672); LG: leaving
group that fluoresces after being cleaved off; pair of scissors symbolize a proteasomal cleavage.
Analyses of mutant yeast proteasomes allowed the assignment of proteolytic activities to
certain proteasomal β-subunits (Heinemeyer et al., 1993; Hilt et al., 1993; Enenkel et al.,
1994; Arendt and Hochstrasser, 1997): β1/Pre3 ↔ post-acidic, β2/Pup1 ↔ T-like,
β5/Pre2 ↔ ChT-like. Today it is clear that results obtained with short fluorogenic
substrates only partially reflect physiological reality, because proteasomes select
cleavage sites not only according to chemical properties of the P1-aa. Positions beyond
P1 influence cleavage site selection (Ustrell et al., 1995ba; Ustrell et al., 1995ab; Cardozo
et al., 1994; Ehring et al., 1996). Our own experiments with natural peptides and wild-type
and mutant yeast 20S proteasomes showed that the cleavage specificities of the three
active sites partially overlap for cleavages after some hydrophobic aa (L, Y, A, M). We
could also demonstrate that the postulated BrAAP-activity was mainly inherent to β1,
                                               




which was subsequently confirmed in inhibition studies by McCormack et al. (1998) and
Cardozo et al. (1999) and by crystallographic studies by Groll et al. (1999). We also found
that some cleavages are exclusively performed by one of the active sites (Dick et al.,
1998; for more details, please refer to 2.1). Later, we could for the first time verify the
reported P1-preferences of yeast 20S proteasome active sites in in vitro digests of a large,
unmodified protein, enolase-1 from yeast (436 aa). More importantly, we were able to
expand the cleavage motifs for the three active sites to residues in a window from P6-P6'
and, using wild-type and mutant 20S proteasomes, could determine the contribution of
each active subunit to enolase degradation (Nussbaum et al., 1998; for more details,
please refer to 2.2). In short, ChT-like cleavages after hydrophobic aa contributed most to
enolase degradation. This finding is paralleled by the observation that a mutation of the
critical Thr residue to Ala in Pre2, the yeast β-subunit harboring the ChT-like activity, is
lethal for yeast cells (Heinemeyer et al., 1997; Groll et al., 1999). However, this effect is
most likely due to ineffective autocatalytic propeptide cleavage in Pre2, resulting in
impaired proteasome assembly.
We also found that cleavage site selection is affected by aa in P4 (Pro!) and saw an
important contribution of P1'. Several reports confirmed the importance of especially Pro
at P4 for proteasomal cleavage site selection: Glas et al. (1998) found that P4 in peptide-
based proteasome inhibitors had a major influence on their binding to the active sites.
Shimbara et al. (1998) observed that Pro residues at P4 of MHC I ligands conferred
protection against internal cleavages by rat liver proteasomes, supporting our findings that
Pro is an unfavorable P1-aa and directs cleavages to peptide bonds 3 aa C-terminal of
Pro. Finally, the Pro-effect was recently verified using systematically mutated peptides as
substrates for in vitro digests using human blood proteasomes (Miconnet et al., 2000).
Mammalian 20S proteasomes preferentially cleave natural polypeptides in vitro after
aromatic (F, Y), aliphatic (L, I, V), basic (K, R) or acidic (D, E) residues. However, not
each single one of these residues is always used. We were able to confirm and extend
these results by enolase-degradation experiments using human erythrocyte 20S
proteasomes (see 2.2.9) and constitutive and immuno-proteasomes from B-cell lymphoma
cell lines (see 2.5). Our own lab also compared the cleavage specificities of human
erythrocyte 20S and 26S proteasomes in in vitro degradation of bovine β-casein and
found an overlapping, but distinct set of cleavage sites (Emmerich et al., 2000). However,
the same rules (cleavage motifs) were employed by both 20S and 26S proteasomes to
generate these cleavages. Due to some experimental limitations (e.g. the normalization of
the two different proteasome batches, the unusual substrate casein and experimental
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variance), it is difficult to draw final conclusions from these results. An additional
argument for similar cleavage specificities is the fact that 26S proteasomes, like 20S
proteasomes, were able to generate the exact MHC I ligand SIINFEKL from a whole
protein in vivo, even without the natural flanking sequences (Ben-Shahar et al., 1999). To
gain more insight into this question, the cleavage specificities of 20S and 26S
proteasomes should be compared systematically using a panel of peptide substrates.
1.3.6 Fragment length distribution
Proteasomes from different species do not degrade peptides and proteins into single aa,
but into fragments of about 3-30 aa in length. Thermoplasma proteasomes generate
fragments in the range of 3-30 aa from bovine β-casein (Kisselev et al., 1998). As the
degradation products of Thermoplasma proteasomes were previously found to average 7-
8 aa, a molecular ruler hypothesis was coined (Wenzel et al., 1994): Either the distance
of active sites or binding constraints for the substrate to the inner surface of the
proteasome were thought to determine the fragment length. In the small community of
proteasome researchers, the term ‘molecular ruler’ was almost exclusively linked to the
former model (fragment length determined by the distance of active sites), especially after
the distance between two active site threonines in the Thermoplasma proteasome had
been determined to be 28 Å or 2.8nm (Löwe et al., 1995), a stretch just fitting a 7-8mer
peptide in extended conformation. For eucaryotic proteasomes, distinct fragment lengths
of 8-9 and 14-15 aa were at first reported (Niedermann et al., 1996). Later, a wide
fragment length distribution similar to that of Thermoplasma proteasomes was detected
for yeast (Nussbaum et al., 1998) and mammalian 20S proteasomes (Kisselev et al.,
1999b; our own unpublished results, see 2.2.9 and 2.5). The predominating and average
fragment lengths still range between 7-9 aa, but no particular fragment lengths really stick
out. In order to describe the shape of the fragment length curve (starting at 3 aa, with a
peak at 7-9 aa and tailing out around 30 aa) the term log-normal distribution was used
(Kisselev et al., 1998). Also, the degradation of denatured lysozyme by bovine constitutive
and immuno-proteasomes yielded final fragments of 6-20 aa, without the prevalence of a
particular size (Wang et al., 1999). However, the strongest piece of evidence against a
molecular ruler based on the distance of the active site threonines came from our own
experiments using mutant and wt yeast 20S proteasomes: Both wt proteasomes
(altogether 6 active sites) and mutants with reduced numbers of active sites due to T1A-
point mutations (4 or 2 active sites left) degraded enolase into fragments of the same
range, 3-25 aa (Nussbaum et al., 1998; please refer to 2.2 for details). Therefore, the
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distance of active sites does not influence the size of the fragments (see Figure 1.3-6
for distances of active sites in eucaryotic proteasomes).
Figure 1.3-6: Distances of active sites in yeast proteasomes
The distances between the active sites in yeast proteasomes range from 28-65 Å. Even proteasomes
harboring only β5 as active subunit (distance: 49 Å, fitting about 12 aa) generate fragments from 3-25
aa, arguing against the classical interpretation of the molecular ruler hypothesis (Nussbaum et al.,
1998; refer to 2.2 for details). [The illustration was taken from Loidl et al. (1999).]
It was proposed before that binding of the regulator PA28 caused proteasomes to directly
generate MHC I ligands by coordinated dual cleavages (Dick et al., 1996). Only later, the
contribution of the different active sites to the generation of some of the dual cleavage
products could be determined using mutant yeast proteasomes. These data, together with
the crystallographic structure of yeast proteasomes, revealed that not all previously
identified dual cleavage products can be generated by two simultaneous cleavages (Dick
et al., 1998). The sheer distances between the active site threonines should theoretically
permit the generation of dual cleavage products from 7 to 16 aa in length (see Figure
1.3-6). Yet, it must be emphasized that these distances do not reflect the shortest possible
stretch of aa that could be cleaved by two active sites simultaneously. Steric requirements
must also be taken into account, for example the correct orientation of the substrate aa
chain towards and its interaction with the inner surface of the substrate binding pocket,
probably over a stretch of 6-10 aa up- and downstream of the cleavage site (Groll et al.,
1997; Nussbaum et al., 1998). This could require some bending of the aa chain that would
substantially increase the length of dual cleavage products. However, as the bulk of
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proteasomal cleavage products does fall into the size range of 7-9 aa, it is likely that
many of them are produced by consecutive cleavages at nearby or distant active sites.
Both 20S and 26S proteasomes from rabbit degraded several denatured or unfolded
proteins (IGF, ovalbumin, casein) into fragments of 3-22 aa, though at the same time
producing a different peptide footprint in HPLC-chromatograms (Kisselev et al., 1999b). A
comparison of the protein degradation by human 20S and 26S proteasomes performed in
our lab showed that 26S proteasomes degrade bovine β-casein into slightly longer
fragments (range: 4-36 aa; average length: 15-18 aa) than 20S proteasomes (3-31 aa, 7-
10 aa). (Emmerich et al., 2000). The pool of generated peptides was only partially
identical between the two proteasome species. However, as stated above, these
discrepancies could be explained by the experimental difficulties to normalize different
proteasome batches. The fact the cleavage site selection followed similar rules for both
20S and 26S proteasomes implies that the cleavage preferences of 20S proteasomes are
not changed after binding of the 19S regulatory particle. Because of the aforementioned
and due to the lack of in vitro substrates for 26S proteasomes, it seems fair to study 20S
proteasomes in vitro to gain insight in the in vivo functions of 26S proteasomes.
1.3.7 Modulation by interferon γ (IFN-γ)
The chemical messenger IFN-γ, which is mainly produced by CTL, NK and inflammatory T
(TH1) cells, regulates several immunologically important processes such as the activation
of macrophages and NK cells, B cell differentiation, antibody isotype switching and the
suppression of helper T (TH2) cell responses. In addition, IFN-γ can directly clear virus-
infection in a noncytopathic way. Antigen presentation is boosted by IFN-γ in two ways:
On the one hand, the transcription of MHC I and II genes is enhanced, resulting in
increased surface expression of MHC I and II. On the other hand, numerous components
of the MHC I antigen processing machinery (TAP, PA28 and immuno-subunits of the
immuno-proteasome) are induced. It is assumed that these components have evolved to
"fine-tune" the protein degradation machinery for its role in immune responses against
viruses. The influence of PA28 and the incorporation of immuno-subunits on protein
degradation by proteasomes is discussed in detail below.
1.3.7.1 PA28, the activator/regulator of mammalian proteasomes
The proteasome modulator PA28 (also called 11S regulator) was discovered through its
ability to stimulate proteasomal hydrolysis of short fluorogenic peptide substrates (Dubiel
et al., 1992). PA28 consists of two homologous subunits, PA28α and PA28β (Mott et al.,
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1994; Ahn et al., 1995; Song et al., 1996), which form a hetero-hexameric ring of α3β3
stoichiometry. Recombinant PA28α or PA28β form homo-heptameric structures which are
also able to stimulate peptide hydrolysis, though less efficiently than PA28α/β hetero-
hexamers (Stohwasser et al., 2000). In the electron microscopic picture, PA28 can be
seen attached to the two ends of the 20S cylinder (Gray et al., 1994). Very recently, the
three-dimensional structure of a PA28-20S complex was solved (Figure 1.3-7): The homo-
heptameric ring of Trypanosoma brucei PA26 (equivalent of mammalian PA28; Yao et al.,
1999) binds to both ends of the 20S cylinder via the C-terminal interaction loops in each
PA28 monomer. These interactions lead to rearrangements in the N-termini of the 20S
proteasome α-rings which cause them to open (see Figure 1.3-8).
Figure 1.3-7: Complex of Trypanosoma brucei PA26 and yeast 20S proteasomes
The homo-heptameric PA26 (yellow) from Trypanosoma brucei can be seen attached to both ends of
the 20S cylinder. The N-termini of the 20S α-subunits (red and pink) become rearranged (arrows),
thereby opening the α-ring. The 20S cylinder is clipped to visualize the central channel. [Image taken
from Whitby et al. (2000).]
Both PA28α and PA28β are strongly induced by IFN-γ and IFN-α (Ahn et al., 1995), a fact
that early on pointed towards an immuno-modulatory role of PA28. Experiments using
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short fluorogenic substrates initially showed an influence of PA28 on the cooperativity
of the active sites of 20S proteasomes (Ma et al., 1992; Yukawa et al., 1993). PA28 was
therefore believed to function as a positive, allosteric regulator. Moreover, a change of the
proteasomal cleavage pattern was observed in natural peptides in the presence of PA28
(Groettrup et al., 1995). Later results, however, demonstrated a different aspect: PA28
induced stronger immunologically relevant cuts, whereas the cleavage pattern was not
changed (Dick et al., 1996; Niedermann et al., 1997). Hence, PA28 caused better lysis of
virus-infected cells by CTL (Groettrup et al., 1996b). PA28β-deficient mice lack PA28α/β-
complexes and display impaired CTL responses and immuno-proteasome assembly
(Preckel et al., 1999), although a role for PA28 in immuno-proteasome assembly was not
observed by a different group (Groettrup, personal communications). A recent report
showed comparable activation of all three proteasomal activities by PA28α/β hetero-
hexamers without a change in the maximal activities. Kinetic modeling led to the
assumption that PA28 exerts its effect by enhancing the uptake and release of short
peptides, possibly through opening of the α-rings of the 20S proteasome (Stohwasser et
al., 2000). This hypothesis was now confirmed by solving the crystallographic structure of
a PA28-20S complex: The binding of PA28 induces an opening in the α-rings of 20S
proteasomes which will probably improve access of substrates to active sites or egress of
degradation products from the proteolytic chamber (Whitby et al., 2000; Figure 1.3-8, top).
Interestingly, both 'open' and 'closed' conformations of the α-rings of yeast 20S
proteasomes were detected by atomic force microscopy in the absence of PA28
(Osmulski and Gaczynska, 2000). The open conformation could be stabilized by addition
of a short fluorogenic peptide or denatured lysozyme, but not by addition of active site
inhibitors. The latter stabilized the closed conformation, suggesting that substrate binding
to the active sites could regulate access to the proteolytic chamber. Latest findings
support the concept that the N-termini of the α-rings function as regulators of substrate
entry: When the α3-subunit N-terminus was shortened by 9 aa, yeast 20S proteasomes
were as active as SDS- or 19S-activated 20S proteasomes, suggesting that the 19S cap
induces the α-rings to open in vivo (Groll et al., 2000; see 1.3.8.1 and Figure 1.3-8,
bottom).
There also exists a highly conserved constitutive PA28 subunit, called PA28γ or Ki
antigen, which is almost exclusively found in the nucleus of cells and which is replaced by
PA28α and PA28β after IFN-γ induction (Jiang and Monaco, 1997; Tanahashi et al.,
1997). Mice lacking PA28γ show retarded growth (Murata et al., 1999), but its role for the
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modulation of 20S proteasomes is not yet understood.
Figure 1.3-8: Open conformations of yeast 20S proteasome α-rings
(Top) Open conformation induced by binding of Trypanosoma brucei PA26 to yeast 20S
proteasomes [taken from Whitby et al. (2000)]: (A, B) 20S proteasome without PA26; (C, D) after
binding of PA26. After binding of PA26, the N-termini of the α-ring subunits become flexible and open
up a pore in the α-ring. (Bottom) Electron density maps of the α-rings in wt and mutated yeast 20S
proteasomes [taken from Groll et al. (2000)]: (A) wt yeast proteasome α-ring; (B) open conformation
in yeast proteasomes with 9 aa deleted at the α3-N-terminus.
1.3.7.2 Exchange of constitutive for IFN-γ-inducible active site β-subunits
In infection, interferons α and γ induce the synthesis of new proteolytically active
proteasomal β-subunits (so-called immuno-subunits) in mammals: β5i / low-molecular-
weight protein 7 (LMP) 7 (replaces β5/X), β1i / LMP2 (replaces β1/δ) and β2i /
multicatalytic endopeptidase complex-like 1 (MECL-1) (replaces β2/Z). These subunits
are then incorporated into newly assembled 20S proteasomes, yielding so-called
immuno-proteasomes. The assembly of 20S proteasomes is tightly regulated, thus
securing that homogeneous subsets of constitutive or immuno-proteasomes are formed:
β1i/LMP2 and β2i/MECL-1 are mutually required for incorporation into 20S proteasomes
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(Stohwasser et al., 1997), probably due to their direct neighborhood in the β-rings
(Schmidtke et al., 1999), and the three immuno-subunits are incorporated cooperatively
(Griffin et al., 1998). However, this regulation seems to be leaky in one direction:
β5i/LMP7 can also be incorporated into β1/δ−β2/Z-containing proteasomes (Kingsbury et
al., 2000). Latest results describe that up to six subtypes of 20S proteasomes can coexist
in one kind of rat tissue (Dahlmann et al., 2000). These subtypes resemble constitutive,
immuno- and intermediate-type proteasomes differing with regard to their enzymatic
characteristics.
As the secretion of IFN-γ coincides with the activation of CTL and APC, it was assumed
that the induction of immuno-subunits improves antigen processing by quantitative or
qualitative changes in the peptide pool generated by proteasomes. The exchange β1/δ ➙
β1i/LMP2 reduces post-acidic cleavages in favor of ChT-like ones, an immunologically
favorable modulation because mouse and human MHC I molecules do not bind peptides
with acidic C-termini (Figure 1.3-9). Besides, TAP has a low affinity for peptides with
acidic C-termini. First studies using fluorogenic peptides, inhibitory peptide analogs or
naturally occurring peptides as substrates showed a prominent influence of the immuno-
subunits onto cleavage site selection (Gaczynska et al., 1993; Gaczynska et al., 1994;
Boes et al., 1994; Eleuteri et al., 1997; Orlowski et al., 1997). To sum up, post-acidic
cleavages were reduced and ChT-like cleavages after branched chain and aromatic aa
were enhanced for immuno-proteasomes. At first, a correlation between selected
cleavage sites in a naturally occurring peptide and the P1-preferences observed with
fluorogenic substrates could not be found (Kuckelkorn et al., 1995). However, later results
confirmed the P1-preferences in polypeptide digests: Cleavages after hydrophobic
residues in denatured lysozyme (129 aa) were augmented with bovine immuno-
proteasomes from spleen, as compared to constitutive proteasomes from pituitary,
whereas post-acidic ones were decreased (Cardozo and Kohanski, 1998; Wang et al.,
1999). However, in these studies only few individual fragments were identified in a purely
qualitative way by mass spectrometry and there was no statistical analysis of cleavage
site selection. We have just completed the analysis of human constitutive and immuno-
proteasome cleavages in digests of enolase. In order to arrive at accurate cleavage motifs
spanning several P- and P'-residues, we for the first time identified more than 100
fragments each in a quantitative way. We did not find differences in fragment lengths, but
confirmed the augmented preference of immuno-proteasomes for hydrophobic aa in P1
(Toes, submitted for publication; see 2.5 for details). Our data will be used for the
prediction of constitutive and immuno-proteasome cleavages.
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Figure 1.3-9: Active site surfaces and their influence by exchange for immuno-subunits
Changes in the cleavage preferences of immuno-proteasomes can be explained by the exchanges of
few aa residues in β1i/LMP2 as compared to β1/δ (Groll et al., 1997). The exchange R➔L abrogates
the preference of this pocket to accommodate acidic aa; the exchange T➔F reduces space, which
could be the reason for the preference of immuno-proteasomes for the aa Gly in P1' (see 2.5 for
detail). The aa lining the pockets of the other two active site subunits are not changed by the
exchange for IFN-γ inducible subunits. [Graph reproduced with the permission of T.P. Dick.]
1.3.7.3 Differential processing of CTL epitopes by constitutive and immuno-
proteasomes
Soon after the IFN-γ inducible proteasome subunits had been discovered, it was shown
that in cell lines they were not generally required for stable MHC I surface expression and
for processing and presentation of antigenic peptides from influenza virus and an
intracellular protein (Momburg et al., 1992; Arnold et al., 1992). However, mice lacking
LMPs showed deficiencies in the immune system: LMP7-deficient mice exhibit reduced
MHC I surface expression and presentation of the endogenous antigen HY (Fehling et al.,
1994). LMP2-deficient mice display lower numbers of CD8+ T lymphocytes, diminished
presentation of an Influenza epitope and a reduced CTL-response against Influenza virus
infection (Van Kaer et al., 1994).
The influence of immuno-subunit incorporation onto antigen processing has been studied
extensively. However, no general rule has been found for the presence of immuno-
proteasomes and CTL-activation. Whereas the presentation of some CTL-epitopes seems
to profit from immuno-proteasomes (Van Kaer et al., 1994; Boes et al., 1994; Fehling et
al., 1994; Schwarz et al., 2000; Sijts et al., 2000a; Sijts et al., 2000b), others seem to be
preferentially destroyed by immuno-proteasomes (Morel et al., 2000). Interestingly, many
epitopes profiting from immuno-proteasome processing are derived from viral proteins,
whereas detrimental effects of immuno-proteasomes have been reported for a
ubiquitously expressed self-protein (see Stoltze et al., 2000a for review). This could reflect
the evolutionary adaptation of the antigen processing machinery (specifically: the
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proteasome) to fight viruses. However, a recent publication shows the generation of
one viral epitope and the destruction of another by immuno-proteasomes (van Hall et al.,
2000). This differential behavior and the opposing results summarized above imply that it
is only the aa sequence of the substrate that determines whether an epitope will be
preferentially generated or destroyed by the cleavage preferences of immuno-
proteasomes.
Recently it was reported that immuno-proteasomes (and PA28) are up-regulated in
dendritic cells, especially after their transition from immature, antigen capturing cells to
mature, antigen presenting and T cell-priming cells (Macagno et al., 1999; Morel et al.,
2000). This could mean that CTL are predominantly activated against epitopes generated
by immuno-proteasomes. The consequences of this are discussed in 2.5.5.
1.3.8 Protein degradation by proteasomes
1.3.8.1 The narrow gate: It is easier for a camel...
The diameter of the Thermoplasma proteasome α-rings, the proposed substrate entry
gates, is only 13 Å, a hole barely allowing the simultaneous passing of 2-3 extended
polypeptide chains. In analogy to a biblical metaphor, it is hence easier for a camel to be
threaded through the eye of a needle than for a folded protein to enter proteasomes. In
other words, substrates probably have to be completely unfolded before they get access
to the proteolytic chamber of 20S proteasomes. This unfolding is probably exerted by
regulatory protein complexes binding to both sides of the 20S cylinder. In the
archaebacterium Methanococcus jannaschii, a proteasome regulator (PAN = proteasome-
activating nucleotidase) with chaperone-like and unfoldase activity was just recently
identified (Zwickl et al., 1999; Benaroudj and Goldberg, 2000). In yeast proteasomes, the
N-terminal residues of the α-rings were found to seal the 20S-cylinder completely (Groll et
al., 1997), raising the question how substrate entry is possible at all. Two very recent
publications have shed light on this problem: A homo-heptameric bacterial (Trypanosoma
brucei) PA28 induced the rearrangement of several α-subunit N-termini, creating a 13 Å
opening in the α-rings (Whitby et al., 2000; see Figure 1.3-8, top). The effect of a 9 aa
deletion in the α3-subunit N-terminus was similar and paralleled activation of 20S
proteasomes by the 19S cap or the detergent SDS (Groll et al., 2000; see Figure 1.3-8,
bottom). For 26S proteasomes, the 19S cap, in addition to its possible role in the α-ring
opening, is thought to exert unfoldase activity through its numerous ATPases (DeMartino
and Slaughter, 1999). However, until now only chaperone-like activity (i.e. prevention of
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protein aggregation and refolding) has been demonstrated for the base of the 19S cap
(Braun et al., 1999; Strickland et al., 2000). It is conceivable that especially hybrid
proteasomes (see 1.3.2) could link protein degradation (through ubiquitin-recognition by
the 19S lid) and efficient generation of antigenic peptides (through activation of proteolysis
by PA28). Whitby et al., 2000 speculate that in hybrid proteasomes the 19S cap could
regulate substrate entry, whereas PA28 would regulate fragment exit resulting in longer
fragments.
For all of the above, it is difficult to investigate the degradation of native proteins by 20S
proteasomes in vitro. Up to now, the digestion of proteins has thus almost exclusively
been shown for denatured or modified proteins. The degradation of oxidized insulin B-
chain was described as 'processive channeling' of degradation intermediates through the
human 20S proteasome cylinder (Dick et al., 1991). The fragment lengths found after
degradation of oxidized insulin B-chain and denatured hemoglobulin by Thermoplasma
proteasomes led to the above mentioned molecular ruler hypothesis (Wenzel et al., 1994).
Also, ovalbumin and β-galactosidase could only be degraded by mammalian 20S after
prior denaturation by S-carboxymethylation (Dick et al., 1994). Only bovine β-casein is
degraded in an unmodified form by 20S and 26S proteasomes (Pereira et al., 1992;
Emmerich et al., 2000). This is probably so because casein is already devoid of tertiary
structure in its native form, possibly due to its many proline residues. To speak with the
above metaphor, casein and denatured proteins thus rather resemble a snake than a
camel when approaching the narrow gate of the proteasomal α-rings.
1.3.8.2 Processive degradation or fierce chopping?
The degradation of fluorescein isothiocyanate (FITC)- labeled casein yielded final
degradation products early on in the digest and accumulating over time, without the
appearance of any large degradation intermediates (Akopian et al., 1997). Therefore, a
processive mechanism was postulated for proteasomal protein degradation. Processivity
was defined as complete degradation of an individual substrate "protein to oligopeptides
before attacking another protein molecule" (Akopian et al., 1997), requiring continuous
channeling of the substrate through the proteasome cylinder and continuous cleaving of
the substrate. A very vivid picture, namely that of a bread-cutter, was used to illustrate
processivity. The lack of large degradation intermediates in proteasomal digests was
confirmed by ourselves using yeast 20S and the substrate enolase (Nussbaum et al.,
1998) and by others using mammalian 20S and 26S proteasomes and FITC-labeled
casein as substrate (Kisselev et al., 1999b). It is unclear, however, whether the observed
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early accumulation of final degradation products really reflects processive, i.e.
continuous channeling of individual substrate molecules through proteasomes. For, the
reported experimental results could also be explained by an exit size filter for
degradation products, which, according to latest results, could be identical to the openings
in the α-rings (Whitby et al., 2000). Moreover, whereas small, final degradation products
accumulate in significant amounts over time, large degradation intermediates might simply
not arise in amounts above the detection limits of the analytical systems. Short peptides
might be spared from further proteasomal degradation for two reasons: (A) They
overcome the exit size filter and diffuse out of the proteolytic chamber. (B) They constitute
bad substrates for proteasomes (Dolenc et al., 1998). Proteasomal 'shredding' of proteins
into small pieces is thought to protect cells from the potential hazards of biologically active
degradation intermediates: For example the separation of a regulatory and an active
domain of a transcription factor by partial degradation could lead to uncontrollable
induction of the target gene. But still, nonprocessive degradation of reduced
carboxyamidomethylated lysozyme (RCM-lysozyme) by bovine constitutive and immuno-
proteasomes was recently reported (Wang et al., 1999). Large degradation intermediates,
which were later cleaved to small peptides, could be detected early on in digests.
According to these results, proteasomal protein degradation would rather be based on
free diffusion than on directional channeling of substrate, as in the processive model.
The authors propose that large cleavage products have the same probability of diffusing
out of the proteasome cylinder and of being cleaved again. Nonprocessive or partial
degradation of substrates could explain degradation intermediates detected in in vitro
experiments using lysozyme (Orlowski and Michaud, 1989), insulin B chain (Dick et al.,
1991) or naturally occurring peptides as substrates (Niedermann et al., 1996; our own
unpublished results). Besides, nonprocessivity could be the prerequisite for the activation
of some transcription factors by partial proteasomal processing: NF-κB can only be
formed after the partial, cotranslational processing of its precursor p105 to p50 (Lin et al.,
1998); SPT23 and MGA2 are only released after the partial processing of their ER
membrane-bound precursors (Hoppe et al., 2000). Intriguingly, in both cases a loop of a
fixed protein needs to be inserted into the proteasome for an initial endoproteolytic
cleavage and for the subsequent complete degradation of the C-terminal part of the
protein. The two processes differ in that for p105, the N-terminus is fixed by the ribosome
and the unfixed, C-terminal part is completely degraded, whereas for the precursors of
SPT23 and MGA2, the C-terminal part is at first fixed in the ER membrane but later
extracted and degraded. However, nonprocessive degradation in vitro has only been
32
reported for relatively short substrates, the longest of which is lysozyme with 129 aa.
Large (and unfixed?) protein substrates, on the contrary, might preferentially be degraded
in a processive fashion for their slower diffusion and/or higher affinity to proteasomal
active sites (Dolenc et al., 1998).
Figure 1.3-10: Models for proteasomal protein degradation
(A) An unfolded substrate aa chain enters the proteasome cylinder and is cleaved by the active sites
(scissors) in the central cavity; protein fragments leave via the α-rings. This model would fit the
proposed role for hybrid-proteasomes in which the 19S cap unfolds and inserts the substrate and
PA28 regulates the exit of fragments (1.3.2 and 1.3.8.1). The distance from the active sites to the
outside of the cylinder approximately equals the length of a 20 aa polypeptide in extended
conformation. (B) Substrate proteins could enter proteasomes from both ends. Fragment exit via the
α-rings would probably still be possible in this model, but might be slowed. (C) Cleavage of a
polypeptide hairpin loop inserted into the proteasome cylinder. In the proposed examples for this
model, one part of the polypeptide chain is completely degraded whereas the other can diffuse away
as partial degradation product (Lin et al., 1998; Hoppe et al., 2000). Size estimates are taken from
Hoppe et al. (2000). Regulatory particles binding to 20S proteasomes were omitted for clarity.
It was observed that short substrate analogs for the post-acidic activity inhibit the ChT-like
one whereas substrate analogs for the ChT-like activity stimulate the ChT-like activity.
Based on these findings, a bite-chew model for protein degradation was proposed
(Kisselev et al., 1999a). According to this model, a protein substrate binds to the ChT-like
active sites and thereby stimulates ChT-like cleavages. After one round of ChT-like
cleavages ("bite"), intermediate degradation products would move on to post-acidic active
sites, thereby inhibiting further ChT-like cleavages, in order to be degraded further
("chew"). The bite-chew model was challenged by the non-catalytic modifier site model
which proposes a regulatory site distinct from the active sites (Schmidtke et al., 2000).
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Both models require allosteric effects which have not been observed yet with any
imaging method such as electron microscopy or crystallography.
1.4 From Proteasomal Degradation Products to CTL Epitopes
1.4.1 What makes proteasomal products good CTL epitopes?
Peptides binding to MHC I molecules must meet two criteria, as pointed out earlier
(1.1.3.1): Their lengths must range between 8-10 aa and their sequences have to
correlate to the MHC I binding motifs, which often require hydrophobic C-termini
(Rammensee et al., 1999). As proteasomes generate peptides with predominantly
hydrophobic C-termini (see 1.3.5) and as a large fraction of degradation products is larger
than 7 aa (see 1.3.6), proteasomal cleavage products seem to fulfill these requirements.
In order to further analyze the relationship between proteasomal cleavage products and
MHC I ligands, one study compared the cleavage specificities of proteasomes from
different species with sequence signals at the peptide termini of 134 MHC I ligands. It was
concluded that (A) the all eucaryotic, but not archaebacterial proteasomes share cleavage
preferences beneficial for the generation of the C-termini of MHC I ligands and (B) that
MHC I binding motifs probably evolved to match proteasomal cleavage products
(Niedermann et al., 1996). A more recent study more systematically checked 286 MHC I
ligands for sequence signals and found that the C-termini, but not the N-termini resemble
proteasomal cleavage sites (Altuvia and Margalit, 2000). As the cleavage preferences of
immuno-proteasomes augment the output of peptides with hydrophobic C-termini and
diminish cleavages after acidic aa (see 1.3.7.2), they are thought to produce more
potential MHC I ligands than constitutive proteasomes. In addition to the fact that no
known mammalian MHC I allele prefers ligands with acidic C-termini (as an exception,
some chicken MHC I alleles do), TAP only poorly translocates such peptides in the ER
(see below).
1.4.2 Additional selection criteria
As mentioned above, the binding motifs of MHC I molecules represent a high obstacle for
amino acid sequences to qualify as CTL epitopes (see 1.1.3.1 and 1.2.2). The MHC
binding motifs can be viewed as the last - and probably finest - of a series of filters that
peptides have to pass before binding to MHC I molecules. One of the first filters in this
chain is proteasomal cleavage specificity (see 1.3.5, 1.3.7.2 and 1.3.7.3). However, some
in-between filters probably also affect the selection of CTL epitopes, most notably TAP.
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Less specific filters include trimming peptidases in the cytosol and the ER and possibly
chaperones that channel peptides from the proteasome to TAP and protect them from
degradation into single amino acids.
1.4.2.1 TAP specificity
The peptide transporter TAP signifies an additional selection step for CTL-epitopes. Its
translocation specificity is species-dependent and has been investigated in detail for rat,
mouse and human TAP (Uebel and Tampe, 1999). Mouse TAP translocates peptides
from 9 aa in length and with hydrophobic C-, whereas rat and human TAP translocate
peptides with both hydrophobic and basic C-termini termini (Schumacher et al., 1994;
Momburg et al., 1994; van Endert et al., 1995). The preference for C-terminal aa
characteristics is in line with binding requirements for MHC I molecules: Human and rat
MHC I molecules bind peptides with hydrophobic and basic C-termini; mouse MHC I
molecules only bind peptides with hydrophobic C-termini. The three N-terminal residues of
peptides are of equal importance for TAP-selectivity: Hydrophobic and charged aa are
preferred whereas aromatic and acidic (in P1) and Pro residues (in P2, P3) are strongly
disfavored. Peptide-binding to some MHC I alleles depends on aromatic aa in P1 (HLA-
A*0201) or on Pro in P2 (the HLA B7 group) of the peptide, leading to the assumption that
the ligands for these MHC alleles need to be transported by TAP as N-terminally
elongated precursor peptides (van Endert et al., 1995). The central part of TAP-
translocated peptides does not display preferences for specific aa residues, however the
peptide backbone seems to be important for binding to TAP (Uebel et al., 1997). The
specificity of human TAP is summarized in Figure 1.4-1.
+ K,N,R R,I,Q W,Y R I F,L,R,Y,V
Position 1 2 3 4 5 6 7 8 9
– D,E,F P,L D,E,G N T D,E D,E,N,S,G
Figure 1.4-1: Binding motif of human TAP
Of a 9mer peptide (shaded rectangle), the N-terminal aa and the C-terminus (dark shading) are most
important for translocation by TAP. Please note that TAP can translocate longer peptides than the
9mer given in the example. However, it is always the N-terminal and C-terminal residues that decide
about affinity to TAP. Preferred (+) or disliked (-) aa residues at the indicated positions; bold residues
show the strongest effects. [The figure was adapted from Uebel and Tampe (1999).]
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1.4.2.2 To trim or not to trim, a nearly philosophical question
Previously, it was observed that proteasomes cleave out the exact MHC I ligand from
protein or peptide sequences, without aa extensions on either end of the fragment
(Wenzel et al., 1994; Dick et al., 1994; Dick et al., 1996; Niedermann et al., 1997).
However, this contradicts the requirement for ligands of certain MHC alleles to be
translocated as N-terminally extended precursors, as imposed by TAP specificity (see
1.4.2.1). Trimming of precursor peptides for MHC I ligands was already suggested 10
years ago (Falk et al., 1990). Later, when the first reports showed proteasome-
independent trimming of the extended N-termini of CTL epitopes, this was propagated by
some researchers in the field as a general mechanism. Experimental data available to
date indicate that proteasomes can contribute to the generation of MHC I ligands in three
different ways: A) They excise the final MHC I ligands by dominant cleavages (Lucchiari-
Hartz et al., 2000). B) They supply final MHC I ligands as side-products next to more
dominant N-terminal extensions (Dick et al., 1994; Groettrup et al., 1995; Niedermann et
al., 1995; Dick et al., 1996; Niedermann et al., 1996; Theobald et al., 1998). (C) They only
generate N-terminally extended precursor peptides of the MHC I ligand which are
subsequently trimmed by non-proteasomal activities in the cytoplasm or ER (Craiu et al.,
1997; Stoltze et al., 1998; Mo et al., 1999; Paz et al., 1999). Several cytosolic proteases
have been suggested to serve as trim-peptidases: the IFN-γ-inducible leucine
aminopeptidase (LAP, Beninga et al., 1998), tripeptidyl-peptidase II (TPPII, Geier et al.,
1999) and bleomycin hydrolase and puromycin-sensitive aminopeptidase (BH, PSA,
Stoltze et al., 2000b). An early report proposing C-terminal trimming in the ER has not
been supported by additional data (Elliott et al., 1995).
Taken together, these data strongly indicate that the C-termini of MHC I ligands must be
generated by proteasomes.
1.5 The Prediction of CTL Epitopes
Many immunologists are searching for CTL epitopes that could be beneficial in prevention
and therapy of infectious diseases or cancers. The search usually involves the prediction
of protein sequences that are likely to bind to MHC I molecules and therefore to activate
the cellular immune response. Different approaches for the prediction of MHC I ligands
exist, all of them based on peptides eluted from MHC I molecules. Two methods deduce
from the aa sequences of known MHC I ligands either minimal matrices (Rammensee et
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al., 1999; www.syfpeithi.de) or more intricate neural networks (Honeyman et al., 1998;
Brusic et al., 1998) for prediction; another draws on structural features of known MHC I
ligands (Schueler-Furman et al., 2000). The prediction of MHC I ligands is reasonable for
two reasons: (A) Binding to MHC I constitutes one of the most downstream and strictest of
several selection criteria for CTL epitopes; (B) the binding motifs of MHC I molecules
follow comparatively simple rules that can easily serve as the basis for prediction.
However, the prediction of MHC I ligands still yields many false-positives. As a
consequence, the synthesis of the peptides and subsequent MHC I binding studies are
indispensable. But there still remains the possibility that the peptides emerging from this
refined testing are not generated by proteasomes in vivo. It should thus be possible to
narrow down the number of potential CTL epitopes by including proteasomal cleavage
preferences into the prediction.
Therefore, several research groups are struggling to develop automated prediction tools
for proteasomal cleavages. A group in Berlin published the first prediction algorithm: It
was based on the experimental cleavage data of only seven naturally occurring peptides,
compiled from different literature sources and thus comprising a small and heterogeneous
data set (Holzhütter et al., 1999). Lately, a refined kinetic model was published by the
same group (Holzhütter and Kloetzel, 2000). We ourselves have only recently created an
algorithm based on proteasomal cleavages in enolase. This algorithm uses simple rules to
model proteasomal cleavage behavior and is able to predict cleavages in any protein
sequence with some accuracy (Kuttler et al., 2000; for details see 2.2). We have just now
incorporated the algorithm into a World Wide Web (www)-site: www.paproc.de, the first
publicly available proteasomal cleavage predictor (for details see 2.4). At least two more
research groups are currently developing proteasomal cleavage predictors: A group in
Leiden, The Netherlands, will link the characteristics of proteasomal cleavage sites with
those of CTL epitopes for more accurate prediction (F. Ossendorp, C. Melief, personal
communications). Researchers in Copenhagen, Denmark, in collaboration with us, have
generated neural networks for proteasomal cleavage prediction (C. Kesmir, S. Brunak,
personal communications). They are based on both the sequences of MHC I ligands and
our proteasomal cleavage data. A group in Berlin will try to link MHC I ligand prediction
and proteasomal cleavage prediction, again, in collaboration with us and based on already
available programs (H. Mollenkopf, personal communications).
The prediction of TAP-binding peptides has only been attempted ones using neural
networks (Daniel et al., 1998). This approach has not been followed up. It is conceivable
that the prediction of CTL epitopes might benefit from including TAP specificity into the
37
selection criteria. However, considering the broad specificity of TAP and the scarcity of
experimental data, it might be premature to incorporate TAP in such a prediction method.
1.6 Goal and Experimental Outline of the Thesis Project
The goal of my thesis project was the characterization of proteasomal cleavage
preferences in whole protein digests. The large amount of data we hoped to collect was
to be used for the development of a prediction device for proteasomal cleavages,
analogous to the database SYFPEITHI (www.syfpeithi.de), a widely-used public predictor
for MHC I binding peptides that was created in our institute (Rammensee et al., 1999).
The basis for my Ph.D. thesis project was already laid during my diploma thesis project
(April-Dec. 1997) when I screened for proteins that - despite of the aforementioned
experimental obstacles (see 1.3.8) - could be degraded in vitro by purified 20S
proteasomes from yeast. I found yeast enolase-1 to be a promising candidate. This 436
aa protein turned out to be a sound model substrate: Enolase represents in all aspects (aa
composition, structure, charge, etc.) a typical and thus representative protein according to
the SAPS database (Brendel et al., 1992). At the same time we received wild-type (wt)
and mutant yeast 20S proteasomes through collaborations with the groups of Drs Wolf
(Inst. for Biochemistry, University of Stuttgart) and Huber (MPI for Biochemistry,
Martinsried). These yeast proteasomes were initially characterized using as substrates
fluorogenic peptides and natural peptides harboring MHC I ligands and CTL epitopes (see
2.1, published in Dick et al., 1998). I started the first enolase digestion experiments
simultaneously and, at the end of my diploma thesis time (i.e. at the beginning of my
Ph.D. thesis time), enolase digestion experiments using all available yeast 20S
proteasomes had been performed, but still awaited their biochemical analysis.
The experimental course of events was as follows: Yeast enolase-1, as model substrate,
was incubated with purified 20S proteasomes from yeast or human cells. The enolase
fragments that were generated by proteasomal degradation were subsequently analyzed
by biochemical methods (HPLC fractionation, Edman sequencing and mass
spectrometry). The identified enolase fragments defined the location of proteasomal
cleavage sites. Both types of information were compiled graphically into so-called
cleavage maps. Simple counting and complicated statistical analysis (hypergeometric
distribution, Student’s t-test, Chi2-test) of fragments, fragment lengths and, most
importantly, cleavage sites allowed us to determine the cleavage preferences for all
proteasome species studied. Systematic analysis of the aa sequences flanking cleavage
38
sites led to the identification of features in the substrate sequence (cleavage motifs)
that are crucial for cleavage site selection by proteasomes (see 2.2, published in
Nussbaum et al., 1998, and 2.5, Toes et al., submitted for publication).
My experimental data were used – in a close and fruitful collaboration with the Department
for Biomathematics at the University of Tübingen (Prof. K.P. Hadeler and Dr. C. Kuttler) –
as training data for computer algorithms modeling proteasomal cleavages. These
algorithms were finally tied into a publicly available www-site named PAProC, for
'Prediction Algorithm for Proteasomal Cleavages', that is already being accessed by many
researchers world-wide (see 2.3, Kuttler et al., 2000, and 2.4, Nussbaum et al., in press).
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2 Results
2.1 Contribution of proteasomal β-subunits to the cleavage of
peptide substrates analyzed with yeast mutants
2.1.1 Summary
Proteasomes generate peptides that can be presented by MHC class I molecules in
vertebrate cells. Using yeast 20S proteasomes carrying different inactivated β-subunits we
investigated the specificities and contributions of the different β-subunits to the
degradation of polypeptide substrates containing MHC class I ligands and addressed the
question of additional proteolytically active sites apart from the active β-subunits. We find
a clear correlation between the contribution of the different subunits to the cleavage of
fluorogenic and long peptide substrates, with β5/Pre2 cleaving after hydrophobic, β2/Pup1
after basic and β1/Pre3 after acidic residues, but with the exception that β2/Pup1 and
β1/Pre3 can also cleave after some hydrophobic residues. All proteolytic activities
including the "branched chain amino acid preferring" (BrAAP) component are associated
with either β5/Pre2, β1/Pre3 or β2/Pup1, arguing against additional proteolytic sites.
Because of the high homology between yeast and mammalian 20S proteasomes in
sequence and subunit topology and the conservation of cleavage specificity between
mammalian and yeast proteasomes our results can be expected to also describe most of
the proteolytic activity of mammalian 20S proteasomes leading to the generation of MHC
class I ligands.
2.1.2 Introduction
The 20S proteasome, a threonine protease (Seemüller et al., 1995) and member of the
Ntn-amidohydrolase family (Brannigan et al., 1995), is the central component of the non-
lysosomal proteolytic system in eukaryotes. It is not only involved in general protein
catabolism but also in major regulatory processes such as cell cycle control and signal
transduction pathways (Hochstrasser, 1995; Coux et al., 1996; Hilt and Wolf, 1996). In
vertebrates the proteasome additionally caters to the immune system: peptides generated
as degradation products are delivered to MHC class I molecules for presentation on the
cell surface (Lehner and Cresswell, 1996). Although localized in the cytosol and
nucleoplasm, the proteasome appears to be responsible for ER-associated protein
degradation as well (Hiller et al., 1996; Wiertz et al., 1996; Sommer and Wolf, 1997).
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The cylindrical 20S proteasome is composed of four longitudinally stacked heptameric
rings. The two outer rings are made up of α-subunits and connect the 20S particle to
supplementary complexes, most notably the 19S cap and the IFNγ-inducible PA28αβ
complex. The 19S cap complex confers specificity for ubiquitinated substrates (Hilt and
Wolf, 1996). The PA28αβ complex appears to be an immunological adaptation,
modulating the cleavage mechanism and improving the yield of antigenic peptides (Dick et
al., 1996; Groettrup et al., 1996).
The two inner rings, composed of β-subunits, harbor the catalytically active subunits,
displaying their active sites on the inner surface of the central tunnel. Most β-subunits are
generated from precursors that undergo N-terminal processing during proteasome
assembly (Seemüller et al., 1996). Three of the mature subunits (MB1, δ and Z in human;
β5/Pre2, β1/Pre3 and β2/Pup1 in yeast) are proteolytically active and carry an amino-
terminal threonine residue as the catalytic nucleophile (Fenteany et al., 1995; Groll et al.,
1997; Heinemeyer et al., 1997; Arendt and Hochstrasser, 1997). Some of these critical
Thr residues can be covalently modified by the proteasome-specific inhibitor lactacystin
(Fenteany et al., 1995). In higher vertebrates, the cytokine IFNγ induces the expression of
three additional active proteasome subunits, LMP7, LMP2 and MECL1, which replace
their constitutive counterparts MB1, δ and Z, respectively (Savory et al., 1993; Reidlinger
et al., 1997; Hisamatsu et al., 1996). However, how these exchanges modulate
proteasome function and specificity is still poorly understood.
Biochemical studies on the specificity of the 20S proteasome led to the description of
three distinct proteolytic components, designated as the chymotrypsin (CT)-like, trypsin
(T)-like and peptidylglutamyl-peptide hydrolyzing (PGPH) activities. Recent studies
confirmed that the yeast homologues of MB1, Z and δ are the only active subunits with a
functional N-terminal Thr nucleophile (Heinemeyer et al., 1997; Arendt and Hochstrasser,
1997) and represent the above mentioned three classical activities, as defined with certain
fluorogenic model substrates.
However, some biochemical studies also pointed towards the existence of additional
proteolytic components within the proteasome (Orlowski et al., 1993): one of those, the
so-called "branched chain amino acid preferring" (BrAAP) component, cleaving after Leu
in certain model substrates, was also assumed to represent the major protein degrading
activity of the proteasome (Pereira et al., 1992). The existence of such additional activities
was concluded from inhibitory studies. While the cleavage of fluorogenic substrates
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representing the three classical activities could be inhibited with the general serine
protease inhibitor 3,4-dichloroisocoumarin (DCI), the same treatment led to an increased
turnover of certain other substrates, defined to represent the BrAAP component (Orlowski
et al., 1993; Cardozo et al., 1992). Using more specific inhibitors evidence was provided
that the BrAAP and the PGPH-activity might be related to each other (Cardozo et al.,
1996; Vinitsky et al., 1994). More recently, the arrangement of the intermediately
processed β7/Pre4 and β6/C5 propeptides in the crystal structure of the yeast 20S
proteasome led to the postulation of an additional catalytic activity, not related to the Thr
sites and possibly involved in the processing of the β-subunit propeptides (Groll et al.,
1997).
In this study we investigated whether the specificities defined with small fluorogenic
substrates do reflect truly distinct catalytic sites and how these specificities relate to the
cleavages that can be observed in peptide substrates containing known MHC class I
ligands. In addition, we addressed the question of additional proteolytically active sites
associated with the yeast 20S proteasome by analysis of the BrAAP component.
Using highly purified wt and mutant yeast proteasomes and several inhibitors of the
proteasomal activities, we examined the cleavage specificity of the three active subunits
towards short fluorogenic peptides as well as peptide substrates derived from the murine
JAK1 tyrosine kinase, the pp89 protein from murine cytomegalovirus (MCMV) and the
nucleoprotein (NP) from Influenza A/PR/8/34. We found that all observed cleavages could
be correlated to the three known active sites showing that no additional proteolytic activity
exists within the yeast 20S proteasome for the given set of substrates. Furthermore, we
found that the specificities of the different subunits towards fluorogenic substrates are
mainly identical to those observed for peptide substrates with few, but notable exceptions.
This allows now the clear association of certain cleavage events within peptide substrates
with certain β-subunits and therefore an assessment of the contribution of the different β-
subunits to the generation of proteasomal degradation products.
The 20S proteasomes from yeast and higher eukaryotes are highly homologous. As
shown in this paper and recently by Niedermann et al. (Niedermann et al., 1997), most
cleavage sites in peptides and proteins are conserved between yeast and man. It is
therefore very likely that results obtained with the yeast proteasome will improve our
understanding of vertebrate proteasome function and specificity and consequently of its
role in the generation of CTL epitopes.
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2.1.3 Materials & Methods
2.1.3.1 Generation of yeast 20S proteasome mutants
The generation of mutant strains YUS4 (pup1-T1A), YUS1 ( pre3-T1A) YUS5 (pup1-T1A
pre3-T1A) and YWH23 (pre2-K33A) (numbering refers to amino acid positions in mature
subunits) have been described recently (Heinemeyer et al., 1997). Wild-type yeast cells
were as described (Groll et al., 1997).
2.1.3.2 Purification of proteasomes
The purification of 20S proteasomes from S. cerevisiae has been described recently (Groll
et al., 1997). The same procedure was applied to the purification of the various mutant
proteasomes.
2.1.3.3 Measurement of proteasomal activities against substrates with fluorogenic
leaving group
Fluorogenic substrates Benzyloxycarbonyl-Gly-Gly-Leu-7-Amino-4-methylcoumarin (Z-
GGL-AMC), Succinyl-Leu-Leu-Val-Tyr-7-Amino-4-methylcoumarin (Suc-LLVY-AMC),
Benzyloxycarbonyl-Ala-Arg-Arg-7-Amino-4-methylcoumarin (Z-ARR-AMC) and
Benzyloxycarbonyl-Leu-Leu-Glu-β-Naphthylamide (Z-LLE-βNA) (all purchased from
Bachem, Heidelberg) were prepared from 10mM stocks in DMSO. Typically 1µg of
proteasome (with and without inhibitors) was incubated in a 100µM substrate solution.
Fluorescence of the leaving group was determined after incubation times of 1-5 h with a
Millipore spectrophotometer at 380nm excitation and 440nm emission for AMC and at
330nm excitation and 410nm emission for βNA.
2.1.3.4 Inhibitors
Lactacystin was purchased from E. J. Corey (Harvard University), 3,4-dichloroisocoumarin
(DCI) and Calpain Inhibitor I (LLnL) were from Sigma.
2.1.3.5  Measurement of non-fluorogenic leaving group by azo coupling
The BrAAP substrate Z-GPALA-p-benzoic acid was a gift from Dr. M. Orlowski (Mount
Sinai, New York). It was incubated in 100mM Tris pH 8.0 at a final concentration of 1mM
together with 1µg of proteasome, in the presence or absence of 0.01 units
Aminopeptidase M (Sigma). The reaction was stopped by addition of one reaction volume
10% trichloroacetic acid and developed by sequential addition of 2 volumes 0.1% NaNO2
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(in 1N HCl), 2 volumes 0.5% Ammoniumsulfamate (in 1N HCl) and 4 volumes 0.05% N-
Naphthylethylendiamine (in 95% ethanol). In the course of the development reaction an
azo dye is generated from free p-Amino-Benzoic acid. The extinction of the dye is
measured at 545nm.
2.1.3.6 Determination of proteasomal cleavages in unmodified 19-25mer peptides
Peptides were synthesized on an ABI 432A (Applied Biosystems, Weiterstadt, Germany)
automated peptide synthesizer applying Fmoc chemistry and purified by RP-HPLC
(Beckman, System Gold). Incubations of 1µg proteasome with peptide substrates at a
final concentration of 50µM were performed at 37°C in a total volume of 300µl assay
buffer (20mM HEPES/KOH pH 7.8; 2mM MgAc2; 1mM DTT).
2.1.3.7 Separation of cleavage products and online analysis by mass spectrometry
Proteasome digests were analyzed with two different LC-MS systems. In case of the first
system, aliquots of 40µl were loaded by autosampler (CTC A200S) and separated by
HPLC (Sykam, Gilching, Germany), equipped with a µRPC C2/C18 SC 2.1/10 column
(Pharmacia, Freiburg, Germany). Eluent A: 0.05% TFA; Eluent B: 80% Acetonitrile
containing 0.055% TFA. Gradient: 23-63% B in 20 min; Flow rate: 50µl/min, gradient
started 5 min after sample injection. Analysis was performed on-line by a tandem
quadrupole mass spectrometer (TSQ 700; Finnigan MAT, Bremen, Germany) equipped
with an ESI-F electrospray ion source. Each scan was acquired in centroid mode over the
range m/z 300-2200 in 3 seconds.
In case of the second LC-MS system, aliquots of 5µl were separated by HPLC (ABI 140D
solvent delivery system), equipped with a 300µm C18 RP column (Gromsil, Grom,
Herrenberg, Germany). Eluent A: 4mM NH4Ac, adjusted to pH3 with formic acid; Eluent B:
2mM NH4Ac in 70% Acetonitrile, adjusted to pH3 with formic acid. Gradient: 20-75% B in
25 min; Flow rate after pre-column split: 6µl/min. Analysis was performed on-line by a
hybrid quadrupole orthogonal acceleration time of flight mass spectrometer (Q-TOF;
Micromass, Manchester, UK) equipped with an electrospray ion source. Each scan was
acquired over the range m/z 400-1500 in 3 seconds.
Peptides were identified by their molecular mass. Additionally, the identity of main
cleavage products was confirmed by fragmentation with argon atoms in ms/ms
experiments. For relative quantitation of single molecular species integrated ion currents
were calculated and compared.
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2.1.4 Results
2.1.4.1 Cleavage of small fluorogenic substrates
Cleavage of the standard fluorogenic substrates GGL, ARR and LLE has been shown
recently to be subunit-specific (Heinemeyer et al., 1997). Using for the first time yeast
proteasome preparations, we repeated the cleavage of fluorogenic peptides to test the
reproducibility of the results in our experimental setup. As expected, the GGL-cleaving
activity, defined to represent the chymotrypsin-like activity, is clearly correlated with the
β5/Pre2 site: Cleavage of the Z-GGL-AMC substrate is only present in those mutants that
retain a functional β5/Pre2 subunit and absent in pre2-K33A mutant proteasomes (Figure
2.1-1A). Identical results were obtained with the Suc-LLVY-AMC substrate (data not
shown). The ARR cleaving activity, defined to represent the trypsin-like activity, depends
on a functional β2/Pup1 site: The cleavage of Z-ARR-AMC is not observed in the
β2/Pup1-mutated proteasomes from the pup1-T1A and pup1-T1A pre3-T1A strains, but in
all other mutants (Figure 2.1-1B). Correspondingly, β1/Pre3 is responsible for the PGPH-
like activity: The Z-LLE-βNA substrate is not cleaved in the double mutant pup1-T1A pre3-
T1A and only cleaved weakly in the pre3-T1A single mutant (Figure 2.1-1C).
The increased activities of some mutant proteasomes compared to wild-type particles are
hard to explain but might be caused by the lack of competition from inactivated subunits
for substrate molecules or by an alosteric activation of the remaining active β-subunits by
the presence of propeptide remnants still associated with the inactivated β-subunits. In
conclusion, the three standard fluorogenic substrates can be used as subunit-specific
functional markers. We therefore decided to test the influence of several inhibitors on the
proteolytic activity of yeast 20S wt and mutant proteasomes.
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Figure 2.1-1: Comparison of the ability of wild-type and mutant yeast proteasomes (β2/Pup1-,
β1/Pre3-, β2/Pup1-β1/Pre3- and β5/Pre2-) to catalyze the release of fluorogenic leaving groups
from three different substrates (Z-GGL-AMC, Z-ARR-AMC and Z-LLE-βNA) in the absence of
inhibitors (A, B, C), in the presence of 1mM lactacystin (LC) (D, E, F) and in the presence of
1mM LLnL (G, H, I).
The same amount of proteasome (1µg) was used in each incubation. Substrates were added after an
inhibitor preincubation time of 45 min. Units of fluorescence are drawn to scale arbitrarily. wt, wild-
type yeast proteasome.
2.1.4.2 Proteasome subunits are differentially inhibited by lactacystin, LLnL and DCI
It has been reported previously that the bovine proteasomal subunits corresponding to
yeast β5/Pre2 and β2/Pup1 (Fenteany et al., 1995) or all six human active β-subunits
(Craiu et al., 1997) are inhibited by lactacystin due to covalent binding to the N-terminal
threonine. Soaking of yeast 20S proteasome crystals resulted only in a covalent
modification of the β5/Pre2 subunit (Groll et al., 1997). In our hands, pretreatment of
proteasomes with 1mM lactacystin for 45 min led to absolute inhibition of GGL and ARR
cleaving activity (Figure 2.1-1D and E), but did not have an inhibitory influence on the
LLE-cleaving activity (Figure 2.1-1F). Preincubation of proteasomes with 1mM LLnL for 45
min reduced GGL cleavage by ca. 90% (Figure 2.1-1G), but to our surprise did not
significantly influence cleavage of the ARR and LLE substrates (Figure 2.1-1H and I),
46
despite the fact that the same concentration covalently modified β5/Pre2, β1/Pre3 and
β2/Pup1 in wt 20S yeast proteasome crystals (Groll et al., 1997). Given the established
specificities of the different subunits for the fluorogenic substrates, this finding shows that
in our setup the β5/Pre2 catalytic site can be inhibited by both lactacystin and LLnL,
β2/Pup1 only by lactacystin and β1/Pre3 by neither lactacystin nor LLnL. The vastly
different sensitivity of the proteasomal activities towards lactacystin and LLnL was also
observed in inhibitor titration experiments (data not shown). Possible explanations for the
apparent difference to the crystal structure data, which showed occupation of all active
sites by LLnL and occupation of only β5/Pre2 by lactacystin, will be discussed.
Figure 2.1-2: Influence of 1mM DCI on wt and mutant yeast proteasomes
Incubation time: 2h (open bars: without inhibitor; crosshatched bars: with inhibitor). Substrates were
added after an inhibitor preincubation time of 45 min. The influence of the inhibitor on the β5/Pre2
subunit is shown with GGL (A), on the β2/Pup1 subunit with ARR (B) and on the β1/Pre3 subunit with
LLE (C).
The third inhibitor tested in our study is 3,4-dichloroisocoumarin (DCI). While yeast
β5/Pre2 is clearly sensitive to inactivation by DCI after an 45' incubation, β1/Pre3 is only
weakly affected by DCI concentrations of even 1mM and β2/Pup1 is not affected at all
(Figure 2.1-2). This result is in line with the observation that the three activities in the
bovine pituitary proteasome are inactivated with widely differing rate constants (CT-like >
PGPH-like > T-like) (Orlowski and Michaud, 1989). However, it has also been reported for
the bovine pituitary proteasome that all three classical activities can be inactivated with
micromolar concentrations of DCI and short incubation times (Orlowski et al., 1993). This
cannot be confirmed in our experiments with yeast wt and mutant proteasomes. To inhibit
β1/Pre3 by 50%, the yeast proteasomes had to be pre-incubated in 100µM DCI for 90
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minutes. Lower DCI concentrations or shorter pre-incubation times did not significantly
affect the β1/Pre3 activity (data not shown).
2.1.4.3 "BrAAP" activity as measured with the Z-GAPLA-pAB substrate is catalyzed by
the β1/Pre3 active site
Micromolar concentrations of DCI have been shown to activate an additional proteolytic
component of bovine 20S proteasomes, the "branched chain amino acid preferring"
(BrAAP) component (Orlowski et al., 1993). We therefore tested whether this activity is
also present in yeast 20S proteasomes. The existence of mutant yeast proteasomes gave
us the unique possibility to test whether or not this component, if present, can be
associated with one of the three active β-subunits or whether it represents an additional,
so far unrecognized, active site.
Using the assay introduced by Orlowski et al. to measure the BrAAP activity of the
proteasome (Orlowski et al., 1993), the Z-GPALA-pAB substrate was incubated with the
different yeast proteasome preparations. Generation of the leaving group (pAB) in the
absence of aminopeptidase M (APM) reflects direct cleavage after the C-terminal alanine,
while the liberation of additional pAB in the presence of APM was described as cleavage
after the penultimate leucine residue, generating Ala-pAB in the first place. The cleavage
after Leu is thought to represent the so-called BrAAP activity. Significant BrAAP activity
was found in all proteasome preparations but the one with an inactivated β1/Pre3 subunit.
Here, the addition of aminopeptidase M does not lead to release of additional pAB (Figure
2.1-3C) indicating that cleavage after leucine in the GPALA substrate is catalyzed by the
β1/Pre3 subunit. On the other hand, cleavage after alanine is clearly independent of
β1/Pre3 (Figure 2.1-3C) and can be attributed to β5/Pre2 or β2/Pup1. The finding that the
BrAAP activity is performed by β1/Pre3 is also supported by the fact that this activity
cannot be inhibited by lactacystin, found previously not to influence β1/Pre3 activity
against LLE (Figure 2.1-1F, Figure 2.1-3A, B, D (+APM, +LC)).
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Figure 2.1-3: BrAAP activity of wt and mutant yeast proteasomes
Release of p-aminobenzoic acid from Z-GPALA-pAB as measured by azo coupling with wt (A) and
mutant (B, C, D) proteasomes, with (+APM, hatched bars) and without (-APM) aminopeptidase M,
with (+LC) and without (-LC) lactacystin.
2.1.4.4 Analysis of the degradation of peptide substrates
Most cleavages in long peptide substrates occur after hydrophobic (F, Y, I, L), basic (R, K)
and acidic (D, E) residues (see below), a situation similar to the cleavage of fluorogenic
substrates, which have been related to chymotrypsin-like, trypsin-like and PGPH-like
activities in the proteasome. To investigate whether these cleavages are catalyzed by
three non-overlapping and separate activities, we digested three different peptides with
yeast wt proteasome and the four different yeast mutant proteasome preparations
containing the inactivated β-subunits β2/Pup1-, β1/Pre3-, β2/Pup1-β1/Pre3- and β5/Pre2-.
Products were separated and analyzed by LC-MS. Three typical sets of HPLC profiles
displaying integrated ion currents for the masses of particular degradation products are
shown in Figure 2.1-4.
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Figure 2.1-4: Three examples of HPLC profiles displaying integrated ion currents for the
masses of particular degradation products.
(A) Degradation product 14-17 (ALVR) from the Influenza NP peptide is only generated by
proteasomes with a functional β2/Pup1 subunit. (B) Product 1-6 (HSNLND), also from the Influenza
peptide, is mostly dependent on a functional β1/Pre3 site. (C) Product 8-15 (PHFMPTNL) from the
pp89 peptide depends on the presence of β5/Pre2. wt, wild-type yeast proteasome.
We limited ourselves to the interpretation of only those cleavages showing a dramatic
reduction or complete absence in digestions using mutant proteasomes and avoided to
compare relative amounts of fragments generated under the influence of different
proteasome mutants. The reason for this is that many peptide fragments generated are
intermediate products and subject to further degradation. For quantitative analysis one
would have to consider consecutive cleavages, stabilizing or destabilizing the fragment
under consideration. This kind of analysis would go far beyond the aim of this study.
However, it is possible to recognize a strong requirement for a certain subunit in those
cases where corresponding mutants exhibit no or greatly reduced product formation
(compare Figure 2.1-4).
2.1.4.5 Degradation of the JAK1-21mer peptide
The JAK1-21mer peptide is part of JAK1 tyrosine kinase and contains the MHC class I
ligand SYFPEITHI (Harpur et al., 1993). Incubation of this peptide with mammalian
proteasomes leads to efficient generation of the MHC I ligand (Dick et al., 1996;
Niedermann et al., 1997), which is flanked by two dominant cleavage sites after F7 and I16,
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respectively. The same two cleavages are efficiently catalyzed by the yeast
proteasome, in addition to minor cleavages which are also conserved between the
mammalian and yeast systems. However, the yeast enzyme additionally cleaves after H15,
a cleavage not observed in digests with the mammalian proteasome (Figure 2.1–5).
Cleavage after F7 is β5/Pre2-dependent, since generation of fragments 1-7 and 8-21 is
nearly absent in β5/Pre2-defective proteasomes (Figure 2.1–5A, B). Cleavage after I16 is
also catalyzed by the β5/Pre2 subunit: generation of the fragment 17-21 is nearly missing
in digests with β5/Pre2-deficient proteasomes Figure 2.1–5C). Correspondingly, a
functional β5/Pre2 subunit is necessary and sufficient for the generation of SYFPEITHI (8-
16): β2/Pup1-β1/Pre3- double mutants (which only carry functional β5/Pre2 subunits)
efficiently generate SYFPEITHI, while β5/Pre2- mutants do not generate any detectable
amount (Figure 2.1–5D). The observation that the formation of fragments 1-7, 8-16 and 8-
21 can be completely inhibited with lactacystin (Figure 2.1–5G-I) is in agreement with an
essential role of β5/Pre2 and indicates that β1/Pre3 does not perform this cleavage.
Cleavage after H15 is only detected in mutants with a functional β2/Pup1 subunit, as
demonstrated for fragment 16-21 (Figure 2.1–5E). Cleavage after Y9, leading to FPEITHI
(10-16) in the mammalian system (Dick et al., 1996), also takes place in the yeast system,
albeit much weaker. The minor product FPEITH (10-15) is an example for a fragment that
depends on two different functional subunits: β5/Pre2 for the N-terminal cleavage and
β2/Pup1 for the C-terminal cleavage. Correspondingly, fragment 10-15 is only formed in
digests with proteasomes that contain both β5/Pre2 and β2/Pup1 (Figure 2.1–5F).
2.1.4.6 Degradation of the pp89-25mer peptide
The pp89-25mer peptide is derived from the MCMV pp89 IE-protein and contains the Ld-
presented CTL epitope YPHFMPTNL (Del Val et al., 1991). In digests with the mammalian
proteasome two main products are generated: 8-15 and 5-15, the latter one being a
candidate precursor peptide for the CTL epitope (Dick et al., 1996). Again, the same
dominant cleavage sites and many of the sub-dominant ones are also used by the yeast
enzyme (Figure 2.1–7).
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Figure 2.1-5: Summary of cleavage sites in the JAK1-21mer peptide as digested with the yeast
20S proteasome (top) and data explaining the correlation between cleavages and proteasome
subunits (bottom).
A-F: Integrated ion currents from mass spectrometry for the main peptide products generated from
the JAK1 peptide after 8h incubation with five different proteasome preparations (wild-type (wt),
β2/Pup1-, β1/Pre3-, β2/Pup1-β1/Pre3- and β5/Pre2-). G-I: Relative inhibition of product formation by
lactacystin (LC) (% of product formed without LC) based on integrated ion currents from LC-MS.
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Figure 2.1-6: Summary of cleavage sites in the pp89-25mer peptide as digested with the yeast
20S proteasome (top) and data explaining the correlation between cleavages and proteasome
subunits (bottom).
A-L: Integrated ion currents for the main peptide products generated from the pp89 peptide after 4h
incubation with five different proteasome preparations (wild-type (wt), β2/Pup1-, β1/Pre3-, β2/Pup1-
β1/Pre3- and β5/Pre2-). M-P: Four examples for the influence of lactacystin (LC) on product formation
by the yeast wt proteasome.
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Cleavage after Y4 is essentially β5/Pre2-dependent, since formation of products 1-4 and
5-25 is only present in minimal amounts in β5/Pre2-defective proteasomes (Figure 2.1-6A
and B), and the generation of fragment 1-4 can be inhibited by lactacystin (Figure 2.1-6O).
However, the situation is more complicated for the cleavage after Y7, which takes places
in all mutants tested (Figure 2.1-6C and D). This observation can be explained only if two
different subunits effectively catalyze the same cleavage. The β5/Pre2 subunit is clearly
capable of performing the cleavage, since it takes place efficiently in the β2/Pup1-
β1/Pre3- double mutant. This leads to the question which subunit catalyzes the same
cleavage in the β5/Pre2-defective mutant. Since formation of fragment 8-25 is only weakly
inhibited by lactacystin (Figure 2.1-6P), which affects only β5/Pre2 and β2/Pup1, we
conclude that β1/Pre3 contributes to this cleavage. It should be noted that cleavage after
Y4 is also, but to a much lesser extent, catalyzable by β1/Pre3, explaining the residual
activity observed with β5/Pre2- mutants.
Cleavage after L15 is strictly β5/Pre2-dependent, since all products that terminate in L15
are only observed in the presence of proteasomes with active β5/Pre2 subunits.
Prominent examples are the main products 5-15 and 8-15 (Figure 2.1-6E and F), as well
as fragment 16-25 (Figure 2.1-6G). A rather weak cleavage after M11 is also observed and
is mainly β5/Pre2-dependent (Figure 2.1-6H and I). Cleavage after D5 is almost absolutely
β1/Pre3-dependent (Figure 2.1-6J and K) and therefore not sensitive to lactacystin (Figure
2.1-6M and N). Cleavage after K20 is absolutely β2/Pup1-dependent: fragment 21-25 only
appears when proteasomes with a functional β2/Pup1 subunit are used (Figure 2.1-6L).
2.1.4.7 Degradation of the Influenza NP 24mer peptide
The 24mer peptide from Influenza nucleoprotein contains the Kd-restricted ligand and CTL
epitope TYQRTRALV (147-155) (Rötzschke et al., 1990). Digests with the mammalian
proteasome (unpublished data) confirmed a strong conservation of preferred cleavage
sites with the yeast 20S proteasome. Most dominant cleavage sites are clustered around
the C-terminus of the epitope, some of them destroying the MHC ligand (Figure 2.1–8).
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Figure 2.1-7: Summary of cleavage sites in the Influenza nucleoprotein 24mer peptide as
digested with the yeast 20S proteasome (top) and data explaining the correlation between
cleavages and proteasome subunits (bottom).
A-L: Integrated ion currents for the main peptide products generated from the influenza nucleoprotein
peptide after 2h incubation with five different proteasome preparations (wt, β2/Pup1-, β1/Pre3-,
β2/Pup1-β1/Pre3- and β5/Pre2-).
The overall degradation of the Influenza peptide is dominated by cleavages after arginine
residues, catalyzed by the β2/Pup1 subunit. Degradation of the substrate peptide (1-24) is
significantly retarded in digests with β2/Pup1-defective proteasomes (Figure 2.1–8A). The
most dominant cleavages after R13 and R17 are absolutely β2/Pup1-dependent (Figure
2.1–8B-E) and the same is true for the less pronounced cleavage after R11 (Figure 2.1–
8F). Interestingly, cleavage after A14 is also catalyzed by β2/Pup1, as shown for the
fragments 1-14 and 15-24, which are missing in digests using β2/Pup1-defective
proteasomes (Figure 2.1–8G and H).
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Cleavage after L15 is a more complicated matter. It is performed by all the mutants; the
data shown in Figure 2.1–8I favor the involvement of both β2/Pup1 and β5/Pre2 over
β1/Pre3. The fragment 1-6 is generated by a β1/Pre3 dependent activity cleaving after D
(Figure 2.1–8J). The cleavage after L4 is the most dominant site in the vicinity of the N-
terminus of the CTL epitope. Because of the dominant cleavages mediated by the
β2/Pup1 subunit (especially R13), fragment 5-24 is usually not observed in digests using
proteasomes with active β1/Pup1 subunits. Only in digests with β2/Pup1-defective
proteasomes this fragment can be detected (Figure 2.1–8K). A similar situation applies to
peptide NDATYQRTRALV (5-16) (Figure 2.1–8L), which is a potential precursor of the
CTL epitope TYQRTRALV (8-16). The formation of this peptide is strongly enhanced in
digests with 20S mutants lacking functional β2/Pup1. The finding that this fragment is
generated when mutants with inactive β2/Pup1, but active β5/Pre2 subunit are used
argues strongly for the involvement of β5/Pre2 in this cleavage event. This is also
supported by the result that cleavage after L4 is inhibited by lactacystin (data not shown).
2.1.5 Discussion
2.1.5.1 Cleavage specificity of the proteasomal subunits
Using short fluorogenic peptide substrates in combination with mutant proteasomes
lacking specific subunit activities we found a clear correlation between active subunits and
cleavage specificity. This finding supports the conventional belief that the three "classical"
fluorogenic substrates are cleaved by three different active sites in the proteasome
[β5/Pre2→ hydrophobic; β2/Pup1→ basic and β1/Pre3→ acidic] and can be used as
subunit-specific probes. However, the study of longer peptide substrates (21 to 25 aa) in
the same system led to more complex results: While the formula [β5/Pre2→ hydrophobic;
β2/Pup1→ basic and β1/Pre3→ acidic] can be applied to many of the cleavage sites,
there is a certain class of hydrophobic and small residues that does not obey this simple
rule. Evidence that the specificies of the different subunits might overlap was provided by
the group of Rivett before proteasomes carrying different inactived subunits have been
available. These experiments were performed with the help of inhibitors for the tryptic and
chymotryptic activities (Savory et al., 1993; Reidlinger et al., 1997). A special case is the
so-called BrAAP activity, cleaving after the hydrophobic residue leucine in the model
substrate GPALA, which can now be clearly attributed to β1/Pre3 (Figure 2.1-3) as
suggested previously (Cardozo et al., 1996; Vinitsky et al., 1994). The observed
specificities are summarized for the different subunits in the following paragraphs:
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β2/Pup1 proved to be responsible for all cleavages after basic residues (R, K) without
any exception. This result is in line with the observed specificity towards fluorogenic
substrates. However, β2/Pup1 is not absolutely limited to cleave after basic residues. A
cleavage after alanine was clearly identified as β2/Pup1-catalyzed (Figure 2.1–8G and H)
and there are indications for β2/Pup1-catalyzed cleavages after hydrophobic residues
(Figure 2.1–8I). Thus, β2/Pup1 is also (at least partially) responsible for cleavages after
small and hydrophobic amino acids.
β1/Pre3 catalyzed all observed cleavages after acidic residues (D, E). In addition, β1/Pre3
is responsible for the cleavage after leucine in the GPALA substrate, as mentioned above
(Figure 2.1-3C), and is involved in the cleavage after Y7 in the pp89 peptide substrate
(Figure 2.1-6C and D). This indicates a broader role of β1/Pre3 in cleavages after
hydrophobic residues.
β5/Pre2 is mainly responsible for cleaving after hydrophobic residues, as expected.
However, some of these cleavages are at the same time also catalyzed by β1/Pre3 or
β2/Pup1.
In conclusion, while cleavages after basic and acidic residues strictly correlate with
subunits β2/Pup1 and β1/Pre3, respectively, cleavages after hydrophobic residues can be
the result of β5/Pre2 alone or with contributions by the β1/Pre3 or, apparently to a lesser
extent, the β2/Pup1 subunit. Likewise, cleavage after small residues appears not to be
restricted to a single subunit.
This overlap might be explained by the contribution of the sequence context around
potential cleavage sites as a major factor in determining which subunit will preferentially
cleave after a certain hydrophobic or small residue (and also whether there is cleavage at
all after a suitable P1 residue). The number of cleavage sites analyzed in this study is too
small to make detailed predictions how flanking sequences guide the involvement of the
three active subunits in cleavages after certain residues. Recent results, however, namely
the extensive characterization of more than 400 degradation products from the 436 aa
protein yeast enolase-1 after digestion with wt and mutant yeast proteasomes, support the
assumption that the presence of certain amino acids in several positions around the P1
site strongly influences proteasomal cleavage activities (Nussbaum et al., manuscript in
preparation; see 2.2).
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2.1.5.2 Influence of inhibitors on distinct active sites
Inhibition studies with wt and mutant proteasomes provided evidence that under the
conditions used in our experiments lactacystin is an inhibitor of both the β5/Pre2 and
β2/Pup1 catalytic subunits, but not of the β1/Pre3 subunit, which is only inhibited after
longer preincubation times (> 4h) and at lactacystin concentrations >1mM (data not
shown). This preferential inhibition is in agreement with (Fenteany et al., 1995) who
described an irreversible inhibition of only chymotryptic and tryptic activities and (Craiu et
al., 1997) who showed that the cleavage after a glutamic acid residue (flanking the N-
terminus of the CTL epitope SIINFEKL) cannot be inhibited by lactacystin at a
concentration of 2µM. In crystal structural data of the yeast proteasome lactacystin was
found covalently associated with only the β5/Pre2 subunit (Groll et al., 1997). However,
the experimental conditions of crystal soaking are very different from those above and this
observation cannot exclude a weaker association with β2/Pup1, resulting in inhibition of
the proteolytic activity of this subunit. The preferential interaction of lactacystin with
β5/Pre2 and β2/Pup1 under the conditions used in our experiments proved to be very
helpful because it provided an additional tool to discriminate catalytic contributions made
by the subunits β5/Pre2 and β2/Pup1 versus β1/Pre3. For example, the use of lactacystin
confirmed the association of the BrAAP activity with β1/Pre3 (Figure 2.1-3) and the
contribution of β1/Pre3 to cleavage after the Y7 residue in the pp89 peptide substrate
(Figure 2.1-6P).
The finding that LLnL inhibits only β5/Pre2 in our hands, at concentrations where it
covalently modifies all three active β-subunits in the yeast crystal structure (Groll et al.,
1997), may be explained by the soaking condition of proteasome crystals. The incubation
with the inhibitor solution was performed for a much longer period of time (6h vs. 45').
Indeed, increasing the preincubation time of the inhibitor with proteasome to 90 minutes
resulted in partial inhibition of the β2/Pup1 and β1/Pre3 subunits at LLnL concentrations
>1mM (data not shown). In addition, hemiacetal formation between peptide aldehyde
groups and the active site threonine 1 Oγ may be favored under the conditions of
crystallization. A similar observation was made for the inhibition by DCI. Preincubations
for 45 min with DCI concentrations up to 5mM resulted only in the inhibition of β5/Pre2,
whereas a 90 min preincubation inhibited also β2/Pup1 and β1/Pre3 to 50% at 100µM and
90% at 1mM (data not shown).
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2.1.5.3 No additional catalytic sites in the yeast proteasome
Orlowski et al. (1993) biochemically defined  catalytic components distinct from the three
classical activities (CT-like, T-like and PGPH-like), one of them was called the "branched
chain amino acid preferring" (BrAAP) activity. This component was also assumed to
represent the "caseinolytic" activity of the proteasome (Pereira et al., 1992). Two other
additional, "non-classical" activities were identified and called the "small neutral amino
acid preferring" (SNAAP) (Orlowski et al., 1993) and acidic chymotrypsin-like (aCT-like)
activities (Figueiredo Pereira et al., 1995).
Testing the wt and mutant yeast 20S proteasomes for cleavage activity against the BrAAP
substrate Benzyloxycarbonyl-Gly-Pro-Ala-Leu-Ala-para-Aminobenzoic acid (Z-GPALA-
pAB) (Orlowski et al., 1993), we observed that the cleavage after the penultimate leucine
residue, defined to represent the BrAAP activity, is performed by β1/Pre3. This is evident
from the missing BrAAP activity in the β1/Pre3- mutant (Figure 2.1-3C) and in addition
from the remaining BrAAP activity of the β2/Pup1- and β5/Pre2- mutants in the presence of
lactacystin (Figure 2.1-3B and C), which inhibits β5/Pre2 and β2/Pup1, but not β1/Pre3
under the applied conditions (Figure 2.1-1F). The cleavage after the ultimate alanine
residue is catalyzed by β5/Pre2 and upon lack of β5/Pre2 or upon its preferential inhibition
by LLnL also by β2/Pup1 (data not shown). The cleavage after alanine is also lactacystin
sensitive (Figure 2.1-3A, B, D), supporting the view that either the β2/Pup1 or β5/Pre2
subunit is involved and not β1/Pre3, which is not inhibited by lactacystin under the applied
conditions (Figure 2.1-1F). The finding that the BrAAP component is not only insensitive
to, but even activated by DCI (Orlowski et al., 1993) might be explained by inhibition of the
β5/Pre2 subunit, otherwise competing with β1/Pre3 for the same substrate molecules. In
summary, we conclude that in our system no additional active site apart from the three
threonine protease catalytic centers is responsible for cleaving the GPALA substrate and
that, as defined by the GPALA substrate, β1/Pre3 represents the BrAAP component. No
evidence for additional activities could be found with any of the other substrates tested in
this study. Since the BrAAP or caseinolytic activity has been described as the most
significant among the additional activities, we regard it as unlikely that other putative
activities (SNAAP and aCT) will turn out to be catalyzed by some unconventional,
additional active site.
Since our evidence is based on wt and mutant proteasomes from yeast, we can not
definitely rule out that the bovine proteasomes used by Orlowski et al. (1993) do harbour
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activities that are distinct from the known threonine-type proteolytic subunits. However,
we regard this possibility as unlikely, for the following reasons: (i) proteasomes from yeast
and mammals are conserved in subunit structure and topology (Groll et al., 1997; Kopp et
al., 1997), as well as in cleavage specificity when tested with long peptide substrates
(Niedermann et al., 1997), (ii) yeast proteasomes were highly purified and homogenous in
subunit composition, while bovine proteasomes might represent a mixture of different
species including inducible subunits. This subunit heterogeneity might lead to
experimental complications; (iii) fluorogenic substrates used in our experiments were
shown to be cleaved by the yeast proteasome in a subunit-specific manner. It is still to be
shown that these and other fluorogenic substrates are cleaved in a strictly subunit-specific
manner by mammalian (bovine) proteasomes.
2.1.5.4 Generation of dual cleavage products
In this study we show that the cleavages generating the SYFPEITHI fragment from the
JAK1 peptide and the DMYPHFMPTNL fragment from the pp89 peptide are all performed
by the β5/Pre2 subunit. These results bear on previous experiments performed with
mammalian 20S proteasomes. There, we found that the generation of the same peptides
is boosted by the presence of PA28 (Dick et al., 1996). Meanwhile, this effect was
confirmed (Niedermann et al., 1997) and observed with additional peptide substrates
(Dick et al., unpublished data). In the absence of PA28, the N- and C-terminal cleavages
that generate an internal fragment occurred independently from each other and could be
outcompeted with excess substrate. Kinetics and competition experiments in the presence
of PA28 however indicated that the second cleavage did not take place independently
from the first cleavage (Dick et al., 1996). These observations led us to propose the model
where two concerted cleavages take place between two neighbouring subunits.
However, the crystal structure of the yeast proteasome made clear that the two β5/Pre2
subunits are not direct neighbours in the 20S particle and are also isolated from the
β1/Pre3 and β2/Pup1 subunits. An identical subunit topology is expected for the
mammalian proteasome (Kopp et al., 1997). Consequently, the positive influence of PA28
on the formation of internal fragments is unlikely to be based on a simultaneous cleavage
event performed by the β5/Pre2-corresponding subunits MB1/LMP7. Furthermore, the
distance from MB1/LMP7 to either Z/MECL1 or δ/LMP2 is too long to generate peptides of
9-11 amino acids by a simultaneous cleavage event. Whether or not β2/Pup1 (Z, MECL-1)
and β1/Pre3 (δ, LMP2), which are neighbours in the same β-ring, might be involved in the
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generation of internal fragments from peptide substrates under the influence of PA28
cannot be tested in the yeast system. No PA28-homologous protein is present in the yeast
genome and we could not find significant activation or modulation of the yeast proteasome
by human PA28 (data not shown). Studies with mammalian proteasomes and inhibitors at
conditions that selectively affect the different proteasomal activities are currently
performed to address the involvement of the neighbouring subunits Z/MECL-1 and
δ/LMP2 in the generation of internal fragments when PA28 is present. Of special interest
here is whether PA28 is able to influence the specificity of subunits Z/MECL-1 and
δ/LMP2 to allow a participation in cleavages after hydrophobic amino acids that might now
be able to generate the SYFPEITHI and the DMYPHFMPTNL fragments by a concerted
cleavage event. Our finding that β2/Pup1 and β1/Pre3 are able to cleave after
hydrophobic amino acids is in favor of this possibility.
Because we used peptide substrates of only up to 25aa in this study, we did not
investigate the length of the fragments generated from wild-type or mutant yeast
proteasomes in detail. It is however interesting to note that the size of internal fragments
generated from synthetic peptide substrates centers around seven amino acids and that
the average fragment length does not seem to differ between wild-type and mutant
proteasomes with fewer threonine active sites. This is of interest because some of us
(Löwe et al., 1995) had suggested that the distance between the subunits carrying the
threonine active sites corresponding to an octapeptide in extended conformation,
determines the length of fragments generated. The data here do not support this
hypothesis. Whether or not this model is correct will be answered by the detailed analysis
of proteasomal digestion products of the yeast enolase-1 protein, where more than 400
protein fragments, generated in digestions with yeast wild-type and mutant proteasomes,
were characterized (Nussbaum et al., manuscript in preparation; see 2.2 for details).
In addition, in the yeast proteasome, processing intermediates cleaved at residues -8 and
-9 of subunits β7/Pre4 and β6/C5 were observed in well defined conformations (Groll et
al., 1997). This led to the suggestion of the existence of an additional unspecific hydrolytic
site at the inner β-annulus of the proteasome. The results presented previously
(Heinemeyer et al., 1997) and here argue against this hypothesis. A reconsideration of the
hydrolytic activity at the inner β-annulus must await the results of the analysis of
processing intermediates in proteasomes with inactivated β-subunits which is on the way
(Groll et al., manuscript in preparation).
The analysis of the proteolytic activity of the yeast proteasomes also revealed that the
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dominant cleavage activity was performed by the β5/Pre2 subunit, generating
hydrophobic C-termini. This effect is even more enhanced by the contribution of the
β2/Pup1 and β1/Pre3 subunits to cleavages after hydrophobic residues as well. We are
aware of the fact the yeast 20S proteasomes lack the interferon-inducible β-subunits of
mammalian proteasomes. But there is no evidence that the presence of these subunits
does alter the specificity of the proteasome in a way that will induce the generation of new
cleavage sites. The only differences observed so far are changes in the quantity of
peptide fragments generated when proteasomes from interferon-induced or LMP2/LMP7
transfected cells were analysed (Niedermann et al., 1997; Groettrup et al., 1995).
Therefore, our results will describe most of the cleavage performed in mammalian
proteasomes as well and provide an explanation for the dominance of hydrophobic
residues at the C-termini of MHC class I ligands. Because the proteasome does not
cleave after every hydrophobic, basic or acidic amino acid however, there must be rules
that govern the selection of cleavage sites. These rules are not evident in the limited set of
data available here but will be looked for in the more than 400 fragments generated from
the yeast enolase-1 protein (Nussbaum et al., in preparation; see 2.2 for details). If it is
possible to identify rules that guide the interaction of substrate molecules with the
proteasome and therefore allow a partial prediction of protein processing, the forecast of
CTL epitopes, which so far is based on MHC ligand motifs only, will become much more
accurate. The knowledge of subunit contribution to the generation of CTL epitopes will
also be extremely useful for the development of subunit-specific proteasome inhibitors
that suppress the generation of some CTL epitopes, enhance the production of others but
do not affect the entire proteasomal activity.
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HPLC high pressure liquid chromatography
LC-MS liquid chromatography-mass spectrometry
LLnL N-acetyl-L-leucinyl-L-leucinal-L-norleucinal
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2.2 The cleavage motifs of yeast 20S proteasomes deduced
from digests of enolase-1
2.2.1 Summary
The 436-amino acid protein enolase-1 from yeast was degraded in vitro by purified wild-
type and mutant yeast 20S proteasome particles. Analysis of the cleavage products at
different time points revealed a processive degradation mechanism and a length
distribution of fragments ranging from 3-25 amino acids with an average length of 7 to 8
amino acids. Surprisingly, the average fragment length was very similar between wt and
mutant 20S proteasomes with reduced numbers of active sites. This implies that the
fragment length is not influenced by the distance between the active sites, as previously
postulated. A detailed analysis of the cleavages also allowed the identification of certain
amino acid characteristics in positions flanking the cleavage site that guide the selection
of the P1 residues by the 3 different active β-subunits. Since yeast and mammalian
proteasomes are highly homologous, similar cleavage motifs might be employed by
mammalian proteasomes. Therefore, our data provide a first basis for predicting
proteasomal degradation products from which peptides are sampled by MHC class I
molecules for presentation to cytotoxic T cells.
2.2.2 Introduction
The eukaryotic 20S proteasome represents the catalytic core particle of the 26S
proteasome which is an essential component of the ubiquitin-dependent protein
degradation pathway. The 20S particle is composed of 14 different but related subunits.
Two outer disks, containing 7 α-subunits each, guard the two inner heptameric β-subunit
rings, which contain three proteolytically active sites each (Groll et al., 1997). How
substrate molecules gain access to the active sites at the inner surface of the β-rings is
not known. It has been hypothesized that upon association of the 20S particle with
regulatory complexes, like the 19S cap structure or PA28, an opening in the middle of the
α-subunit rings is induced allowing unfolded proteins to be fed into the 20S particle.
Probably as a consequence of this closed structure, very few proteins have been found to
be degraded by 20S proteasomes in vitro and only very few individual fragments and
cleavage sites generated during the degradation of proteins by eukaryotic 20S
proteasomes have been analyzed until now. This kind of analysis is of interest for several
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reasons.
 First, it still has to be confirmed that the specificities of the proteasomal β-subunits
observed in experiments using peptide substrates (Orlowski and Michaud, 1989; Cardozo
et al., 1992; Heinemeyer et al., 1997; Niedermann et al., 1996; Niedermann et al., 1997;
Dick et al., 1996), summarized as trypsin (T)-like, chymotrypsin (ChT)-like and
peptidylglutamyl-peptide hydrolyzing (PGPH)-activity, correspond to cleavages performed
in intact proteins, a situation physiologically more relevant.
Second, the mechanism of protein degradation by the proteasome is not known. For the
archebacterial proteasome, which is a less complex structure consisting of 14 identical α-
and β-subunits (Löwe et al., 1995), a processive model has been proposed (Kisselev et
al., 1998; Akopian et al., 1997). Because of the high structural homology with the
archebacterial particle a similar mechanism can be expected for eukaryotic proteasomes.
Furthermore, it has been postulated that the 20S proteasome is equipped with a
molecular ruler that determines the length of fragments generated (Wenzel et al., 1994).
In the archebacterial proteasomes, the ruler was postulated to reflect the distance
between each of the seven active β-subunits (Dick et al., 1994). Therefore, a reduction of
active sites is predicted to change the average length of fragments generated. In yeast
proteasomes carrying only three active sites, another kind of ruler was proposed to reflect
the distance of the 3 active β-subunits to putative proteolytically active sites at the
carboxy-terminal ends of α-helices at the β-annulus (Groll et al., 1997). Two studies
recently performed using yeast 20S mutant proteasomes with inactivated β-subunits,
however, excluded the latter model and revealed instead that no proteolytically active
sites exist within the proteasome besides the β-subunits containing the active site Thr
(Dick et al., 1998; Ditzel et al., 1998). The factor determining the length of the degradation
products is therefore imposed either by the distance between the three active sites,
analogous to the prediction for the Thermoplasma model, or by so far unknown
mechanisms.
The third reason for an in-depth analysis of fragments resulting from proteasomal protein
digests is the lack of knowledge about the selection of cleavage sites during the
degradation of substrates. Why the proteasome selects certain cleavage sites and ignores
others with identical P1/P1' composition is not known at all. A compilation of cleavage
sites from a large panel of fragments should be very helpful in identifying amino acid
motifs that explain the selection and allow the prediction of cleavage sites. Because the
subunit topology and structure of mammalian proteasomes is analogous to that of yeast
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(Kopp et al., 1997), the results will provide crucial information for the general
understanding of the proteasomal activity.
We therefore examined in detail peptide fragments generated in digestions of yeast
enolase-1 protein by wt and mutant yeast 20S proteasomes containing inactivated β-
subunits (Heinemeyer et al., 1997). Degradation products of the individual digests were
analyzed for processive substrate degradation, fragment length and the presence of
cleavage motifs recognized by the three proteasomal subunits β2/Pup1, β1/Pre3 and
β5/Pre2. The data obtained allow us to present proteasomal cleavage maps of a large,
unmodified protein for the first time. We find strong evidence for a processive degradation
of the protein substrate and demonstrate that the number of active sites does not affect
the average fragment length. From this we can exclude that the rules governing the
fragment length in yeast 20S proteasomes are the result of the distance between active
sites. The detailed analysis of cleavage sites in digests using wt and mutant yeast
proteasomes also allows us for the first time to propose distinct cleavage motifs for the
three active sites of eukaryotic 20S proteasomes that go far beyond the specificities
described using peptide substrates.
2.2.3 Materials & Methods
2.2.3.1 Generation of mutant proteasomes and purification of yeast 20S proteasomes
Generation of yeast proteasome mutants and the purification of yeast 20S proteasomes
has recently been described elsewhere (Groll et al., 1997; Heinemeyer et al., 1997).
2.2.3.2 HPLC-Separation of enolase digests
For the separation of degradation products unfractionated enolase digests were subjected
to µRP SC 2.1/10-columns (Pharmacia) on a Microbore HPLC-system (SMART-system,
Pharmacia). Buffer A: 0,1% TFA; buffer B: 0,081% TFA, 80% acetonitril. Gradients were
10% B for 5 min, in 35 min to 40% B, in 8 min to 75% B and up to 85% in another 7 min at
a flow rate of 150 µl/min.
2.2.3.3 Fragmentation of degradation products
Ms/ms experiments were performed on a hybrid quadrupole orthogonal acceleration
tandem mass spectrometer (Q-TOF, Micromass). Fragmentation of the parent ions was
achieved by collision with argon atoms. Q1 was set to the mass of interest +/- 0.5 Da and
the collision energy optimized for each fragment. Integration time for the TOF analyzer
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was 1s with an inter scan delay of 0.1s.
2.2.3.4 Digestions
Digests were incubated at 37ºC and stopped by freezing at -20ºC. Conditions in all digests
were:  0,01% SDS, 10mM EDTA at molar ratios of enolase (10-20 µM) to 20S proteasome
(40-60 nM) of 200-400:1. Buffer: 20mM Hepes-KOH, pH 7.6, 2mM MgAc2, 1mM DTT.
2.2.3.5 MALDI MS analysis
1 µl of DHAP-matrix (20mg 2,5-dihydroxy-acetophenon, 5mg ammoniumcitrate in 1ml
80% isopropanol) was mixed with 1 µl of each HPLC peak fraction on a gold target.
Measurements were executed using a LD-TOF (laser desorption- time of flight)-system
(Hewlett-Packard G2025A) at a vacuum of 10-6 Torr. For signal generation 50 to 150 laser
shots were added up in the single shot mode.
2.2.3.6 N-terminal sequencing (Edman degradation)
Routinely, 15 µl of each HPLC peak fraction from digest fractionations were applied to the
pulsed-liquid sequencer Procise 494 (Applied Biosystems).
2.2.3.7 Statistical analysis
2.2.3.7.1 Frequencies of amino acids.
The probability q(k) for finding a given amino acid exactly k times in a given position by
random selection of cleavage sites (considering that each single peptide bond can be
randomly selected only once for each enolase molecule) can be calculated according to
the hypergeometric distribution.
q(k) values were used to calculate 2-sided tail probabilities p to indicate deviation of
observed frequencies from a random selection of certain amino acids at a given position.
Because we considered positions P6 to P6' surrounding a cleavage site the total number
of potential cleavage sites (N) in enolase-1 was reduced from 435 to 425.
2.2.3.7.2 Comparison of amino acid characteristics.
To compare the characteristics of amino acids the 2-sided Student's t-test for two
independent data sets was performed. Hydropathicity parameters were taken from Kyte
and Doolittle (Kyte and Doolittle, 1982), bulkiness parameters from Zimmerman et al.
(Zimmerman et al., 1968), and normalized frequency parameters for beta-turn from Levitt




2.2.4.1 Degradation of enolase-1
Denaturation of proteins is a prerequisite for their digestion by 20S proteasomes. In order
to perform digestions of proteins without prior covalent modifications we used protein
substrates known for their thermolability, like yeast enolase-1. Enolase-1 was incubated
with yeast 20S proteasomes at a molar ratio of about 300:1. Aliquots were taken at
different time points and separated by reversed phase HPLC. Peaks containing
degradation products increase over time, while the signal for undigested enolase
disappears (Figure 2.2-1).
Figure 2.2-1: Enolase-1 degradation by yeast wt 20S proteasomes
Percent values represent the degree of enolase degradation as determined by linear regression.
(Bottom) Dotted line in lower panel: Incubation of enolase without proteasome.
Substrate degradation was linear with a degradation velocity of 6 min (data not shown).
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The observed stability of the peak pattern over time and the lack of larger enolase-1
fragments, especially at early time points (Figure 2.2-1) argue for a processive substrate
degradation mechanism as proposed for the Thermoplasma proteasome (Akopian et al.,
1997). The peaks A-E observed at different digestion times indeed contained identical
fragments as determined by MALDI-MS analysis and Edman degradation (data not
shown). The fragments in the range of 12 minutes coelute with digestion buffer
components and the peak height therefore does not reflect the amount of peptides.
2.2.4.2 Digestion map of enolase-1 by wt yeast 20S proteasomes
All peak fractions obtained during reversed-phase HPLC separation of digests were
analyzed by MALDI-MS, Edman sequencing and Q-ToF-MS/MS analysis and compiled
into a digestion map (Figure 2.2-2). The digests were reproduced two times, yielding
comparable HPLC profiles.
Figure 2.2-2: Digestion map generated from degradation of enolase-1 by yeast wt 20S
proteasomes
Vertical lines: Cleavage sites determined by Edman degradation and mass spectrometry. Closed
bars ( ): Degradation products identified by Edman degradation and mass spectrometry.
Open bars ( ): Degradation products identified by Edman degradation; C-terminus not yet
confirmed by mass spectrometry.
As summarized earlier (Coux et al., 1996), proteasomes are able to perform cleavages
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after almost every amino acid, whereby some residues are disfavored (such as Pro,
Gln, Asn, Gly, Thr, Ser and Lys) and others favored (Ile, Leu, Trp, Tyr, Asp and Arg) (see
Table 2.2-1 for details). The selection of amino acids at positions flanking the cleavage
sites will be discussed later.
Three conclusions can be drawn from the observed cleavages: (i) the yeast 20S wt
proteasome clearly prefers certain peptide bonds over others as cleavage sites; (ii) not all
possible cleavage sites are used in one individual substrate molecule, resulting in the
production of overlapping peptides; (iii) some regions of the enolase sequence are
characterized by a high number, others by a low number of cleavage sites. This clustering
cannot be correlated to charge clusters and repetitive elements which were not detected
in the enolase-1 sequence using the SAPS program (Brendel et al., 1992). The fragments
identified (n=66) in a single digest of enolase by wt 20S proteasomes cover a range of 3-
23 amino acids (Figure 2.2-4). Fragments with a size of 3-9 amino acids clearly dominate
with a mean fragment length of 7.5 amino acids (SD = 3.5). The digestion of enolase-1
using human 20S proteasomes resulted in a similar set of fragments, indicating a highly
conserved selection of cleavage sites (Nussbaum et al., in preparation; see 2.2.9).
2.2.4.3 Digestion of enolase-1 by mutant yeast 20S proteasomes
To analyze the contribution of the three active β-subunits to the observed cleavages we
digested enolase-1 with the following mutant yeast 20S proteasomes carrying inactivated
β-subunits, which were purified from the following mutant strains: pre2-K33A, pup1-T1A,
pup1-T1A pre3-T1A and pre3-T1A (Heinemeyer et al., 1997). Cleavage activity was
analyzed as described for wt proteasomes. The β2/Pup1- proteasome did not cleave
peptide bonds after basic amino acids (Figure 2.2-3A, Table 2.2-1), the β1/Pre3- particle
performed only one of the 17 cleavages found in wt proteasomes after acidic residues
(Figure 2.2-3B, Table 2.2-1) and the β2/Pup1-β1/Pre3- proteasome completely lacked
proteolytic activity after basic and acidic residues (Figure 2.2-3C, Table 2.2-1). The
β5/Pre2- proteasome, completely lacking ChT-like activity as tested with fluorogenic
substrates (Heinemeyer et al., 1997; Dick et al., 1998), surprisingly performed a high
number of cleavages after hydrophobic amino acids (Figure 2.2-3D, Table 2.2-1).
Because yeast 20S proteasomes contain no proteolytically active sites besides the three
active β-subunits, the β1/Pre3 and β2/Pup1 subunits, previously thought to cleave only
after charged residues, also harbor ChT-like activity. These features were already
observed during the analysis of synthetic peptide substrates digested with the same
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mutant proteasomes (Dick et al., 1998) and during experiments using inhibitors of the
T-like and ChT-like activities (Savory et al., 1993; Reidlinger et al., 1997).
Figure 2.2-3: Digestion maps generated from degradation of enolase-1 by yeast mutant 20S
proteasomes
The maps include all the degradation products of enolase-1 identified after digestion by (A) β5/Pre2-,
(B) β2/Pup1-, (C) β2/Pup1-β1/Pre3-, (D) β1/Pre3- 20S proteasomes. Degradation products were
identified by Edman degradation and mass spectrometry. Symbols as in Figure 2.2-2.
In addition, the number of cleavages after basic and acidic residues performed by the
β5/Pre2- particle was increased compared to wt proteasomes, most likely due to lack of
competing cuts normally performed by the β5/Pre2 subunit. Even more surprising, all
mutant proteasomes generated fragments of an average length of 7-9 amino acids (7.9,
SD=3.5 for β5/Pre2-; 7.9, SD=3.3 for β2/Pup1-; 8.8, SD=4.3 for β2/Pup1-β1/Pre3-; 7.8,
SD=3.5 for β1/Pre3-), which is in the range of fragments generated by wild-type
proteasomes (Figure 2.2-4). Therefore, the size of fragments generated by yeast
proteasomes is not related to the distance between the active β-subunits, as postulated
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previously for the Thermoplasma proteasome (Wenzel et al., 1994).
Figure 2.2-4: Distribution of fragment lengths generated by wt and mutant proteasomes from
enolase-1
For each proteasome only internal fragments with known C-terminus and identified from one single
digestion experiment were included. M: mean fragment length. SD: standard deviation. n: number of
interanl fragments identified. Numbers to the right: Number of active β-subunits present in the
different proteasome species.
2.2.4.4 P1 amino acids and statistical analysis of flanking residues
The observed frequencies of amino acids in the P1 position of fragments generated by
wildtype and mutant proteasomes indicate dominant cleavages after Leu or Arg, which are
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used approximately every second time these residues appear in enolase-1. On the
other hand, only 2 of 37 Gly residues are used for cleavage (Table 2.2-1). Despite
exerting a significant influence, the P1 amino acid is obviously not the only factor
determining the location of a cleavage site. By considering only the P1 position for
example, it remains unclear why cleavages were detected after certain Leu residues, but
not after other Leu residues.
Table 2.2-1: Frequencies of amino acids in the P1 position
















Ala 55 11 10 13 10 10
Arg 14 8 0 5 0 9
Asn 19 3 1 3 1 3
Asp 31 12 9 1 0 14
Cys 1 1 0 0 0 0
Gln 9 0 1 2 1 1
Glu 25 6 8 1 0 9
Gly 37 2 0 2 1 2
His 11 2 0 1 1 2
Ile 22 7 7 6 8 3
Leu 40 19 16 18 20 10
Lys 37 4 0 3 0 4
Met 5 1 0 1 1 1
Phe 16 5 8 9 8 2
Pro 15 0 0 0 0 0
Ser 31 5 2 3 4 8
Thr 20 2 1 2 1 0
Trp 5 4 4 4 4 2
Tyr 9 3 7 4 7 5
Val 34 10 6 10 6 11
This table only comprises cleavage sites that are not within the 6 N- or C-terminal aa; i.e. it only
contains cleavage sites that were also included in the statistical analysis. Therefore, wt and β2/Pre2-
have each 1 cleavage site fewer than in the cleavage maps (Figure 2.2-2 and Figure 2.2-3).
In order to statistically evaluate the frequency of all amino acids in positions ± 6
surrounding cleavable peptide bonds, we compared the observed frequencies with those
frequencies expected from a random cleavage distribution. Using the hypergeometric
distribution, a value is assigned to each amino acid in every position, representing the
probability (p) for the observed frequency to be the result of randomly distributed
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cleavages. A statistically significant accumulation or scarcity of particular amino acids in
certain positions is taken as an indication for a positive or negative influence on the
selection of peptide bonds hydrolyzed by the proteasomal subunits. To justify this
approach, a set of cleavages of the same size as the data set was generated by a random
number generator and statistically evaluated as a control, resulting in no significant
accumulation of amino acids (data not shown).
2.2.4.5 Specificity of the wildtype proteasome
Examination of cleavages performed by the wildtype proteasome (n=105) revealed the
following deviations from randomness in the cleavage pattern (p values are two-sided tail
probabilities). Leu as a P1 residue has the highest significance (p<0.00082) and reflects
pronounced ChT-like activity within wt proteasomes. Weaker preferences for Arg in P1
(p<0.0084), Pro in P4 (p<0.0033) and Gln in P5 (p<0.0011) are also evident. On the other
hand, certain residues appear to exert negative influence in certain positions. In the P1
position, Gly is less abundant than expected (p<0.0011). When observed cleavage sites
(n=105) are compared to the remaining sites (not observed as cleavage sites, n=320)
using the two-sided Student's t-test, a preference for small residues becomes apparent in
P1' (p<0.0072; 1.57 ± 1.15).
2.2.4.6 Specificity of the β5/Pre2 active site
To evaluate a 'cleavage motif' for a single active β-subunit, in this case β5/Pre2,
cleavages performed by the β2/Pup1-β1/Pre3- 20S particle were analyzed (n=73). The
statistical analysis clarifies the order of preference for the different hydrophobic P1
residues relative to their abundance in the substrate: Leu (p<0.0000003) > Tyr (p<0.0001)
> Phe (p<0.002) > Trp (p<0.0035) > Ile (p<0.02), but no accumulation is apparent for Val.
This is, however, in agreement with recent studies on the cleavage of peptide substrates,
indicating that cleavage after Val can be efficiently catalyzed by β2/Pup1 (Dick et al.,
1998). Similar to the wt proteasome, Gly is disfavored in the P1 position. When amino
acids are grouped (hydrophobic, basic, acidic and others) the preference for hydrophobic
residues in P1 is even more impressive (p<3*10-17) together with a weak preference for
basic residues at P1' (p<0.0012). When comparing the observed cleavages (n=73) to the
remaining sites (n=352), the following preferences are observed: In positions P3 and P5'
polar residues are clearly favored over non-polar ones (p<0.000072; 1.54 ± 0.75 and
p<0.0032; 1.15 ± 0.76, respectively) and a preference for β-turn-promoting residues is
seen in position P3 (p<0.0093; 0.13 ± 0.10). To determine more precisely why β5/Pre2
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selects certain Leu as P1 residues, but not others, observed cleavage sites with Leu in
P1 (n=20) were compared to the corresponding unobserved sites with Leu in P1 (n=19):
Again there is a positive correlation between cleavage and the presence of polar
(p<0.00076; 3.2 ± 1.8) and turn-promoting residues (p<0.0022; 0.38 ± 0.24) in the P3
position.
2.2.4.7 Certain cleavages are not restricted to a single active site
β5/Pre2-catalyzed cleavages as defined by the β2/Pup1-β1/Pre3- double mutant (n=73)
should belong to a set complementary to that provided by the β5/Pre2- mutant (n=96).
However, there is considerable overlap between these two sets of cleavages. Cleavages
common to both β5/Pre2- and β2/Pup1-β1/Pre3- proteasome digests (n=31) therefore
represent features not dependent on a single subunit. We find Tyr preferred at the P1
position (p<0.0002) and Pro at P4 (p<0.0003). When comparing cleavage sites of this
intersecting subset (n=31) against the remaining sites (n=394), P1 residues tend to be
more hydrophobic (p<0.0013; 1.8 ± 1.1) and P3 residues more hydrophilic (p<0.00023;
2.1 ± 1.1).
2.2.4.8 Specificity of the β2/Pup1 active site
Because the respective double mutant proteasomes were not available, the motifs for
β2/Pup1 and β1/Pre3 subunits must be approximated. One possibility for approximating
β2/Pup1-specificity is to consider those cleavages catalyzed exclusively by β1/Pre3-
 proteasomes (n=88), but not by β1/Pre3- β2/Pup1- proteasomes (n=73). For these
cleavages (n=41) analysis points out weak preferences for Gly in position P1' (p<0.001)
and Pro in position P3' (p<0.001). Another possibility of approaching the β2/Pup1 motif is
to look at those cleavages common to both β1/Pre3- (n=88) and β5/Pre2- (n=96)
proteasomes, which should mostly originate from the β2/Pup1 subunit (n=46). Analysis of
amino acid frequency reveals a strong preference for Pro in P4 (p<0.00004) and P3' and
Lys in P3 (p<0.0031). However, this set of 46 cleavages includes 31 cleavages that can
be found in either β1/Pre3-β2/Pup1- or β2/Pup1- proteasomes and therefore belong to the
category of cleavages that are not subunit-specific. Analysis of the remaining 15, strictly
β2/Pup1-specific cleavages reveals Arg in P1 (p<0.000044), Pro in P3', Gly in P1', but not
Pro in P4, again showing that the preference for Pro in P4 is strongly associated with
those cleavages that can be catalyzed by more than a single subunit.
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2.2.4.9 Specificity of the β1/Pre3 active site
Again, there are several possibilities of approximating a β1/Pre3 cleavage motif. Looking
at those cleavages common to both digests with proteasomes lacking active β5/Pre2
(n=96) and active β2/Pup1 subunits (n=80), the intersecting set includes 44 cleavages:
Pro in P4 is the most prominent feature (p<0.000002), followed by Tyr in P1 (p<0.0009). If
those cleavages not specific to a single subunit are eliminated, only 14 cleavages remain
as truly β1/Pre3-specific. Asp now is significant in P1 (p<0.0000007) and Glu in P1 also
becomes evident (p<0.0063). Comparing the cleavages common to proteasomes with
active β1/Pre3 subunits (n=44) against the remaining sites of enolase (n=381), the P5
position turns out to prefer hydrophilic residues (p<0.0001; 3.2 ± 1.6). The P3 position
favors hydrophobic residues (p<0.00061; 2.82 ± 1.6) and disfavors turn-promoting
residues (p<0.0076; 0.29 ± 0.21). If cleavages with Asp or Glu in P1 (n=31) are compared
against the remaining Asp and Glu sites (n=24), amino acids at the P4' position tend to be
more hydrophobic (p<0.0056; 2.07 ± 1.43). The proposed cleavage motifs are
summarized in Table 2.2-2.
2.2.5 Discussion
The specificity of 20S proteasomes has been investigated so far either by the use of
peptide substrates and inhibitors of the proteasomal activities. To analyze the
proteasomal specificity under more physiological conditions we established a protocol that
allowed the digestion of an entire protein, yeast enolase-1, without denaturation by
covalent modification of amino acids. The identification of more than 400 enolase-1
fragments generated in digests using wild-type and mutated yeast 20S proteasomes
carrying different combinations of inactivated β-subunits allowed a detailed analysis of the
length of fragments generated, proteolytic specificity, β-subunit contribution to the
observed cleavages and a description of motifs that explain the selection of cleavage
sites.
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Table 2.2-2: Cleavage motifs of yeast 20S active subunits
Position
































*Amino acids in parentheses indicate P values below the significance level after the adjustment for
multiple testing according to the Bonferroni method (Bland and Altman, 1995). Significances are,
however, supported by amino acid characteristic analysis or crystal structure data. A minus indicates
a disfavored amino acid.
2.2.5.1 Protein degradation and fragment length
We determined a duration of 6 min for the degradation of one molecule of enolase by one
yeast wt 20S proteasome. This value is in the range of activities found so far for
degradation of whole proteins by eukaryotic and archaeal 20S proteasomes (Kisselev et
al., 1998; Dick et al., 1994; McGuire et al., 1989; Dick et al., 1991), but is likely to be far
from physiological levels. In vivo it takes less than 60 min from viral infection to MHC class
I restricted presentation of viral peptides to cytotoxic T cells (Hosken et al., 1989).
Numerous possibilities can explain this discrepancy, ranging from the lack of crucial
components in the digestion buffer to missing in vivo 'helpers of proteasomal proteolysis'
such as the 19S cap complex, hsc70 (Bercovich et al., 1997) or activators such as PA28
in mammalian cells (Dick et al., 1996; Dubiel et al., 1992; Ma et al., 1992; Groettrup et al.,
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1996).
Our experiments using yeast 20S proteasomes and enolase-1 as a substrate show a very
stable pattern of degradation products in HPLC-separated digests over time (Figure 2.2-1)
as reported for the Thermoplasma 20S proteasome (Kisselev et al., 1998; Akopian et al.,
1997). In addition, the same degradation products could be identified at early time points
when only 5% of the substrate is degraded and also at late time points when 95% of the
substrate molecules are digested (data not shown). This demonstrates that final
degradation products are generated without the presence of large degradation
intermediates.
The finding that all proteasomes analyzed so far generate peptides with an average length
of 7-9 amino acids led to the proposal of an intrinsic molecular ruler determining the
fragment size (Groll et al., 1997; Löwe et al., 1995; Wenzel et al., 1994). Our finding that
proteasomes carrying 6, 4 or 2 active β-subunits generate fragments of similar length
strongly argues against the distance between the active sites influencing the length of
proteasomal digestion products (Figure 2.2-4). The small fragment length increase from
the wild-type proteasomes to the β1/Pre3-β2/Pup1- proteasomes is most likely due to lack
of cleavage activity after charged amino acids which represent 25% of the amino acids in
enolase-1. Our observed fragment length distribution is also in agreement with recent
results using partially modified protein substrates and archaeal proteasomes (Kisselev et
al., 1998). An explanation might be that proteasomes either have an exit size filter
preventing the dissociation of products above a certain size or that active β-subunits
preferentially bind polypeptide stretches of 7-8 amino acids. The nonsymmetrical shape of
the fragment length distributions (Figure 2.2-4) might indicate a log-normal distribution of
the fragment size, as postulated (Kisselev et al., 1998; Akopian et al., 1997). The fact that
the main part of cleavage products does not fall into the range of MHC-ligands (8-10aa)
probably mirrors the predominant contribution of the proteasome to general intracellular
proteolysis, which preceded its participation in antigen processing in evolution.
2.2.5.2 Specificity and selectivity of the active β-subunits
Analysis of the specificity of the different β-subunits revealed that the β5/Pre2 subunit is
responsible for the ChT-like activity, as expected. Proteasomes containing inactivated
β2/Pup1 or β1/Pre3 subunits lacked only cleavage activity after basic or acidic residues,
respectively. By analyzing the cleavage sites performed by the double mutant containing
β5/Pre2 as the only active subunit we found the strongest selection for Leu in P1 followed
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by Tyr, Phe and Trp. By comparing the flanking residues around the β5/Pre2 cleavage
sites with the rest of the observed cleavages we found a strong preference for polar and
β-turn promoting amino acids at P3. This observation correlates to characteristics of
amino acids at the inner surface of the proteasome surrounding the active site Thr1 of
β5/Pre2. A polar pocket formed by His98, Asp114, Glu120 and Arg125 of the β6/C5
subunit might accommodate P3 residues of substrates. A similar situation might exist at
the P1' position, where basic residues are enriched and might interact with the negatively
charged side-chains of Asp114 and Asp116 of  β5/Pre2.
The analysis of cleavages performed by β2/Pup1 revealed a preference for Arg over Lys
in P1. The reasons for this selectivity are not known but have already been observed
(Ossendorp et al., 1996). Flanking residue analysis revealed also an enrichment of Lys at
P3 of the fragments generated by β2/Pup1. The basic side-chain might interact with an
acidic pocket formed by Asp28 (β2/Pup1) and Asp114, Glu120 and Glu121 of β3/Pup3.
On the P' side, flexible and β-turn promoting amino acids like Gly at P1' and Pro at P3' are
enriched. This feature of β2/Pup1 substrates might be imposed by amino acids, including
His35 of β2/Pup1, which block the end of a putative substrate binding cleft and thus
require substrate bending.
The β1/Pre3 subunit favors aspartate over glutamate in P1 and at position P5 polar amino
acids, and at position P3 hydrophobic residues are enriched. Whether these features are
reflected by the amino acids surrounding the active site Thr1 remains to be determined.
Surprisingly, the β2/Pup1 and β1/Pre3 subunits also contribute substantially to the ChT-
like activity as evident from the analysis of the β5/Pre2- proteasome, where only a slight
reduction in the number of cleavages after hydrophobic amino acids was found. After
analyzing the cleavages performed by the β5/Pre2- and the β2/Pup1-β1/Pre3-
proteasomes, expected to contain complementary sets of cleavage sites, 31 identical
cleavages were found in both groups. By examining the residues flanking these cleavage
sites, we found Pro at P4 significantly enriched possibly favoring a turn at this position.
When we extended the analysis of amino acid frequencies and characteristics to 10 amino
acids flanking observed cleavage sites in both directions, we did not observe any
additional significant amino acid preferences. This finding might indicate that a stretch of
about 10 amino acids (P5 to P5') is critical for the selection of a cleavage site by the β-
subunits.
The cleavage motifs for proteasomal cleavages described here represent the first tools for
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developing an algorithm for the prediction of proteasomal cleavage sites. These motifs
will be relevant for  the prediction of peptides generated by mammalian proteasomes
since the cleavages in enolase-1 generated by yeast or human 20S proteasomes overlap
to a large extent (Nussbaum et al., unpublished observations; see 2.2.9). Nevertheless,
detailed studies using human 20S proteasomes, lacking or containing interferon-inducible
β-subunits, will be performed to assess their contribution to the generation of epitopes for
cytotoxic T cells and to refine the cleavage motifs.
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2.2.9 Additional data: Cleavage motif of human erythrocyte 20S
proteasomes
Soon after analysing the yeast 20S cleavage motifs, I finished the analysis of the digest of
enolase by human erythrocyte 20S proteasomes, with the help of members of the
analytics group in the lab (Dr. Stevanović and M. Schirle).
The results have only been published in detail as poster contributions at several
conferences (e.g. DGfI Jahrestagung 1999, Hannover) and are summarized below:
2.2.9.1 Fractionation of the degradation products by HPLC
Figure 2.2-5: HPLC-chromatogram of digest of enolase-1 by human erythrocyte 20S
proteasomes
The digest was stopped by freezing at -20°C after 5 days of incubation at 37°C. At this time, enolase
was degraded to about 80%. No enolase disintegration was observed in a control without
proteasomes. For buffer conditions, check 2.2.3.2.
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2.2.9.2 Cleavage map
Figure 2.2-6: Cleavage map of the degradation of enolase-1 by human erythrocyte 20S
proteasomes
The map comprises the 107 full fragments (horizontal bars) and the 118 cleavage sites (vertical
lines) identified in digests of enolase by human erythrocyte 20S proteasomes. (Solid bars) full
fragments of which both N- and C-termini are known. (Open bars) fragments for which only the N-
termini were identified.
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2.2.9.3 Fragment length distribution
Figure 2.2-7: Human and yeast proteasomes generate fragments of similar length in digests of
enolase
The general fragment length distribution is similar for yeast and human 20S proteasomes, with a
range from 3-23 aa. The slightly longer average length for human 20S proteasomes can be
explained by improved analytical methods which made it possible to identify more (especially longer)
fragments. Only internal fragments with known C-terminus and identified from one single digestion




Table 2.2-3: The cleavage motifs of yeast (wt) and human erythrocyte 20S proteasomes
overlap largely
Both proteasome species prefer large, hydrophobic and aa in P1, whereas they dislike the small aa
Gly at this position. They both like small aa in P1' and Pro in P4. For the human 20S proteasome, the
statistical analysis yielded p-values of barely significant numbers.
In summary, the cleavage preferences of yeast and human 20S proteasomes are similar.
We used the yeast and human 20S proteasome cleavage data to generate algorithms for
the prediction of proteasomal cleavages. This is shown in the next section (2.3) of the
Results part.
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2.3 An algorithm for the prediction of proteasomal
cleavages
2.3.1 Summary
Proteasomes, major proteolytic sites in eukaryotic cells, play an important part in major
histocompatibility class I (MHC I) ligand generation and thus, for the regulation of specific
immune responses. Their cleavage specificity is of outstanding interest for this process.
In order to generalize previously determined cleavage motifs of 20S proteasomes, we
developed network-based model proteasomes trained by an evolutionary algorithm with
experimental cleavage data of yeast and human 20S proteasomes. A window of 10
flanking amino acids (AAs) proved sufficient for the model proteasomes to reproduce the
experimental results with 98-100% accuracy. Actual experimental data were reproduced
significantly better than randomly selected cleavage sites, suggesting that our model
proteasomes were able to extract rules inherent to proteasomal cleavage data. The
affinity parameters of the model, which decide for or against cleavage, correspond with
the cleavage motifs determined experimentally. The predictive power of the model was
verified for unknown (to the program) test conditions: the prediction of cleavage numbers
in proteins and the generation of MHC I ligands from short peptides.
In summary, our model proteasomes reproduce and predict proteasomal cleavages with
high accuracy. They present a promising approach for predicting proteasomal cleavage
products in future attempts and, in combination with existing algorithms for MHC I ligand
prediction, will be tested to improve cytotoxic T lymphocyte (CTL) epitope prediction.
2.3.2 Introduction
Proteasomes are cytosolic multisubunit proteases which are involved in cell cycle control,
transcription factor activation and the generation of peptide ligands for MHC I molecules
(for reviews, see Baumeister et al. (1998), Rock and Goldberg (1999), Uebel and Tampe
(1999)). They exist in several forms: The proteolytically active core complexes, or 20S
proteasomes, and, when associated with the ATP-dependent 19S cap complexes, the
larger 26S proteasomes that are able to recognize proteins marked by ubiquitin for
proteasomal degradation (Jentsch and Schlenker, 1995; Hershko and Ciechanover,
1998). Another protein complex known to associate with the 20S core particle is PA28, the
11S regulator (Ahn et al., 1995), which was shown to improve the yield of antigenic
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peptides (Groettrup et al., 1996; Dick et al., 1996).
Eukaryotic 20S proteasomes consist of four stacked rings (overall stoichiometry α7β7β7α7),
each consisting of 7 different subunits (Groll et al., 1997). Each of the two inner β-rings
carries three catalytically active sites on its inner surface. Their proteolytic specificities
have been described as chymotrypsin-like (cleaving after large, hydrophobic AAs),
trypsin-like (cleaving after basic AAs) and peptidyl-glutamyl-peptide-hydrolyzing (cleaving
after acidic AAs) (for review, see Uebel and Tampe (1999)). Strings of unfolded proteins
are thought to be inserted into the cylinder and to be cut into pieces by the active sites;
the resulting peptide fragments are then released into the cytosol. Functionally,
proteasomal protein degradation is believed to proceed from one substrate end to the
other (“processively”), without the release of large degradation intermediates (Akopian et
al., 1997; Nussbaum et al., 1998; Kisselev et al., 1999a).
In vertebrate cells, some of the proteolytic fragments produced by the proteasome are fed
into the antigen processing machinery. Since peptide presentation by MHC I molecules at
the cell surface is an intrinsic requirement for the ability of the immune system to eradicate
virus-infected or transformed cells (Rammensee et al., 1993; Pamer and Cresswell,
1998), it is of general interest to know exactly how the proteasome is involved in this
process. Proteasomal cleavage specificity has been assessed by in vitro digestion
experiments using either tri- or tetrapeptides with fluorogenic leaving groups (Kuckelkorn
et al., 1995; Heinemeyer et al., 1997; Arendt and Hochstrasser, 1997), peptides of 15-40
AAs (Boes et al., 1994; Niedermann et al., 1995; Niedermann et al., 1996; Dick et al.,
1998), or denatured proteins (Dick et al., 1991; Dick et al., 1994; Kisselev et al., 1998,
Kisselev et al., 1999a) as substrates. We analyzed the cleavage preferences of yeast
wild-type and mutant proteasomes in a non-modified protein (Nussbaum et al., 1998)3.
Using statistical analysis of cut sites, it was possible for the first time to determine so-
called cleavage motifs, i.e. the preferred sequences around cleavage sites, for the three
active β-subunits of yeast proteasomes.
In order to apply this cleavage site information to any possible proteasome substrate, one
needs an automated prediction device. Such devices already exist for the binding of
                                               
3 Mutant yeast proteasomes: β5/Pre2-, β2/Pup1-, β1/Pre3- carrying one inactivated β-subunit are
denoted here as “single mutants”; β2/Pup1- β1/Pre3- carrying two inactivated β-subunits is denoted
here as “double mutant”.
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peptides to MHC I molecules (Rammensee et al., 1997) and have been described for
peptide transport by the transporter associated with antigen processing (TAP) (Daniel et
al., 1998). However, devices for the prediction of proteasomal cleavages are only at the
beginning of their development. Recently, published peptide cleavage data were used to
develop a prediction algorithm (Holzhütter et al., 1999), which reproduced its training data
with 93% and predicted non-training cleavages in one peptide substrate with 80%
accuracy. For different AAs in the P1 position4, cleavage motifs spanning up to 13 AAs
were calculated by the algorithm. However, it has recently been shown that the three
different proteolytic activities of eukaryotic proteasomes exhibit overlapping specificities
(Dick et al., 1998; Nussbaum et al., 1998). We therefore planned to generate a prediction
device that does not rely on various motifs for different P1-AAs, but reflects a combination
of the cutting of three active sites. This should mirror the experimental situation more
efficiently where observed cleavages arise from a mixture of three different, partly
overlapping proteasomal cleavage specificities. More importantly, we wanted our
approach to be based on a more homogeneous set of training data, possibly generated
under identical conditions. A device for proteasomal cleavage prediction would take us
one step further in predicting the selection of CTL epitopes presented on MHC I by the
three well-described “funnels of specificity”: proteasome cleavages, TAP transport, MHC I
binding.
To this end, we developed a network-based model for proteasome cleavages, trained by
an evolutionary algorithm on cleavages in protein and some peptide substrates
(Nussbaum et al., 1998; Nussbaum et al., in preparation; Niedermann et al., 1995;
Niedermann et al., 1996; Niedermann et al., 1997). Our program performed significantly
better for experimental data than for randomly positioned cuts, suggesting that it extracts
rules inherent to proteasomal cleavages from training data. Besides, it reproduced the
training data with very high accuracy (98-100%). The parameters of the proteasome
model largely reflect the roles of particular AAs in the cleavage motifs determined
experimentally. Prediction of non-training cleavages was tested for some peptide
substrates containing known MHC I ligands. The results indicate our approach to
represent a promising starting point for refined algorithms for proteasomal cleavage and
                                               





2.3.3 Materials & Methods/Procedures
2.3.3.1 The experimental training data
Before designing a prediction tool, it was necessary to carefully inspect the experimental
training data5. In brief, the experimental setup was as follows: purified 20S proteasomes
were coincubated with a protein substrate (enolase, 436 AAs), enolase fragments were
generated by the proteolytic action of the proteasome, and these fragments were
identified by biochemical methods, allowing to locate proteasomal cleavage sites. Thus,
the experimental data consist of fragments and cleavage sites. The cleavage sites are not
randomly distributed. Hence, the question is: What are the rules for cutting the protein?
Figure 2.3-1:Typical experimental distribution of cuts and fragments
Vertical bars indicate proteasomal cut sites; horizontal bars depict the detected cleavage products.
The cut positions represent the training data for the model proteasomes. The example shown here
illustrates the fragments produced by the yeast double mutant in enolase (taken from Nussbaum et
al. (1998); see 2.2).
In each experiment, a large set (1010) of proteasome molecules of a given type (wild-type,
                                               
5 The training data for the program and some working hypotheses used herein are largely taken
from Nussbaum et al., 1998 (see 2.2). If not stated otherwise, this source is refered to throughout
this section.
94
single mutant, double mutants) was exposed to enolase molecules, typically 300
enolase molecules to one proteasome. The experiments show overlapping fragments
(Figure 2.3-1), which can only be explained by assuming that cutting is a probabilistic
event on the level of individual molecules. However, the sample is so large that the
probability of a cut occurring at a given position in enolase can be viewed as a
deterministic parameter.
Due to the biochemical nature of the detection process, some fragments are more easily
detected than others, and there may be undetected fragments and cleavage sites.
Stretches of AA with few detected cleavage sites can be explained in two ways: Either
very few cleavages are made in this region or many cleavages (fragments) of very low
frequency are generated and are hence not detectable (Figure 2.3-2). We thus assume
that the experiment provides information on the most frequent cuts.
Figure 2.3-2: Two ways in which substrate regions with few detected cleavage sites can be
explained
(A) Few cleavages are made, generating few fragments of high abundance. (B) Many cleavages are
performed, thus producing many different fragments of low abundance each, possibly below the
detection limit.
Experiments using short peptide substrates have already demonstrated that cleavage
sites are used with different frequencies (Boes et al., 1994; Niedermann et al., 1995; Dick
et al., 1996). Our training data behave similarly, as suggested by the existence of
overlapping fragments, but relative frequencies of fragments were not determined. This
will affect our modeling approach: There are underlying statistical parameters (cleavage
probabilities at given positions) that until now have not been experimentally determined for
the training data.
Due to these limitations in fragment detection, of the two fragments meeting at one
cleavage site only one may be found. Therefore, the present modeling approach is
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directed towards cleavage sites rather than fragments. We did not to consider fragment
structure, although overlapping fragments exist. Instead we simulated the observed cut
patterns. We shall return to the problem of overlapping fragments below.
2.3.3.2 The model
A (possible) cleavage always occurs between two positions (two AAs). A “cut after
position i” denotes a cut between positions i (e.g. Y190) and i+1 (e.g. H191). With respect
to a (possible) cleavage site, these positions are also denoted by Pk,...,P1,P1’,...,Pm’. If a
peptide and cut positions are presented to us at random, then the AA in position Pi (Pi
ranging over Pk,...,P1,P1’,...,Pm’) is a random variable assuming the values A, C, D,..., Y,
representing the twenty AAs in the one-letter code. Thus, X3’ = G is the third position after
the cut when occupied by the AA G.
A simple random cutting device would inspect the positions successively (or
simultaneously) and would cut with a certain probability P∈(0,1), regardless of which of
the possible twenty AAs occupy the positions and independently of any other cuts; the
lengths of the fragments would follow a geometric distribution. This is clearly not the case
in the experimental situation (Nussbaum et al., 1998; Kisselev et al., 1999a). More
sophisticated devices would either A) use distance information, e.g. the distance from the
previous cut, or B) neighborhood information, e.g. the AAs adjacent to the prospective
cleavage position. Neighborhood information could be limited to the pair P1/P1’ or
comprise a wider window, Pk-Pm. For these more sophisticated devices, the proteasome
would either A) work on the positions successively and cut with probability Pν, if ν is the
distance from the previous cut, or B) cut at a position with a probability depending on the
AAs in P1 and P1’, but not on any previous cuts. In this case P(X1,X1’) is a measure for the
affinity of the adjacent AAs to the active site of the proteasome. In even more complex
devices, the probability of cutting would depend on previous cuts plus neighborhood
information. Many of these suggested cleavage mechanisms will be rather artificial and
will not provide insight because enolase is just one given protein of finite length: The total
experimental data on cuts and fragments can be encoded in many different ways in terms
of distance and neighborhood information. Thus, one encounters the usual problem of
biological modeling: A detailed model with many parameters can reproduce a finite data
set exactly but does not provide any information on the underlying biochemical
mechanism. Consequently, simple and plausible hypotheses on proteasomal cleaving
should be specified. These hypotheses should be minimal (i.e., simpler models cannot
explain the observed features) and there should be a nontrivial test for the model.
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Therefore we proceeded as follows: First, a hypothesis was formulated for the
mechanism. Then a model proteasome was designed in the form of a “neural network”
and trained on the experimental data in order to yield an optimal parameter set. The
training procedure can also be viewed as an evolutionary algorithm to determine an
appropriate model proteasome. Finally the performance of this optimized model
proteasome was tested.
As a working model, the following hypothetical mechanism was chosen: The enolase
molecule is inserted into the proteasome starting with its N-terminus (for notational
convenience, the results do not depend on the direction) and is then threaded along the
proteolytic sites. According to the findings that there are no statistically significant effects
of positions Pi or Pi’ with i>6 or i’>6 (Nussbaum et al., 1998), it is suggested that the
decision for a cleavage is based on local properties of the substrate molecule. Obviously,
the P1/P1’-pair plays a prominent role in this process (e.g. combination LT appears four
times and is cleaved four times; double mutant). However, if a cutting algorithm is based
on these positions alone, the performance will be rather poor (e.g. combination SK
appears six times, but is only cleaved three times; double mutant).
In detail, our proteasome model is based on the following hypotheses:
In determining whether to cut or not, the proteasome inspects only a neighborhood
Pk...P1 | P1’...Pm’ of the prospective cleavage site; k and m are fixed small numbers ≤ 6.
The main effect results from the affinity of the pair of AAs in the P1 and P1’ positions to
the active subunits in the proteasome. This effect is modeled by an affinity parameter
α1(X1,X1’). This parameter is not an affinity of the two AAs per se but affinity when
exposed to the active sites of proteasome. The value -α1(X1,X1’) could be interpreted as
an affinity of the pair of AAs to the active sites of the proteasome, i.e., a negative α1
indicates a positive influence on cleavage.
Each of the positions Pi, i=2,...,k, (or Pi’, i=2,...,m,) exerts an affinity αi(Xi) (αi’(Xi’)) towards
the prospective cut which depends on Xi (Xi’) but not on the AAs at the other positions.
The affinities can be positive, negative, or zero.











Notice that the two sums start with i=2, i.e. there is no additional affinity parameter for
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positions P1, P1’.
The probability of a cut depends only on the total affinity δ. The cutting process is
deterministic: The probability of a cut is equal to 1 if δ is negative or zero and it is equal to
0 if δ is positive (choosing the threshold zero is a mere normalization). Of course,
assumption 5 excludes the occurrence of overlapping fragments (in contrast to the
experiments).
2.3.3.3 The learning process
For a given set of affinities, the model proteasome will work along the enolase and apply
the local rule consecutively to each position from k to n-m, where n is the length of the
substrate. Thus, following assumption 5, it will always perform certain (the same) cuts in
enolase. Then, comparing the results with the experimental data, for each position there
are four possibilities: A) There is no cut in the experimental data and the model
proteasome did not cut. B) There is a cut in the data and the model did indeed cut. C)
There is a cut in the data but the model did not cut (missing cut). D) There is no cut in the
data but the model did cut (superfluous cut).
A stochastic hill-climbing algorithm (evolutionary algorithm) was used to train the network,
and for this purpose a measure was chosen to “tell” the network how good or bad its
present performance was. The choice of the measure was somewhat arbitrary (for the
lack of biochemical or mathematical guidelines for judging the performance), but we felt
that a superfluous cut is less significant than a missing cut. Hence the performance
measure was defined as:
F = K ×  the number of missing cuts + the number of superfluous cuts,
where typically K = 2. Choosing K > 1 amounts to penalizing missing cuts. A good
performance correlates with a small number F, and the data are reproduced if F=0 has
been achieved. The training algorithm works as follows, starting from an arbitrary or
suitably chosen initial affinity configuration and the corresponding number F, called F0.
1. Store the present affinity configuration and compute a new affinity configuration
by applying a random perturbation.
2. Compute the value F for the new affinity configuration and call it F1.
3. If F1 ≤ F0 then store the new affinities and go to 1.
4. If F1 > F0 then keep the old affinities and go to 1.
98
The training process obviously depends on the choice of the random variations. If k=5
and m=1, for example, then we have 20×20 (for the AAs in pair P1P1') + 4×20 (for
positions P5-P2) = 480 parameter values. Thus, a hill-climbing algorithm is applied to a
landscape on a space with dimension 480; this space is very large and there is no way to
explore it by a deterministic screening procedure. We decided to vary only one parameter
(affinity) at a time (i.e., in the parameter space, each variation is parallel to a coordinate
axis). Varying several parameters at a time did not accelerate the optimization process
(data not shown). Thus, in the algorithm a parameter is chosen at random, and then a
number from the uniform distribution on some interval [-ε,ε] is selected, where ε may even
depend on the affinity in question. The length ε, measuring the variance of the
perturbations, has to be carefully selected. If ε is too small or too large, the process will
take very long to approach a local optimum or will often skip over it, respectively. In the
actual program, non-constant variance was adapted to the temporal increase of the goal
function F.
Since the unknown parameters vary over a continuum and the goal function F assumes
entire values, the goal function is constant on certain sets and a unique optimal parameter
configuration cannot be expected. In general there is a whole set in the parameter space
such that all configurations in this set produce the same result. This observation
corresponds to biochemical reality, where slight variations in non-essential parts of the
proteasome would probably not lead to malfunction of the enzyme. In principle, there
could be parameter configurations in quite distant regions of the parameter space which
also produce F=0.
As with any hill-climbing optimization procedure, good initial guesses do provide
assistance. We chose the following approach based on the relative frequencies of AA
pairs around cleavage sites: For two AAs X1 and X1’ let S = S(X1,X1’) be the frequency of
the pair X1X1’ in the substrate and C = C(X1,X1’) be the frequency of cleaved pairs. If S > 0
then α1(X1,X1’) = 2(1-2C/S), and otherwise equals zero. Similarly, let Si = Si(Xi) be the
frequency of Xi (up to an error near the terminus, this number is the frequency of Xi in the
substrate) and let Ci = Ci (Xi) be the frequency of Xi in position Pi such that a cut is
performed at P1. Then the initial guess is α4(X4) = 2(1-2C4/S4) and α5(X5) = 0.5(1-2C5/S5).
We chose αi = 0 for all other positions.
2.3.3.4 Testing the model
As explained earlier, our goal is to obtain a proteasome model rather than a mere
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computational device or statistical analysis. There are about 2.5×1010 potential
octameric peptide sequences of which only about 500 occur in enolase (later, the cutting
algorithm is based on such octamers, see next section). If the model proteasome just
extracted information and reproduced the cuts, then it should perform similarly on
experimental and random data sets. However, if the model proteasome recognized
inherent rules in the experimental data, it should perform better on experimental training
data.
To test this hypothesis, we compared the performance of the model on artificial, randomly
distributed cleavage sites as opposed to cleavages generated by yeast wt 20S
proteasomes in enolase, in each case 105 cleavages. Ten independent runs were
performed for each and the F value was checked after 200,000 steps. The algorithm
reproduced the experimental data significantly better than the random cuts (p=0.00026):
The mean F-value for the experimental cleavages was 1.9 versus 8.8 for the random cuts
(Figure 2.3-3).
Figure 2.3-3: Performance of algorithm when fed with random cleavage data (circles) or yeast
wt proteasome cleavages in enolase (squares).
The training data comprised 105 cleavages, both for the experimental data generated with yeast wt
proteasomes and for the randomly selected data. Dashed lines: mean values of ten independent
runs. The results shown were reached after a constant number of 200,000 iteration steps.
100
Interestingly, for the experimental data only superfluous cuts contributed to F, i.e., the
model recovered all training cleavages and made some additional cuts (data not shown).
On the other hand, for random cleavage data, the high value of F resulted from both
superfluous and missing cuts (with respect to the training data) although the latter were
strongly penalized during the learning process. Similar results were obtained for two more
sets of randomly selected cuts (data not shown). Thus, the model performs better on
experimental data and for these it recovers all cuts. These findings demonstrate on the
one hand that our concept of cleavage affinities leads to a working model, even with
relatively few parameters. On the other hand, they show that the experimental cleavage
data (proteasome cuts in enolase) contain a large amount of hidden regularity that can be
extracted by the present algorithm.
2.3.4 Results
2.3.4.1 Reproduction performance
Our method was applied to experimental cleavage data generated by different 20S
proteasomes (yeast wild-type, single mutants, double mutant, human wild-type) in the
substrate enolase (Nussbaum et al., 1998; Nussbaum et al., in preparation), yielding
different model proteasome “species” ## 1-8 (Table 2.3-1).
In initial attempts, the double mutant data were utilized because of their “cleavage
homogeneity”. The decision to cut was based on information from the octameric interval
P4,...,P4’, i.e. k = m = 4. An initial parameter configuration was based on the frequencies
of AAs in P1 and P1’ around cleavage sites in the experiment. This rather crude
approximation led to a value F = 72 (with K = 2), which appears rather weak, but is far
from the performance of an arbitrary parameter configuration. After approximately 194.000
steps of the training algorithm, an optimal solution with F = 0 was reached. When the
search for a good initial choice was automated as outlined above, the same result was
obtained after 176.000 steps. In all subsequent runs, automated initial guesses were used
(data not shown).
In an attempt to gradually reduce the number of parameters, both shorter intervals and
intervals with “holes” were used. These attempts were made by trial and error, guided by
the statistical analysis of cleavage sites. The intervals P6,...,P1’,P4’ (65.000 steps),
                                               
6 The p-value was determined by a two-sided, paired Student’s t-test.
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P5,...,P1’,P4’ (71.000) and P4,...,P1’,P4’ (80.000) indicated that shorter AA windows
contain sufficient information for the correct reproduction of the training data, and that P5
seems to play an important role for β5/Pre2. Choosing the interval P5,...,P1’ reduced the
number of steps further to 36.000 (Table 2.3-1), suggesting that positions P2’-P4’ contain
information that obscure the data and hence decelerate the process. It also shows that the
positions N-terminal (“to the left”) of the cleavage site seem more important than the ones
C-terminal (“to the right”) of the cleavage. (It should be emphasized that the number of
iteration steps is not entirely relevant for the biological  problem or interpretation, since it
depends on the quality of the initial guess. These numbers are quoted to give an
impression of how a training algorithm behaves in spaces of very high dimensions.)
Similarly, for all model proteasomes other than the double mutant, the interval
P6,...P1’,P4’ turned out to be the most suitable for the reproduction of the experimental
data. (Note that positions P2’, P3’ were left out.) Particularly, the data generated with
human proteasomes are badly reproduced when P5 and especially P4 are not included in
the interval (data not shown). The results of the reproduction performances are
summarized in Table 2.3-1.
A substrate molecule of finite length only contains a finite amount of information as far as
cleavage data are concerned. A set of affinity parameters reproducing data for one
sequence might not be suited for other sequences. A finite set of training data might
“teach” the program rules specific only for the training data. The capacity for generalizing
the model proteasomes should thus improve if the set of training data is extended.
Therefore, for two model proteasomes (#7 and #8), the cleavage data of two short
ovalbumin-peptides (Niedermann et al., 1995; Niedermann et al., 1996; Niedermann et al.,
1997) were added to the enolase cleavage data generated by human proteasomes (for
the reproduction performances see (Table 2.3-1).
The different proteasome models reproduce their training data with nearly perfect scores
(98-100%). The majority of the wrongly assigned cuts are superfluous cuts and could
theoretically represent cuts that remained undetected in the experiment. The system
simulating the yeast double mutant 20S proteasome (β5/Pre2+) uses the shortest interval
(P5,...,P1’) to assess the cleavages, probably reflecting the fact that these cleavages are
performed by one single proteolytic activity, thus rendering the training data rather
homogeneous. For wild-type and single mutant proteasomes the cleavages are generated
by three and two different proteolytic activities, respectively. The training data are
therefore expected to be less homogeneous, which could be a reason why a wider interval
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(P6,...,P1’,P4’) is needed. This inhomogeneity might be brought about by the need for
the active sites β1/Pre3 and/or β2/Pup1 to inspect a wider environment of the substrate.


















#1 yeast wt 105 P6-P1’, P4’ 116,000 105 none none 100
#2 yeast β5/Pre2- 95 P6-P1’, P4’ 297,000 95 “ “ 100
#3 yeast β2/Pup1- 80 P6-P1’, P4’ 270,000 80 “ “ 100
#4 yeast β1/Pre3- 88 P6-P1’, P4’ 500,000 88 “ “ 100
#5 yeast β1/Pre3-
 β2/Pup1-
73 P5-P1’ 36,000 73 “ “ 100
#6 human wt 117 P6-P1’, P4’ 275,000 117 “ 2 99.5
#7 human wt+  || 136 P6-P1’, P4’ 500,000 136 “ 4 99.2
#8 human wt+  ¶ 151 P6-P1’, P4’ 445,000 150 1 4 98.9
* 20S species used to generate cleavages  in enolase; + additional training data;
‡ number of iteration steps until the reported performance was reached
§ reproduction performance reached after so many steps of the algorithm; the three columns on the
left refer to the cleavages made by the algorithm, the %-value in the right column refers to all
possible cleavage sites (theoretical number of cleavage sites in enolase: 427 = 435-(k+m)+2)
|| learning data: cleavages in ovalbumin peptides 37-77 and Y249-269 [human 20S] (Niedermann et
al., 1997) + enolase data [20S from human erythrocytes] (Nussbaum, in preparation; see 2.2.9)
¶ learning data: the most dominant cleavages in ovalbumin peptides 37-77 and 239-282 [human and
mouse 20S] (Niedermann et al., 1995; Niedermann et al., 1996; Niedermann et al., 1997) + enolase
data [20S from human erythrocytes] (Nussbaum, in preparation; see 2.2.9)
In brief, theoretical proteasomes, which do not produce overlapping fragments, were able
to reproduce the experimental cleavage data with 98-100% accuracy. A minimal window
size of 6-10 AAs, containing 6-8 individual AA positions, provided sufficient information for
highly accurate reproduction. Using experimental data from proteasomes bearing more
than one active site seems to complicate the cutting rules and therefore requires a wider
window for the reproduction, probably reflecting the fact that three different proteolytic
specificities operate in eukaryotic proteasomes.
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2.3.4.2 Computed affinities
Will the affinities of an optimal solution (F=0) yield information on the “physical” nature of
the cleaving process? As stressed previously, there is no unique optimal affinity
parameter configuration. Indeed, for the same problem with the same initial guess,
different optimal solutions are found due to the stochastic nature of the search process.
Although these optimal solutions vary in detail, some characteristic affinity patterns do
emerge. In order to “extract” these characteristics, mean values of affinity parameter
configurations were computed, and the results were compared to the experimental
findings.
First 1α , a measure for the influence of the P1 position on cleavage, based on the P1,P1’






where χ(X1,X1’) is equal to 1 if the pair X1,X1’ occurs somewhere in enolase and zero
otherwise. The affinity parameters were normalized in such a way that the sum of the













These values were then averaged over the set of the runs of evolutionary algorithm. For
the yeast wt proteasome, the results are presented in Table 2.3-2, similarly for positions
P1’ and P4.
For position P1, large hydrophobic AAs (F, L, W) and the basic AA R were found to
promote a cleavage by the program. This is in line with the experimental results (L and R
promoting cleavage). A similar agreement was found for the AAs inhibiting a cleavage
when appearing in P1: For both the program and the experimental data, G was the most
cut-inhibiting AA in P1. For position P1’, the program found P, R, Y, and F to be cut-
promoting, whereas the large branched AAs V, L, and I,  as well as the acidic ones E and
D, were cut-inhibiting. This is in agreement with the experiments, where β-turn-promoting
AAs (e.g. P) are enriched at P1’ and large AAs are rare at P1’ (e.g. V, L, I). The cut-
promoting influence of R in P1’ in the program could reflect the preference of the
chymotryptic site Pre2 for basic AAs at this position. The reason for the cut-promoting
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influence of the large aromatic AAs Y and F at P1’ is currently unclear. As our group,
as well as others, (Nussbaum et al., 1998; Shimbara et al., 1998) have already reported
on the influence of P at P4, it was interesting to find the cleavage-promoting power of P in
P4 in the program. On the other hand, H in P4 seems to strongly inhibit cleavage, a result
not observed in the statistical analysis of the experimental data. We are currently
examining experimentally whether there is a cut-inhibiting influence of H in P4.
Table 2.3-2: Cleavage characteristics of yeast wild-type proteasomes deduced from computed
affinity parameters









P1 F, L, W‡, R
(I, Y)
L, R G, K, P, Q, N
(A, T, M‡, S)
G
P1’ P, R, Y, F, M‡
(K, T)
small, β-turn V, L, I, E, D
(W‡, S, G)
 ---
P4 P P H ---
Strength of AA influence in descending order from left to right. AAs in brackets only show a minor
influence. The affinity parameters for the AA cystein, which only appears once in enolase, are prone
to a large variance and were not included in the table.
* determined by statistical analysis of cleavage data (hypergeometric distribution)
‡ low frequency in enolase (n=5); large variance of computed affinity parameters possible
In conclusion, the cleavage motifs of the model proteasome, i.e., the rules the program
has learned to reproduce the training data, can be extracted from the computed affinity
parameters in order to gain insight into the biochemical mechanism. For the yeast wild-
type proteasome, they largely reflect the results obtained from statistical analysis of the
experimental data. Some differences between computed affinity parameters and
experimental results were detected. Such variances can serve as working hypotheses for
experimental investigations.
2.3.4.3 Number of cleavages predicted in proteins
The number of proteasomal cleavages in proteins has been estimated by a calculation
using the experimentally determined mean fragment length (Kisselev et al., 1998; Kisselev
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et al., 1999a). However, this indirect approach does not account for the presence of
overlapping fragments. We found many more cleavages by yeast and human 20S
proteasomes in enolase than predicted by the above method (Nussbaum et al., 1998;
Nussbaum et al., in preparation; Toes et al., in preparation). We therefore had our
program theoretically cleave protein substrates of different lengths (results depicted in
Figure 2.3-4). The program trained on cleavages in enolase generated by human 20S
proteasomes “cleaved” the test substrates with a frequency of about 33 cuts per 100 AAs
in the substrate molecule, 2.5 times more cuts than proposed before (Kisselev et al.,
1999a). According to the above mentioned method, 22 cuts are made in casein by
mammalian 20S proteasomes (Kisselev et al., 1999a), whereas we found 50-60 cuts by
individual fragment detection (Emmerich et al., in preparation). The program predicted
about 64 cuts. We therefore conclude that our program mirrors the number of 20S
cleavages in protein substrates more realistically than previous methods.
The regression line for the number of cleavages versus protein length does not go through
zero. If this effect is relevant at all, then it possibly indicates that short peptides are bad
substrates, as reported before (Dolenc et al., 1998). The number of predicted cleavages
clearly depends on the AA composition of the test substrate, as suggested by the strong
deviation of the number of cleavages predicted in Epstein-Barr-virus nuclear antigen 1
(EBNA1), a viral protein of 641 AAs, from what would be expected (Figure 2.3-4). A
glycine-alanine repeat region (GARR) of approximately 240 AAs in EBNA1 is the reason
why EBNA1 is not degraded by proteasomes in EBV-infected cells (Levitskaya et al.,
1995; Levitskaya et al., 1997; Sharipo et al., 1998). Our model proteasomes on average
only perform 7 cleavages in the 240 AAs of this repeat. This can be explained by the
influence of the AA G, which is known to be cut-preventing in P1 (Table 2.3-2). Our
experimental data agree with this finding: peptides containing short GARR’s are hardly
ever cleaved within the GARR’s (Nussbaum, unpublished observations). Also the
deviation of the number of expected cuts from the regression line of predicted cuts could
stem from the program using actual sequence information, as opposed to length
information, to decide about cuts. Moreover, it could reflect the fact that it is easier to find
cleavages in short proteins in the experimental setup (because there are fewer
fragments), while the program is not limited by the number of fragments.
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Figure 2.3-4: Number of cleavages predicted in proteins of different lengths.
The results for the predicted cuts are a mean value of 7 programs (error bars indicate standard
deviations). The number of expected cuts (dashed line) was calculated by applying the enolase-
specific ratio of cuts per AAs (117 cuts/436 AAs) to other substrates. The number of cuts produced
by Thermoplasma 20S (dotted line) and rabbit 20S (dash-dot) are taken from Kisselev et al. (1998)
and Kisselev et al. (1999a), respectively. Test substrates: lactalbumin (123 AAs), bovine β-casein
(209), influenza A matrixprotein (285), ovalbumin (385), E.coli alkaline phosphatase (471), influenza
A nucleoprotein (479), and EBNA3 (812). EBNA1 (641) was not included in the regression of the
predicted number of cuts.
In summary, based only on cuts made in enolase, our program predicts the number of
cleavages in other test substrates more realistically than previous methods, as indicated
by the comparison with experimental cleavage numbers in casein. This information is
useful for the estimation of the number of potential MHC I binding peptides generated
during protein degradation.
2.3.4.4 Predicting the generation of MHC I ligands
The true challenge for a prediction device should be the correct identification of individual
cleavages in sequences not included in the training data. For this purpose, a 25mer
peptide of pp89 from murine cytomegalovirus (corresponding to positions 162-186) and a
21mer peptide from murine JAK1 tyrosine kinase (positions 348-368) were chosen,
because they contain MHC I ligands and are common experimental proteasome
substrates. They were cleaved by model proteasomes #6-8 (described in Table 2.3-1) and
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the performance was assessed (Table 2.3-3).
Table 2.3-3: Predictive power of the algorithm in peptides containing MHC I ligands
Cleavage performance in peptide sequences (pp89 (a) and JAK1 (b)) containing known MHC I
ligands. lit.: extract of experimental findings as described in Boes et al. (1994), Kuckelkorn et al.
(1995), Groettrup et al. (1996), Dick et al. (1996), Dick et al. (1998). #6-8: model proteasomes
(compare to Table 2.3-1). Short vertical bars indicate cuts; gray coloring indicates experimental cuts
in regions close to the termini that the program cannot predict. Long dotted lines indicate the position
of experimentally observed cuts. The underlined sequences represent MHC I ligands. Calculations
as in Table 2.3-1.
The prediction performance reached values of 75-88% (counting both missing and
superfluous cuts, the latter of which we consider less critical). At first glance, it appears
contradictory that for the pp89-peptide program #7 performs better than program #8
(Table 2.3-3 A), but vice versa for the JAK1-peptide (Table 2.3-3 B). The training data for
program #7 seem to contain information more suitable for the prediction of cleavages in
pp89 than those for program #8, and vice versa for the JAK1-peptide. Presumably, adding
data to the training set improves the prediction performance. A good example is the cut
between L15 and G16 in the pp89-peptide. This cut is not generated by program #6
(trained on cuts in enolase only), probably because the pair LG appears three times in
enolase but is never cut. However, the cut is generated by programs #7 and #8 (trained
on cuts in enolase and ovalbumin-peptides), which can be explained by the appearance of
a cut between L and G in the ovalbumin-peptides. The situation for the JAK1-peptide is










lit. R L M Y D M Y P H F M P T N L G P S E K R V W M S ---
# 6 R L M Y D M Y P H F M P T N L G P S E K R V W M S 2 2 4 62.5
# 7 R L M Y D M Y P H F M P T N L G P S E K R V W M S 4 0 2 87.5
# 8 R L M Y D M Y P H F M P T N L G P S E K R V W M S 4 0 5 68.8
lit. R E E W N N F S Y F P E I T H I V I K E S ---
# 6 R E E W N N F S Y F P E I T H I V I K E S 3 2 2 66.6
# 7 R E E W N N F S Y F P E I T H I V I K E S 2 3 3 50
# 8 R E E W N N F S Y F P E I T H I V I K E S 5 0 3 75
1 5 10 15 20 25
1 5 10 15 20
a
b
3 1 3 75
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conclude that the training data do not yet contain enough information to predict every
single possible cleavage.
In summary, the predictive power of the program is high for certain short test sequences.
Shortcomings of the model proteasomes are likely to be caused by the scarceness of
training data and could be influenced by not considering the effects of in vivo regulators of
proteasome function, e.g. PA28, the 19S cap or interferon (IFN)-γ-inducible subunits. We
therefore assume that by including such data and generally by enlarging the set of training
data the performance of the program will improve.
2.3.4.5 Refined model
As described above, proteasomes use the cleavage sites with distinct preferences, which
can be determined by quantifying cleavage products. However, the cleavage products
(fragments) in enolase, the data our model proteasomes are based on, had not been
quantified. Nevertheless we wanted to refine the model in such a way that a cut is
performed with some probability depending on the flanking AAs. These probabilities were
therefore included as parameters of the model. Again, we chose numbers k and m to
define the neighborhood of the prospective cleavage site. Hypotheses 1-4 were imposed
as before, but property 5 was replaced by a more subtle procedure.
In accordance with the additivity requirement we assume that the probability of a cut does
not depend on all the particular AAs in the neighborhood (as the affinities do) but only on
the total affinity δ. Since the variable δ ranges over the real numbers, we must specify the
probability of a cut in terms of the total affinity δ. Thus a function P(δ) depending on few
parameters was determined by training. It is evident what the properties of P(δ) should be:
P(δ) is a decreasing function, P(δ)→1 for δ→-∞, and P(δ)→0 for δ→+∞. In the previous
case of “deterministic cutting” the function was just P(δ)=1 for δ≤0 and P(δ)=0 for δ>0. For





= , which depends on a positive
parameter κ. In the limit of κ→0 the deterministic cutting can be recovered.
We wanted to choose a simple model to avoid too much arbitrariness when assigning
probabilities to cuts. Thus we defined only two cases: A) A high probability cut is a cut not
overlapped by any fragment, e.g. the cuts after L183, Y190, L193, Y201 and A203 (Figure
2.3-1). B) A low probability cut is a cut overlapped by some fragment (i.e. not every
fragment is cleaved a this site), e.g. the cuts after L196, F252, F253 and Y258 (Figure
2.3-1).
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A goal function for measuring the prediction was introduced as follows: If δ>0, the
probability of cleaving is so low that cleavages will not be observed. Then there is a critical
level δ1<0. If δ<δ1, the probability of cleaving is high. That means fragments containing
(i.e. overlapping) the cleavage site in question will not be observed, because this cleavage
site is always used. If δ1<δ≤0, the probability of cleaving is so far from 0 and 1 that
fragments resulting from cleaving at this site but also fragments overlapping the site can
be found. In view of the homogeneity of our model we can assume that δ1 = -1. An energy
function was chosen to estimate the correctness of the prediction:
  F = 2 × # of missing cuts + # of superfluous cuts + # of wrongly assigned cuts
The refined model was applied to the experimental cleavage data of the yeast double
mutant because of their “homogeneous consistency”. The data were classified according
to the rules described above. First an optimal solution for the mere reproduction of the
cleavages was generated using the positions P6,...,P1’,P4’. Starting from this point, a
parameter set was found which reproduced exactly (F = 0) the training data with their
assigned probabilities (data not shown). This finding demonstrates that, at least in the
case of the double mutant, the network system has sufficient "freedom" to determine, in
addition to cleavage positions, probabilities for cuts to occur. Thus there should be
sufficient freedom to accomodate information on experimental fragment frequencies in the
future. The refined model has not been applied to other experimental data yet.
2.3.5 Discussion
Here we present a simple (one-layer) network capable of generating proteasomal
cleavages in any given AA sequence. For training the network, goal functions counting
missing and superfluous cuts (and cleavage probability in case of overlapping fragments
in a refined model) were used together with a stochastic, hill-climbing optimization
process. Thus, parameter sets were found which reproduced the training data (cuts
performed by 20S proteasomes in enolase plus some cuts in ovalbumin peptides) with
almost perfect scores (98-100% exactness, Table 2.3-1). More interestingly, they
predicted cleavages in two non-training sequences containing MHC I ligands with an
accuracy of 75-87% (Table 2.3-3). Thus, the theoretical proteasomes described here
represent the most successful prediction tool for proteasomal cleavages to date.
The precision with which the training data were reproduced (98-100%) and the much
poorer reproduction performance when applied to a set of random cuts (Figure 2.3-3)
imply that the selected approach is able to extract actual proteasomal cleavage rules
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inherent to experimental training data. A window spanning 10 AAs (positions P6-P4’)
contains sufficient information for this excellent reproduction performance, probably
indicating that only a short stretch of about 10 AAs is “seen” by the inner surface of the
proteasome at the site of cleavage. This result is in line with the experimental data, where
no statistically significant AA effects were observed beyond positions P6 and P6’. It is also
in accordance with Holzhütter et al. (1999), who found no significant influences beyond P8
and P6’. Whether there are long-distance effects on cleavage site selection, as suggested
by Kisselev et al. (1999b), beyond the intervals checked so far, remains to be determined.
The fact that the P-side (AAs P6-P1 needed for the program) is more critical than the P’-
side (P1’, P4’) was detected earlier (Nussbaum et al., 1998; Holzhütter et al., 1999). It
could indicate that the P-side of prospective cleavage sites is more strongly bound by the
inner surface of the proteasome near its active sites than the P’-side. The theoretical
proteasomes relied on parameters similar to the cleavage motifs determined
experimentally, as shown by the correspondence of computed affinity parameters with the
statistical analysis of the experimental data for yeast wt proteasomes (Table 2.3-2). This is
especially true for the preference for large hydrophobic AAs (F, L, W) in P1, the cut-
inhibiting influence of G in P1, and the accumulation of P in P4. Thus, the program has not
reproduced the training data “by chance”, but by applying supposedly proteasome-specific
rules. Certain affinity parameters the program uses to decide for or against a cleavage
differ from the ones observed experimentally. We cannot exclude that artifacts imposed by
the nature of the training algorithm are to blame in such cases. However, in these cases,
the influence of the AAs in question can be tested experimentally. An example for this is
the cut-inhibiting effect of the AA H at P4, which we are now examining by in vitro peptide
digestions. Thus, the program can provide working hypotheses to be explored
experimentally and thereby possibly accelerate the investigation process.
Other important aspects of our approach are the homogeneity and the size of the set of
training data. In a previous approach, published cleavage data from different literature
sources were used as training data of an algorithm (Holzhütter et al., 1999). The data
encompassed roughly 200 scissile peptide bonds and had been generated under
dissimilar experimental conditions (source of 20S, IFN-γ-treatment, incubation times). It
cannot be excluded that these differences influenced the proteasomal cleavage pattern.
We thus based our model largely on cuts generated in one single experiment, forming a
set of around 400-500 scissile peptide bonds. The likelihood of experimental variations
and statistical artifacts should therefore be low.
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The number of cleavages in proteins predicted by the program (Figure 2.3-4) very
accurately reflects the occurrence of overlapping fragments, as suggested by the
comparison with the number of cuts we found in casein (Emmerich et al., in preparation).
Previous attempts to determine cleavage frequencies in protein substrates yielded
considerably lower numbers of cleavages, probably due to the fact that they had been
determined indirectly (by calculation) instead of directly by fragment identification, thereby
not giving full credit to the presence of overlapping fragments (Kisselev et al., 1998;
Kisselev et al., 1999a). As the number of possible cleavage sites will determine the
number of different peptides generated, our program reflects this point of interest for
immunological questions more realistically.
Typically, a limited window containing 8 AAs (positions P6,...,P1’,P4’), or altogether about
500 parameters, was sufficient to reproduce the training data. Similar networks usually
contain an enormous set of free parameters (Chou et al., 1996; Thompson et al., 1995)
which do not reflect the biochemical nature of the process under investigation. Keeping
the number of free parameters to a minimum prevents the program from putting too much
weight on minor characteristics and makes it easier to extract rules and to interpret their
meaning for the biological process.
Our program predicts cleavages on the basis of AA “names”, not AA properties such as
volume or hydrophobicity, as in Holzhütter et al. (1999). The significance of such
properties might hence be underestimated by our approach. However, AAs can be
classified according to many additional characteristics such as polarity, tendency to
promote β-turns, positive or negative charge, etc. Thus we felt that a sequence of AAs in
the one-letter code possibly contained important information beyond selected traits. In
order to avoid overlooking this information, our training data were in the form of AA
sequences in the one-letter code. This code can be translated into AA characteristics to
test for the influence of selected side chain properties (e.g. the proline-effect at P4 is
probably caused by the kink-inducing properties of this AA, not by its size or
hydrophobicity). In the above mentioned approach, two AA properties were sufficient to
yield satisfactory results, suggesting that proteasomes only check a limited amount of AA
features to decide for or against a cleavage. However, before this point is resolved, we
consider it premature to base an automated prediction device on selected properties only.
The predictive power of the program is not strong for all test data, e.g. the cuts at the C-
termini of MHC I ligands (data not shown). It is possible that test data consisting of
selected MHC I ligands do not fit our program because the involvement of trimming
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proteases different from proteasomes in the generation of the C-termini of MHC I
ligands cannot be excluded (Elliott et al., 1995). However, from examining falsely
predicted cuts in different types of test sequences, it is more likely that the lack of a larger
set of training data is responsible (data not shown). Many “cases”, i.e. AA sequences, do
not exist in the training data. For example, only 214 AA pairs, i.e. 54% of all possible 400
(theoretical P1,P1’-) pairs, occur in enolase. Therefore, in judging a prospective cut site,
the program will base its decision partly on chance. It should consequently be possible to
improve the predictive power of the program by increasing the set of training data. For this
purpose we are currently generating more cleavage data in new protein substrates, using
the same conditions as for the enolase data in order to guarantee the homogeneity of the
training data.
Studies on in vivo antigen processing indicate that, for certain CTL-epitopes, proteasomes
only participate in the generation of their C-termini and that their N-termini can be trimmed
to the correct size by cytosolic or ER-resident aminopeptidases (Craiu et al., 1997; Stoltze
et al., 1998; Paz et al., 1999; Mo et al., 1999). However, a recent report claims that
proteasomes do generate both termini of CTL-epitopes (Lucchiari-Hartz et al., 2000). It is
therefore possible that antigen processing contains an epitope-specific component and
that the prediction of proteasomal cleavages will turn out to be valuable only for the C-
terminus of certain CTL-epitopes.
At present the program is only able to predict cleavage sites, not individual fragments, and
does not “know” about overlapping fragments. However, fragment prediction will be more
useful for the application to immunological questions than just cut prediction. Also, the
program only generates deterministic cuts (in the basic model) or cuts based on estimated
probabilities (in the refined model) at the moment. Both shortcomings should be overcome
by using quantified cleavage fragments as training data. Quantitation will provide the
network with probabilities for cleavages and for fragments to occur, a necessity for
probabilistic cut and fragment prediction. As predicted cuts and fragments will be coupled
to defined probabilities for them to occur, the presence of overlapping fragments will no
longer pose a problem. The new cleavage data currently being generated are therefore
quantified on a routine basis.
In summary, we have created automated prediction devices for cuts by yeast and human
20S proteasomes. They reproduce their training data nearly perfectly and show strong
predictive power in selected test substrates. The program provides information on the
functioning of “real” proteasomes, which mirror experimental findings (e.g. number of
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cleavage sites in proteins, cleavage motifs) better than previous approaches.
Shortcomings in the prediction of individual cuts are likely to be caused by the limited
amount of training data. However, as network-based prediction programs can
continuously be fed with new training data, the predictive power of the program should
improve as new experimental data are incorporated. The program therefore represents a
suitable format for the development of fragment prediction programs. It can be tested in
the future in combination with existing programs for the prediction of MHC I ligands to
improve the forecast of CTL-epitopes.
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2.4 PAProC: A Prediction Algorithm for Proteasomal
Cleavages available on the WWW
2.4.1 Summary
The first version of PAProC (Prediction Algorithm for Proteasomal Cleavages) is now
available to the general public. PAProC is a prediction tool for cleavages by human and
yeast proteasomes, based on experimental cleavage data. It will be particularly useful for
immunologists working on antigen processing and the prediction of major
histocompatibility class I molecule (MHC I) ligands and cytotoxic T-lymphocyte (CTL)
epitopes. Likewise, in cases in which proteasomal protein degradation has been indicated
in disease, PAProC can be used to assess the general cleavability of disease-linked
proteins. On its web site (http://www.paproc.de), background information and hyperlinks
are provided for the user (e.g. to SYFPEITHI, the database for the prediction of MHC
class I ligands).
2.4.2 Introduction
Proteasomes are the key players in cytosolic protein degradation. Some of the “waste”
products of this process, peptides of 3-40 amino acids in length, are spared from further
degradation to single amino acids and are translocated by the transporter associated with
antigen processing (TAP) into the endoplasmic reticulum (ER) (Rock and Goldberg, 1999;
Pamer and Cresswell, 1998; Uebel and Tampe, 1999; van Endert, 1999). Whereas the C-
termini of MHC I ligands most likely have to be generated by proteasomes (Craiu et al.,
1997; Stoltze et al., 1998; Mo et al., 1999), cytosolic or ER-resident trimpeptidases can
reduce longer fragments to the correct size of 8-10 aa for them to bind to MHC I and be
presented on the cell surface (Paz et al., 1999; Stoltze et al., 2000). The recognition of
MHC I-bound peptides is responsible for the induction of cytotoxic T-lymphocytes (CTL)
against intracellular pathogens, such as viruses, and against mutated proteins, e.g. in
tumor cells. Thus, it is conceivable that proteasomal cleavage specificity regulates
immune responses, albeit indirectly. It would therefore be beneficial to be able to predict
proteasomal cleavages. In combination with MHC I ligand predictors such as SYFPEITHI
(Rammensee et al., 1999), in particular, proteasomal cleavage prediction should help to
improve the forecast of MHC class I restricted CTL epitopes. More specifically, it could
support researchers seeking CTL epitopes by limiting the number of predicted MHC class
I ligands from protein antigens. In addition, the effect of amino acid mutations in viral or
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tumor-specific proteins on antigen presentation could also be assessed. Proteasomal
cleavage prediction can thus play an important part in rational vaccine design.
It is well-established that altered proteasomal protein degradation can be a factor in
disease processes. A change in the general cleavability of a protein could be one possible
mechanism by which disease-linked proteins are spared from degradation, thus
increasing their intracellular levels and possibly killing cells. EBNA-1, a viral protein from
EBV is spared from proteasomal degradation due to a Gly-Ala repeat region (GARR)
(Levitskaya et al., 1995; Levitskaya et al., 1997). The length of the GARR is critical for this
effect (Dantuma et al., 2000). Our proteasomal cleavage algorithm predicts hardly any
cleavages within the GARR (Kuttler et al., 2000), and short GARRs are not cleaved by
proteasomes in vitro (Nussbaum, unpublished observations). Poly-glutamine (polyQ) –
containing proteins are involved in  neurodegenerative diseases such as Huntington’s
disease (HD) and spinocerebellar ataxias (SCA). Conformational changes in mutant forms
of polyQ-proteins possibly result in altered proteasomal degradation and lead to the
formation of protein deposits (Wanker, 2000; Evert et al., 2000; Zoghbi and Orr, 2000;
Cummings et al., 1998). Again, longer polyQ-sequences more readily cause disease
(Krobitsch and Lindquist, 2000), possibly by more efficiently inhibiting proteasomal
degradation. For disease-linked proteins such as the polyQ-proteins, PAProC can predict
whether proteasomal cleavage specificity might be involved in protein accumulation and
the initiation of disease.
Recently, the first prediction algorithms for proteasomal cleavages were published on
paper (Holzhütter et al., 1999; Kuttler et al., 2000), and a third, neural network-based
approach, has just been completed (Kesmir et al, submitted). In addition, several other
groups are currently working on this intriguing topic.
We now introduce the first publicly available tool for proteasomal cleavage prediction,
PAProC, and present its mode of function. PAProC is a prediction tool for cleavages by
human as well as wild-type (wt) and mutant yeast proteasomes that is based on
experimental cleavage data (Nussbaum et al., 1998; Kuttler et al., 2000). On the PAProC-
web site (http://www.paproc.de), easy-to-handle predictions of proteasomal cleavages in
amino acid sequences can be performed. In addition, background information on
proteasomes and on PAProC and hyperlinks (e.g. to SYFPEITHI, the database for the
prediction of MHC class I ligands) are available.
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2.4.3 Materials & Methods
2.4.3.1 Experimental training data and algorithm
The experimental training data for PAProC have already been described in detail
(Nussbaum et al., 1998; Kuttler et al., 2000). In brief, a non-modified protein (yeast
enolase-1) was incubated with purified yeast or human erythrocyte 20S proteasomes,
resulting in the proteasomal fragmentation of enolase. Enolase fragments were identified
by biochemical methods (fractionation, sequencing, mass spectrometry) and led to the
compilation of a cleavage map (see Figure 2.4-1). All the detected cleavage sites were
then used to train an algorithm, which has recently been described in detail (Kuttler et al.
2000). The algorithm “sees” a window of 10 amino acids around cleavage sites (6 to the
“left”, 4 to the “right”). Based on this amino acid window, the algorithm can reproduce its
training data and, more importantly, is able to predict proteasomal cleavages in
sequences not included in the training data. All the PAProC-predictions mentioned in this
paper are based on algorithms trained with human 20S proteasome data.
Figure 2.4-1: Cleavage map of the degradation of yeast enolase-1 by human erythrocyte
proteasomes
The figure shows the 107 full fragments (horizontal bars) and the 118 cleavage sites (vertical lines)
identified in digests of enolase by human erythrocyte 20S proteasomes. (Solid bars) full fragments of
which both N- and C-termini are known. (Open bars) fragments for which only the N-termini were
identified. See 2.2.9 for details.
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2.4.3.2 Server requirements and programming language
PAProC runs on any common internet browser (successfully tested for Netscape versions
3.0, 4.05, 4.5, 4.7, Microsoft Internet Explorer 5.0 and Lynx). The PAProC algorithm was
written in PERL 5, a standard programming language that guarantees functioning of the
program independent of the users’ computer systems.
2.4.3.3 Comparison of MHC I binding prediction and proteasomal cleavage prediction
of CTL epitopes
The SYFPEITHI database (http://www.syfpeithi.de) (Rammensee et al., 1999) was used
to predict MHC I ligands from the tumor associated proteins HER-2/neu, pmel/gp100, p53
and the influenza (strain A/Japan/305/57) protein hemagglutinin (HA). We then checked in
PAProC if any proteasomal cleavages were predicted to generate the exact C-termini of
the predicted MHC I ligands. This was carried out for all the predicted ligands down to the
SYFPEITHI prediction score of the known CTL epitope with the weakest predicted binding
ability (at the most 75 ligands), or for at least the 20 best predicted binders. Example: For
HER-2/neu, two decameric HLA-A*0201-restricted CTL epitopes are known. Their
predicted MHC I binding scores are 24 and 20, respectively. We therefore checked all the
predicted binders, from the highest score (in this case: score 29) down to the score for the
known CTL epitope with the weakest predicted binding ability (here: score 20), for C-
terminal cleavage in PAProC and came up with 38 peptides. For influenza HA, where all
known CTL epitopes fell into the first few predicted ligands, we checked the predicted
cleavages for the 20 MHC I ligands with the highest predicted binding scores.
2.4.4 Results
2.4.4.1 Sequence submission
We have recently described the development of an algorithm for the prediction of
proteasomal cleavages (Kuttler et al., 2000) and have now incorporated it into a publicly
available web site, the Prediction Algorithm for Proteasomal Cleavages (PAProC),
available at http://www.paproc.de. The homepage of PAProC is also the submission page
for amino acid sequences (Figure 2.4-2). From this page, information on the functions of
PAProC and on proteasomes can be accessed.
Amino acid sequences must be entered in the one-letter code, e.g. as FASTA- or original
SWISS-PROT-format. With the exception of letters coding for aa, spaces, numbers and
carriage returns, PAProC will not tolerate additional characters in the sequence. A
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sequence name can be entered that will appear on the result output form for user
information only. A proteasome species (human or yeast) must be selected before
submission. For the human proteasome, it is possible to choose between three predictors
based on slightly different training data (type I: based only on cleavages in enolase; types
II + III: based on cleavages both in enolase and in different ovalbumin peptides). For the
yeast proteasome, it is possible to choose between predictors trained with wt or different
mutant proteasome data. Please refer to (Kuttler et al., 2000), for detailed information.
The default setting for the proteasome species is human proteasome type III.
Figure 2.4-2: Entry and submission web site of PAProC
The entry and submission web site of PAProC displays spaces for sequence entry and click buttons
for prediction and result output options. It additionally provides links to background information for the
first-time user.
As PAProC needs a window of at least 6 aa N-terminal (“to the left”) and 4 aa C-terminal
(“to the right”) of the cleavage site of interest, the minimum length for submitted
sequences is 10 amino acids. Within a 10 aa sequence, PAProC can only predict the
cleavage between positions 6 and 7.
In order to fill in blanks in submitted sequences or to prolong short sequences to reach the
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minimal length of 10 aa, the letter “X” (or “x”) can be used as a wildcard. Please note
that “X” has a neutral (zero) effect on the cleavage decision by PAProC.
2.4.4.2 Results output
Figure 2.4-3: Two formats for result output
There are two output formats for results: Short form (A, C) and long form (B). The short format is
more graphical and displays predicted cleavages as red, vertical bars, inserted into the submitted
sequence. The long format gives in a tabular form detailed information on cleavage positions and
approximate cleavage strength. Examples: (A, B) cleavages predicted in a CTL epitope-containing
peptide from murine cytomegalovirus pp89 IE-protein; (C) cleavages predicted in the C-terminal 175
aa of Presenilin-1, a protein whose mutated forms are involved in Alzheimer‘s disease (Checler et al.,
2000).
For the results, a short and a long output format can be selected. The short format is more
graphical and shows the cleavages inserted into the submitted sequence as red, vertical
bars (Figure 2.4-3 A, C). This format is recommended for a quick overview and serves as
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the default setting. The long format gives more detailed tabular information on
cleavage positions and estimated cleavage strength (Figure 2.4-3 B). It is useful, for
example, for testing effects of mutations on the cleavage pattern and cleavage strength.
(Please note that the assessment of cleavage strength is not based on quantified
cleavage data, but purely on the qualitative nature of the aa flanking the prospective
cleavage site.)
2.4.4.3 Prediction results – mutated peptides containing CTL epitopes
PAProC can rapidly assess the changes of proteasomal cleavage imposed by mutations
in an amino acid sequence containing CTL epitopes. In the case of a Moloney murine
leukemia virus (MuLV) epitope, it was reported that a mutation N→D (as in the related
Friend MuLV), but not N→S (as in the endogenous AKV-type MuLV), just C-terminal of
the CTL epitope abrogates the generation of the C-terminus of the epitope by inducing a
new cleavage site after D (Beekman et al., 2000). PAProC predicts these experimentally
verified cleavages correctly (Figure 2.4-4 A). In another case, the R→H point mutation at
position 273 of the tumor suppressor p53 was shown to abrogate the cleavage generating
the C-terminus of the HLA-A*0201-epitope 264-272 (Theobald et al., 1998). Again,
PAProC correctly predicts this change of the proteasomal cleavage pattern (Figure 2.4-4
B). It should be stressed that PAProC predicts the C-terminal cleavages in the viral and in
the p53-peptides to be very strong cleavages, i.e. the mutations in the peptides turn
strong cleavage sites into non-cleavage sites in PAProC.
In yet another example, the exchange of the N-terminal residue of a viral CTL epitope
rescues it from proteasomal destruction. Whereas the residue R promotes an epitope-
destroying cleavage in the FMR type MuLV sequence, the R→K exchange in the
AKV/MCF type of MuLV weakens this cleavage considerably, thus conserving the
AKV/MCF CTL epitope (Ossendorp et al., 1996). PAProC correctly predicts the epitope-
destroying cleavage behind R; however, PAProC does not predict a cleavage behind K
any more (Figure 2.4-4 C). The latter is in contrast to the experimental results, where a
very weak cleavage was found behind K. However, the result is in line with the
experimental finding that the R→K mutation rescues the CTL epitope.
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Figure 2.4-4: PAProC predictions of changes in the proteasomal cleavage pattern in
sequences containing CTL epitopes, imposed by aa mutations within the epitope or at the
flanking residue
(A) PAProC prediction of the C-terminal cleavage in related viral sequences (experimental results in
Beekman et al., 2000); (B) PAProC prediction of the C-terminal cleavage in a wt and mutant p53-
epitope (experimental results in Theobald et al., 1998); (C) PAProC prediction of an epitope-
destroying cleavage at the N-terminus of related viral sequences (experimental results in Ossendorp
et al., 1996). See text for details. Arrows indicate predicted cleavages. The mutated position is
indicated by large letters. The underlined sequence corresponds to the CTL epitope. Please note that
mouse 20S proteasomes were used to generate the experimental results for the CTL epitopes from
MuLV (A and C). The predictions were done using human proteasome option type III.
2.4.4.4 Prediction results – proteins linked to disease
For polyQ-diseases, altered proteasomal degradation of disease-linked proteins probably
contributes to their intraneural aggregation, a crucial step in the pathogenesis of these
diseases (Wanker, 2000). PAProC can serve to assess the general cleavability and the
proteasomal cleavage pattern in such proteins. For both huntingtin in Huntington’s
disease (HD) and ataxin in spinocerebellar ataxias (SCA), altered proteasomal
degradation has been indicated in development of disease (Evert et al., 2000; Wyttenbach
et al., 2000). We now report that two out of three PAProC-algorithms trained by human
20S proteasome cleavage data (types II and III) predict the polyQ-regions of wt human
ataxin-7 (10 aa) and of wt huntingtin (repeat length: 23 aa) to be resistant to proteasomal
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cleavage (not shown). As the algorithm behind PAProC only inspects a window of 10
aa, the same is true for mutated huntingtin and ataxin with longer polyQ-sequences. It is
conceivable that especially pathologically elongated polyQ-sequences could protect
polyQ-containing proteins from proteasomal degradation, thus leading to protein
accumulation within neurons and to cytosolic and nuclear inclusions. It must be mentioned
that it is not an intrinsic feature of our prediction algorithm to leave poly-aa-sequences
uncleaved: One-third of the 20 possible poly-aa-sequences (like AAAA..., CCCC...,
DDDD..., etc.) are still predicted to be cleaved by proteasomes (not shown).
2.4.4.5 Prediction results – combination of SYFPEITHI and PAProC
For immunologists, PAProC will be most interesting when used in combination with
predictors of MHC I binding. To assess whether PAProC-predictions correlate with known
CTL epitopes, we tested whether PAProC predicts cleavages at the C-termini of CTL
epitopes in the melanoma-associated proteins MAGE-1 and MAGE-3. For MAGE-1, the
C-terminal cleavage was predicted for 8 of 10 CTL epitopes (human proteasome type III,
not shown). In 6 of the 8 cases, cleavages at both the N- and C-terminus of the CTL
epitope were predicted. For MAGE-3, 4 of 7 C-termini were predicted to be cleaved
correctly. In 3 of the 4 cases, PAProC predicted cleavages at both the N- and C-terminus
of the epitope (data not shown). Known CTL epitopes in MAGE-1 include peptides binding
to different HLA-alleles, e.g. to A2 (Pascolo S, submitted), A3, A24, A28, B7, B37, B53,
Cw2 and two epitopes binding to both A1/B35 and Cw3/Cw16, respectively. Known CTL
epitopes in MAGE-3 include peptides binding to A1, A2, A24, B37 and B44 (for references
see Rammensee et al., 1999).
For the combination of MHC I ligand prediction and proteasomal cleavage prediction, one
would probably first predict MHC I binders from a protein sequence of interest. In the
second step, one would check the predicted MHC I binders for correct C- (and perhaps N-
) terminal processing by proteasomes. To mimic this approach, we a) asked SYFPEITHI
to predict MHC I-binding peptides from the tumor-associated proteins HER-2/neu,
pmel/gp100 and p53 and from the influenza HA protein, b) asked PAProC to predict the
cleavages in these proteins and c) compared the outcome to that of known CTL epitopes
from these proteins (Table 2.4-1).
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Table 2.4-1: PAProC predictions of the C-terminal cleavages of CTL epitopes
















2/2 (III) 12/25 (III)
Infl. Jap. HA H2-Kd
(nonamers)
2/3 (I/II) 6/20 (I), 7/20 (II)
# MHC class I molecule for which ligands were predicted; HLA: Human leukocyte antigen; H2:
mouse MHC I; in brackets: length of predicted MHC I ligands
§ PAProC predictions of the C-terminal cleavage for CTL epitopes (Number of correctly predicted C-
termini / number of CTL epitopes tested). Proteasome type: algorithms used for PAProC predictions.
Types I-III, all based on human 20S proteasome cleavage data, slightly differ in parts of their training
data (Refer to Kuttler et al. (2000) for detail; see 2.3).
$ PAProC predictions of the C-terminal cleavage for predicted MHC I ligands (Number of predicted
cleavage sites corresponding to the C-termini of predicted MHC I ligands / number of predicted MHC
I ligands tested). In brackets: proteasome type.
For HER-2/neu decamers, the C-termini of the two known HLA-A*0201-restricted CTL
epitopes were predicted to be cleaved correctly by PAProC’s human proteasome type III
(one of two for types I + II). However, PAProC’s overall hit rate was only 12 of 38 for the
C-termini of predicted MHC I ligands from HER-2/neu, including the two correctly
predicted CTL epitopes (see Material & Methods for details). This discrepancy reflects the
influence of antigen processing on actual MHC I ligand generation. Similarly, for the three
other proteins tested, fitting PAProC predictions were “enriched” among the CTL epitopes
as compared to predicted MHC I ligands (Table 2.4–1). These results suggest that
PAProC can indeed be used in combination with the prediction of MHC I binding to narrow
down the search for CTL epitopes from any protein sequence.
2.4.5 Discussion
Here we have described the first publicly available prediction tool for proteasomal
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cleavages, PAProC (Prediction Algorithm for Proteasomal Cleavages). This internet-
based program (http://www.paproc.de) allows the rapid submission of aa sequences and
provides an output of possible proteasomal cleavages sites within these sequences
(Figure 2.4-2, Figure 2.4-3). PAProC offers information on both the general cleavability of
amino acid sequences (cuts per amino acids) and the individual cleavages (positions and
estimated strength) (Figure 2.4-3). Our results suggest that PAProC can be used to
assess the influence of aa mutations on CTL epitope generation (Figure 2.4-4). More
importantly, PAProC will support the search for CTL epitopes by making it more efficient.
The number of candidates (i.e. predicted MHC I ligands) will be reduced by excluding
those not predicted  to be cleaved correctly (Table 2.4–1).
2.4.5.1 Benefits of PAProC
Proteasomes are involved in many essential cellular processes, such as cell cycle control
and transcription factor activation (Rock and Goldberg, 1999; Pamer and Cresswell,
1998). They have also been linked to disease, e.g. Alzheimer’s, Parkinson’s and
Huntington’s disease (Checler et al., 2000; Wanker, 2000). Thus, PAProC might be
attractive for researchers in a wide range of fields. However, as proteasomal cleavage
specificity can regulate immune responses (see 2.4.2 Introduction), immunologists
studying antigen processing will most likely constitute the largest group of future PAProC-
users. Rational vaccine-design in particular could profit from proteasomal cleavage
prediction. For multi-epitope vaccines, PAProC could for example be used to determine
epitope-linking regions that most efficiently support correct processing of the amino acid
sequence. Moreover, proteasomal cleavage predictors such as PAProC could be used for
the design of peptide-based proteasome inhibitors.
2.4.5.2 Prediction success rate of PAProC
There are examples in which PAProC does not predict proteasomal cleavages at the C-
termini of known CTL epitopes (hit rate in HER-2/neu HLA-A*0201-restricted nonamers: 3
of 7 CTL-epitopes, 15 of 40 predicted MHC I ligands; pmel17/gp100 HLA-A*0201-
restricted decamers: 1 of 6 CTL-epitopes; EBV EBNA-6 HLA-B*2705-restricted nonamers:
1 of 2; EBV EBNA-3 HLA-B*08-restricted nonamers: 0 of 4 CTL-epitopes; not shown).
Although C-terminal trimming cannot be excluded to play a role in vivo (Elliott et al., 1995),
it is more likely that the limited amount of training data for the PAProC algorithm is
responsible for this (Kuttler et al., 2000).
PAProC also predicts epitope-destroying cleavages within known CTL epitopes (not
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shown). We do not consider this a problem because there are many examples of
proteasomal cleavage sites within CTL epitopes that do not abrogate presentation of the
epitope in vivo (Ossendorp et al., 1996; Theobald et al., 1998; Morel et al., 2000;
Lucchiari-Hartz et al., 2000, to name a few). Moreover, epitope-destroying cleavages
might be weak ones, whereas cleavages at the C-termini of CTL epitopes might be
dominant ones. Our preliminary prediction data suggest this notion (Kuttler, unpublished
observation). However, only predictions based on quantified cleavage data will solve this
problem adequately. The assessment of cleavage strength from non-quantified data, as
executed in PAProC at present, is only a rough estimate.
The PAProC algorithms trained with human 20S proteasome data correctly predict
cleavages that were generated experimentally or in vivo by mouse proteasomes (Figure
2.4-4, Table 2.4–1). This result suggests that PAProC’s human proteasome algorithms
can be used to predict cleavages generated by any other mammalian proteasome. This
concept is supported by the finding that the cleavage preferences of mammalian
proteasomes are similar (Bjorkman et al., 1987). The successful prediction results for CTL
epitopes binding to different human HLA- (text and Table 2.4–1) and the mouse H2-Kd
MHC I molecules (Table 2.4–1) confirm that the success rate of PAProC predictions does
not depend on factors imposed by distinct MHC I binding motifs.
2.4.5.3 Future developments
PAProC was developed by antigen processing and proteasome specialists in close
collaboration with biomathematicians, and has thus profited from competent biological and
mathematical expertise. However, we are aware of the fact that PAProC is still in its
"childhood years". The precision of PAProC predictions varies depending on the substrate
and, for human proteasome, on the proteasome type chosen. The lack of training data is
probably responsible for this (Kuttler et al., 2000). For this reason, we are continuously
working on improving PAProC both by the generation of additional training data and by
the fine tuning of the prediction model itself. For example, in the future we will use
quantified cleavage data for greater accuracy. We will use cleavages by 26S proteasomes
(Emmerich et al., 2000) and cleavages by immuno- or constitutive human 20S
proteasomes (Toes et al., in preparation; see 2.5 for details) as training data. The latter
approach in particular will be of great interest for immunologists. Moreover, we are
developing an algorithm based on fragments, not cleavage sites, hence allowing the
prediction of fragments, not just cleavage sites. This approach will give more insight into
whether cleavages within MHC-ligands will still allow the generation of the uncut ligand.
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However, PAProC will profit most efficiently from working experience, which is one of
the main reasons for making it public at this point. We therefore encourage PAProC users
to let us know how the program performed for them. We will be happy to include
experimental data generated outside our lab into our training data. However, strict quality
measures will be applied.
2.4.5.4 Distant goal
For immunologists, proteasomal cleavage prediction will be most useful in combination
with the prediction of MHC I ligands. Several groups are preparing such combined
approaches. A group in Berlin is combining the previously reported proteasomal cleavage
algorithm (Holzhütter et al., 1999) and PAProC to available predictors of MHC I binding,
such as SYFPEITHI (H. Mollenkopf, personal communications). In Copenhagen,
NetChop, a  neural network for proteasomal cleavage prediction (C. Kesmir, submitted),
and PAProC will be combined to different available MHC I ligand predictors (C. Kesmir
and S. Brunak, personal communications). A group in Leiden is preparing an approach by
which  proteasomal cleavage data will be combined with characteristics of known CTL
epitopes (F. Ossendorp, C. Melief, personal communications).
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2.5 Discrete cleavage motifs of constitutive and immuno-
proteasomes revealed by quantitative analysis of cleavage
products
2.5.1 Summary
Proteasomes are the main proteases responsible for cytosolic protein degradation and the
production of MHC class I-ligands. Incorporation of the IFN-γ-inducible subunits LMP2,
LMP7 and MECL-1 leads to the formation of immuno-proteasomes which have been
associated with more efficient MHC class I antigen processing. Although differences in
cleavage specificities of constitutive- and immuno-proteasomes have been observed
frequently, cleavage motifs have not been described.
Using the 436-amino acid protein enolase-1 as unmodified model substrate and a novel
quantitative approach, we analyzed a large collection of peptides generated by either set
of proteasomes. Inspection of the amino acids flanking proteasomal cleavage sites
allowed the description of two different cleavage motifs. These motifs finally explain recent
findings describing differential processing of CTL-epitopes by constitutive- and immuno-
proteasomes and are important to the understanding of peripheral T cell
tolerization/activation as well as for effective vaccine development.
2.5.2 Introduction
Cytotoxic T lymphocytes (CTL) are crucial for the defense against many invading
organisms and certain tumors. Presentation of antigenic peptides bound to major
histocompatibility complex (MHC) class I molecules is a prerequisite for stimulation of a
CTL-response, and therefore plays a pivotal role in providing CTL with the capacity to
respond to foreign antigens (Rammensee et al., 1993).
Peptides that meet the restrictive binding characteristics of MHC class I molecules for
presentation to CTL are generated after intracellular protein degradation by cytosolic
proteases. The central enzyme responsible for protein degradation is the proteasome
(Rock and Goldberg, 1999). Because of their intimate involvement in antigen processing
and presentation (Pamer and Cresswell, 1998), detailed knowledge on the cleavage
preferences of proteasomes will be crucial for understanding CTL-epitope generation and
thus for the regulation of specific immune responses.
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The 20S proteasome represents the proteolytic core of the larger 26S proteasome
complex that encompasses either one or two regulatory particles of at least 18 subunits
(Coux et al., 1996). The eukaryotic 20S particle is composed of 14 different but related
subunits organized in a barrel-shaped complex with the stoichiometry α7β7β7α7. Three
subunits of the two inner β-rings (β1, β2 and β5) participate directly in peptide bond
cleavage. They represent three distinct proteolytic activities, designated as the
chymotrypsin (ChT)-like, trypsin-like and peptidylglutamylpeptide-hydrolyzing (PGPH)
activities (Heinemeyer et al., 1997; Dick et al., 1998). As the NH2-terminal threonine
residues responsible for peptide bond cleavage do not directly prefer certain peptide
bonds over others, the basis for the three distinct proteolytic activities most likely resides
in the characteristics of the amino acids in the vicinity (pockets) of each active NH2-
terminal threonine (Groll et al., 1997).
Upon interferon-γ (IFN-γ) exposure of cells, the three active β-subunits that are
constitutively expressed in 20S-proteasomes can be replaced by three IFN-γ-inducible
homologues, LMP-2 (=β1i) (for Y  (β1)), MECL-1 (β2i) (for Z (β2)) and LMP-7 (β5i) (for X
(β5)).  Although there is extensive sequence homology, these replacements alter the
nature of peptides that are generated by proteasomes (Boes et al., 1994; Groettrup et al.,
1995; Gaczynska et al., 1993; Eleuteri et al., 1997; Cardozo and Kohanski, 1998).
Proteasomes harboring these IFN-γ-inducible subunits are also called immuno-
proteasomes, as opposed to the constitutively expressed "constitutive" proteasomes,
because immuno-proteasomes were found to process a number of viral epitopes with
greater efficacy in vitro (Sijts et al., 2000a; Sijts et al., 2000b; van Hall et al., 2000;
Schwarz et al., 2000). Using several artificial fluorogenic substrates in vitro, it was found
that immuno-proteasomes display a better capacity to cleave after hydrophobic and basic
residues, but are less well equipped for cleavage after acidic amino acids (Gaczynska et
al., 1994). The finding that proteasomes are responsible for the generation of the correct
COOH-terminus of several CTL-epitopes (Craiu et al., 1997; Stoltze et al., 1998), and the
notion that hydrophobic or positively charged amino acids serve in most cases as COOH-
terminal anchor-residues of MHC class I-ligands, led to the concept that immuno-
proteasomes contribute to more efficient MHC class I antigen-processing. Nonetheless,
more recent studies have shown that some antigenic peptides are efficiently produced by
constitutive proteasomes but cannot be produced by immuno-proteasomes (Morel et al.,
2000). This clearly contradicts the concept that the immuno-proteasome is generally
better suited for the processing of MHC class I-ligands.
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To better understand the reasons why certain MHC class I-ligands are destroyed and
others generated with greater efficiency in cells expressing different sets of proteasomes,
we have performed an in-depth analysis of peptide fragments generated after
proteasomal cleavage.
We have employed, for the first time, a strictly quantitative method to analyse a large
collection of peptide-fragments produced by either set of proteasome. Our observations
allowed the identification of certain amino acids (or their characteristics) in positions
distant, or directly flanking the cleavage sites selected by either set of proteasomes. The
(quantified) mapping of cleavage sites using a large protein substrate provides the basis
for a better understanding of proteasomal cleavage specificity, allowing a refined
proteasomal cleavage prediction, which will be helpful for the identification of new CTL
epitopes, the design of new (recombinant) vaccines, and for better insight into immunity
against infection.
2.5.3 Materials & Methods
2.5.3.1 Purification of 20S proteasomes
20S proteasomes were isolated as described before (Groettrup et al., 1995). Frozen
pellets of LCL-721 cells or LCL-721.174 cells were lysed in a buffer containing 0.1%
Triton-X-100 on ice and homogenized in a Dounce homogenizer. The 40.000xg
supernatant of the lysate was bound to DEAE-Sephacel. After elution, the protein fraction
was concentrated and loaded onto a 10 - 40% sucrose gradient. After centrifugation,
gradient fractions were tested for protease activity using the fluorogenic substrates Suc-
LLVY-AMC and Suc-YVAD-AMC. Active fractions were pooled and further purified by
anion exchange chromatography on a MonoQ HR5/5 FPLC column (Pharmacia). The
purity of the proteasome preparates, checked by SDS-PAGE, was >95%. Quantification of
native proteasome protein was determined by a variation of the Lowry Method (Bio-Rad
Protein Assay, Bio-Rad) and bovine serum albumine as a standard.
2.5.3.2 Immunoblotting
5 µg of purified proteasome polypeptides were separated by 12% SDS-PAGE, and
transferred to polyvinyldifluoride (PVDF) (DuPont) with a semidry transfer system. Human
LMP-7 was detected using a rabbit polyclonal antiserum by chemoimmunoluminescence
(PW8200, Affiniti research Products Ltd. Mamhead, UK).
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2.5.3.3 Measurement of proteasomal activities against substrates with fluorogenic
leaving group
The flourogenic substrates benzyloxycarbonyl-Leu-Leu-Glu- β-naphtylamide (Z-LLE- β-
NA), succinyl-Tyr-Val-Ala-Asp-7-amino-4-methylcoumarin (Suc-YVAD-AMC), succinyl-
Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC), and benzyloxycarbonyl-
Ala-Arg-Arg-7-amino-4-methylcoumarin (Z-ARR-AMC) (all from Bachem, Heidelberg,
Germany) were prepared from 10 mM stocks in Me2SO. 1 µg proteasome was incubated
with 100 µM substrate solution. Fluorescence of the leaving group was determined after
incubation for 0 - 6 hours with a Tecan spectrophotometer (Tecan, Crailsheim, Germany)
at 360 nm excitation and 450 nm emission for AMC and at 330 nm excitation and 410 nm
emission for β-NA. Fluorescence readings of released AMC or β-NA were recorded as
arbitrary units.
2.5.3.4 In vitro degradation of enolase 1
150 µg of yeast enolase 1 was incubated in digestion buffer (20mM Hepes/KOH (pH 7.6),
2 mM MgAc2, and 0.01% SDS) with proteasomes in a molar ratio of 150:1. Digestions
were stopped by freezing the samples at -80°C when approximately 50% of the substrate
was digested (usually after approximately 48 hours).
2.5.3.5 Separation and analysis of cleavage products
For the separation of degradation products, unfractionated enolase digests were
subjected to µRP SC 2.1/10 columns (Pharmacia) on a Microbore HPLC-system (SMART
system, Pharmacia). Buffer A contained 0.1% trifluoroacetic acid (TFA); buffer B
contained 0.081% TFA and 80% acetonitrile. Gradients were 0% for 5min, in 40 min to
40% B, in 8 min to 75% B, and up to 85% in another 7 min at a flow rate of 150 µl/min.
Fractions were collected by peak fractionation with a maximal volume of 500 µl/peak.
Peak fractions were dried and redissolved in 25µl of 40% methanol, 1% formic acid and
subsequently analysed by Matrix-associated Laser desorption ionization-time of flight
(MALDI-TOF) mass spectrometry (G2025A, Hewlett Packard, Waldbronn, Germany) and
N-terminal sequencing (Edman degradation) (pulsed liquid protein sequencer procise
494A, Applied Biosystems, Weiterstadt, Germany). Alternatively, peptides were analysed
on a hybrid quadrupole orthogonal acceleration tandem mass spectrometer (Micromass).
All these techniques were applied as described recently (Nussbaum et al., 1998). Pmol
amounts for each peptide detected in the HPLC fraction were determined by Edman
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sequencing and used for the quantitative analysis of the data.
2.5.3.6 Statistical analysis - frequencies of amino acids
To detect statistically significant features in the amino acid distributions flanking the
cleavage sites, we compared percent values using a classical Chi2-test for four tables
(variance assumed due to counting). This method was used to compare constitutive and
immuno-proteasomes with each other and with enolase. For a more thorough comparison
of the absolute pmol-amounts of constitutive and immuno-proteasomes, we accounted for
the experimental variability and, according to the quasi-likelihood approach of
Wedderburn, assumed a mean-variance structure. We assumed the variance to be
proportional to the mean and fitted the proportionality constant α from all the data. Then,
the usual Chi2-test variable was scaled by 1/α, which led asymptotically to a test variable
that is Chi2 distributed with one degree of freedom. – The results of the latter, more
thorough approach correlated to the approach neglecting experimental variability and
using percent values. Only Chi2-values above 3.841 are considered to be significant.
2.5.3.7 Statistical analysis - comparison of amino acid characteristics
To compare the characteristics of amino acids, The observed frequencies of amino acids
at P6 to P6' around cleavage sites in both proteasomes were compared to each other
using the Chi2-test. Hydrophobicity, bulkiness, and flexibility characteristics (values as in
24) of both proteasomes, and enolase were compared by translating the percentage
amino acids found to the corresponding  hydrophobicity, bulkiness, and flexibility scales.
This resulted in spectra per cleavage site, and these were compared by means of
regression analysis.
2.5.4 Results
2.5.4.1 Isolation of proteasomes
Proteasomes were isolated from EBV-transformed B cells. Constitutive proteasomes were
purified from cells (LCL721.174) lacking LMP2 and LMP7 due to a chromosomal deletion
in the MHC-locus (Spies et al., 1990; DeMars et al., 1985). The lack of LMP2 or LMP7
results in inefficient maturation of MECL-1 in 20S proteasomes. Therefore, this cell line
contains only proteasomes carrying active constitutive subunits (Griffin et al., 1998). The
immuno-proteasome preparation was isolated from the parental line (LCL721) that served
for the generation of LCL 721.174.
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Figure 2.5-1: Immuno-subunit-incorporation into 20S proteasomes purified from LCL-721 cells
(left), but not into 20S-proteasomes derived from LCL-721.174 cells (right).
20S proteasomes were isolated from LCL-721 and LCL-721.174 cells as described in materials and
methods. Proteasome subunits were separated by SDS-PAGE (a) and probed with an LMP-7-
specific antiserum (b). LMP-7 was only detected in 721-proteasomes.
As expected, only proteasomes isolated from LCL721 cells expressed immuno-subunits,
as examplified by the presence of LMP7 (Figure 2.5-1a,b). Moreover, these proteasomes
showed an increased cleavage activity after the hydrophobic amino acid tyrosine and a
reduced ability to release fluorogenic groups linked to acidic amino acids, compared to
proteasomes isolated from LCL721.174 cells (Figure 2.5-2). Both proteasome
preparations harboured the constitutive subunit Z (not shown). This indicates that not all
constitutive subunits were exchanged in the proteasome pool of the LCL721 cells, which
most likely gives a good reflection of the intracellular proteasome pool present in IFN-γ
treated cells.
Together, these data indicate that proteasomes purified from LCL721, although containing
some constitutive proteasomes, behave like immuno-proteasomes with very little PGPH-
activity, whereas LCL721.174-derived proteasomes can be classified as constitutive
proteasomes with high PGPH-activity.
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Figure 2.5-2: Comparison of the ability of 20S proteasomes isolated from LCL-721 and LCL-
721.174 cells to catalyze the release of fluorogenic groups from three different substrates.
Peptidylglutamylpeptide-hydrolyzing activity was analyzed using Z-LLE-βNA and Suc-YVAD-AMC as
substrates. The substrates Suc-LLVY-AMC and Z-ARR-AMC were used to analyze chymotrypsin-like
and trypsin-like activities, respectively. One representative experiment of three is shown.
2.5.4.2 Digestion of Enolase
Although the ability of constitutive- and immuno-proteasomes to cleave a set of standard
fluorogenic substrates or some CTL-epitope containing peptides has been well
documented, little is known about the selection of cleavage sites during the degradation of
proteins, especially on a quantitative basis. To obtain further insight into these cleavage
preferences, we used the complete protein enolase-1 from yeast as substrate, which can
be digested by proteasomes in vitro without prior modifications. Enolase is a 436 amino
acid long protein in which the frequency of amino acids resembles the average amino acid
frequency in proteins (Brendel et al., 1992). Digestion of enolase was performed by
incubation with constitutive- or immuno-proteasomes at a molar ratio of 150 : 1 (enolase :
proteasome). The reaction was stopped when approximately 50% of the substrate was
degraded, and subsequently separated by reversed phase HPLC (Figure 2.5-3a,b).
Comparison of two independent digests obtained after incubation with two independent
constitutive proteasome batches, revealed that highly comparable degradation profiles
were obtained (Figure 2.5-3c). These data indicate that different incubations by the same
proteasome type yields a similar set of degradation products, as was confirmed by
MALDI-MS analyses of several fractions that eluted at the same time (not shown).
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Figure 2.5-3: Enolase degradation by proteasomes purified from LCL-721 and LCL-721.174
cells.
Enolase was incubated with constitutive proteasomes (a), immuno-proteasomes (b) or was left
untreated (dotted lines). A magnification of the degradation-profile is shown in the inserts. The
comparison of two independent digestion-profiles (in c) acquired after incubating enolase with two
different constitutive proteasome-batches purified from LCL-721.174 cells shows high reproducibility,
indicating that a similar set of peptides is generated by different "174-proteasome"-batches. Optical
density at 214 nm of eluted digestion products from reversed phase HPLC is shown.
After having established the reproducibility of the digestion profiles, the peptide fragments
in all fractions were analysed by Edman sequencing, in combination with MALDI-MS, and
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compiled in a digestion map (Figure 2.5-4). Approximately 50% of cleavages
generated by constitutive proteasomes were not produced by immuno-proteasomes.
Indeed, when the identity of fragments produced by either set of proteasome was
compared on a qualitative basis, only around 25% of peptides produced by immuno-
proteasomes were also found in constitutive proteasome digests.
Therefore, the pool of peptides generated by cells expressing immuno-proteasomes is
very different from the peptide-pool generated by cells harbouring constitutive
proteasomes only.
2.5.4.3 Quantification of digestion profiles
For careful examination of proteasomal cleavage preferences, it is important to know the
quantity of each fragment to calculate how often particular cleavage sites are selected. In
contrast to MS-data, data acquired by Edman-sequencing are quantitative, and can thus
be used to determine the amount of peptide liberated. The combination of MS-analysis
and the quantified Edman-sequencing data identified the absolute amount of each peptide
detected in HPLC-fractions. In the constitutive proteasome digests, a total of 136
fragments was detected, representing 6135 pmol of peptide (Table 2.5-1). By adding the
pmol of all fragments starting or ending at a particular cleavage site (and then choosing
the higher one of the two sums), pmol amounts of peptide generated from a given
cleavage site, and thus the frequency of cleavage site utilization was determined. The
most frequently used cleavage sites were found at amino acid position 278 and 404,
resulting in the liberation of 265 pmol peptide each (Table 2.5-1 top). As usage of many
other cleavage sites resulted in only 5 pmol of peptide, these data indicate that the relative
usage of cleavage sites within one protein can differ substantially.
Similar data were obtained for the immuno-proteasome digest (123 peptides representing
6370 pmol of peptide) (Table 2.5-2). The most abundant cleavage site was found at amino
acid position 419, resulting in the generation of 250 pmol peptide (Table 2.5-2 top). As for
constitutive proteasomes, many other cleavage sites were used less often, indicating that
both proteasome species prefer certain peptide bonds over others as cleavage sites. The
almost identical amounts of peptides generated by both proteasomes (6135pmol versus
6370 pmol) demonstrate a comparable substrate turnover, allowing a direct comparison of
pmol amounts of amino acids at different positions around cleavage sites as well as a
comparative statistical analysis of both digests.
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Figure 2.5-4: Digestion map generated from degradation of enolase by constitutive
proteasomes (A) and immuno-proteasomes (B).
Vertical lines: cleavage sites determined by Edman degradation and/or MS; solid bars: degradation
products identified by Edman degradation in combination with MS; open  bars: degradation products
identified by Edman degradation only (COOH- terminus of peptide not identified).
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Table 2.5-1: Absolute amounts of amino acids found in positions P6 to P1 and P1’ to P6'
of peptides generated by constitutive proteasomes.
Position pmol P6-P1  P1'-P6'
278 265 LTGPQL ADLYHS
404 265 APARSE RLAKLN
383 185 TEDTFI ADLVVG
31 175 EKGVFR SIVPSG
142 165 SKSKTS PYVLPV
183 165 TFAEAL RIGSEV
230 165 LDLIVD AIKAAG
330 155 TNPKRI ATAIEK
146 150 TSPYVL PVPFLN
79 145 PAFVKA NIDVKD
P6 P5 P4 P3 P2 P1  P1' P2' P3' P4' P5' P6'
A 865 595 1020 485 620 825 1545 330 710 590 930 365
C 0 0 0 0 130 0 0 0 0 0 0 0
D 580 460 255 215 185 805 300 1185 315 235 170 400
E 530 465 385 455 250 605 300 275 460 150 465 440
F 50 275 430 165 430 145 190 250 165 575 220 50
G 300 575 750 230 545 175 185 415 760 185 320 780
H 175 125 10 150 280 65 165 110 65 35 385 90
I 505 125 385 335 180 510 60 845 220 450 405 170
K 220 580 240 945 455 80 365 115 370 675 600 655
L 540 550 535 525 230 1185 345 900 1120 435 670 565
M 10 0 95 10 15 35 70 40 75 65 10 60
N 120 285 235 140 240 95 390 215 195 160 270 730
P 365 475 550 365 95 40 480 20 255 240 330 315
Q 45 260 25 20 340 60 75 60 155 305 35 75
R 125 45 45 425 290 275 595 95 155 145 80 60
S 575 365 380 90 535 395 500 215 170 530 490 555
T 735 460 140 365 365 140 150 430 140 360 250 105
V 270 380 365 920 840 450 275 410 695 705 355 695
W 40 15 35 30 20 30 0 50 0 0 50 10
Y 85 100 255 265 90 220 145 175 110 295 100 15
sum 6135 6135 6135 6135 6135 6135 6135 6135 6135 6135 6135 6135
(Top) 10 most abundant cleavage sites from P6-P1 and P1'-P6', the position of the cleavage site
(pos) and the calculated amount of enolase that has been cleaved at this position (pmol) (see also
Materials and Methods).
(Bottom) Based upon quantified data (as exemplified in Top), the absolute amounts of amino acids
(in pmol) around all identified cleavage sites are shown.
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Table 2.5-2: Absolute amounts of amino acids found in positions P6 to P1 and P1’ to P6'
of peptides generated by immuno-proteasomes.
Position pmol P6-P1  P1'-P6'
419 250 RIEEEL GDNAVF
390 200 DLVVGL RTGQIK
183 155 TFAEAL RIGSEV
313 155 HFFKTA GIQIVA
133 150 PLYKHL ADLSKS
142 150 SKSKTS PYVLPV
253 150 ASSEFF KDGKYD
285 150 DLYHSL MKRYPI
289 150 SLMKRY PIVSIE
383 150 TEDTFI ADLVVG
P6 P5 P4 P3 P2 P1  P1' P2' P3' P4' P5' P6'
A 680 615 940 420 590 745 1440 665 560 775 480 810
C 0 0 0 0 0 0 0 0 0 0 0 0
D 725 360 190 225 160 150 335 1210 255 325 220 375
E 300 370 515 870 580 155 255 320 410 270 400 515
F 0 495 280 105 665 550 50 100 120 260 190 250
G 500 550 485 180 360 170 880 475 970 265 465 675
H 300 35 80 285 205 130 140 40 50 40 340 285
I 440 345 290 470 145 585 20 800 295 420 730 395
K 90 475 400 1065 620 175 450 275 290 405 590 830
L 560 975 450 235 160 2305 65 370 1025 410 105 510
M 20 0 215 10 80 50 295 0 0 100 0 50
N 245 285 290 165 205 95 520 290 560 575 190 290
P 325 370 255 380 35 0 375 175 305 180 440 80
Q 10 260 210 105 170 10 175 75 225 250 100 20
R 365 100 65 215 395 200 480 0 190 290 320 100
S 545 250 610 225 735 185 345 320 265 695 380 520
T 890 200 85 235 570 195 310 560 275 195 275 55
V 255 485 585 940 695 320 85 535 495 555 925 610
W 25 60 0 25 0 70 0 0 0 75 0 0
Y 95 140 425 215 0 280 150 160 80 285 220 0
sum 6370 6370 6370 6370 6370 6370 6370 6370 6370 6370 6370 6370
(Top) 10 most abundant cleavage sites from P6-P1 and P1'-P6', the position of the cleavage site
(pos) and the calculated amount of enolase that has been cleaved at this position (pmol) (see also
Materials and Methods).
(Bottom) Based upon quantified data (as exemplified in Top), the absolute amounts of amino acids
(in pmol) around all identified cleavage sites are shown.
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Comparison -on a qualitative and quantitative basis- of the fragment length
distributions revealed that both proteasome species generated peptides in the size range
from 4-24 (c20S) and 3-26 (i20S) amino acids with an average length of  7 - 9 amino acids
(Figure 2.5-5).  As observed after qualitative analysis, quantitative comparison of the data
sets showed that only 30% of the peptides produced by constitutive fragments were also
produced by immuno-proteasomes (data not shown). Together, these findings strongly
indicate that in cells harbouring constitutive- or immuno-proteasomes, respectively, the
pool of peptides generated from proteasomal protein turnover will differ substantially.
Figure 2.5-5: Distribution of fragment lengths generated by constitutive proteasomes and
immuno-proteasomes.
The frequencies (a and c) and absolute amounts (b and d) of different fragments with the same size
obtained from enolase after digestion with constitutive proteasomes (c and d) and immuno-
proteasomes (a and b) is depicted.
2.5.4.4 Analysis of cleavage site-usage
As outlined above, some cleavage sites are used often, whereas others are used less
frequently or not at all by one or both proteasome species. Until now, most studies
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addressing the specificity of proteasomal peptide/protein degradation did not take the
frequency of cleavages into account. To study more accurately the influence of all 20
amino acids flanking proteasomal cleavage sites, we determined the frequencies of amino
acids around cleavage sites (P6 to P1 NH2-terminal of cleavage site; P1' to P6' COOH-
terminal of cleavage site) using the quantified data set described above (Table 2.5-1,
Table 2.5-2 and Figure 2.5-6). No statistically significant differences in cleavage site
selection were observed between the quantified cleavage data of two independent digests
performed by two independent immuno-proteasome batches, indicating that their
cleavage preferences were highly reproducible (not shown).
Figure 2.5-6: Relative frequencies of amino acids in position P1 (a) P1' (b).
The absolute amount of amino acids found in a defined positions (P6 to P6') around cleavage sites
used by constituve proteasomes and immuoproteasomes was divided by the total amount of
peptides detected in the digests resulting in the relative frequency of amino acid-usage in that
position. Big white bars: relative frequency of amino acids found in enolase; black bars: relative
frequency of amino acids at P1 or P1' positions in peptide-fragments generated by constitutive
proteasomes; grey bars: relative frequency of amino acids at P1 or P1' in peptide-fragments
generated by immuno-proteasomes.
Examination of cleavages performed by immuno-proteasomes revealed several deviations
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from randomness at the amino acid level (i.e. the background in enolase) as
determined by Chi2 analysis (not shown). L as P1 residue has the highest preference
(Chi2: 21) and reflects a pronounced ChT-like activity within immuno-proteasomes.
Weaker preferences for T at P6 (Chi2: 5.2) and D at P2' (Chi2: 6.2) are also evident. On
the other side, several residues appear to exert a negative influence on cleavage site
selection, with the hydrophobic residues I, L and V (Chi2: >4.3) at P1' being the most
prominent. Apart from these amino acids at the P1' position, L at P2 and P5', as well as K
at P6 (all Chi2: 4) were found less abundantly as expected. When amino acids are
grouped according to their characteristics, it was found that there was a positive
correlation between cleavage and the presence of hydrophobic, and bulky amino acids in
P1 (p < 0.0002).
An analogous examination for the cleavages selected by constitutive proteasomes
revealed that the frequency of S as P3- and the positively charged amino acid K as P1-
and P2'-residue is reduced (all Chi2: 3.9), indicating that these amino acids are disfavored
by constitutive proteasomes at these positions. Constitutive proteasomes, like immuno-
proteasomes, prefer A at P1' and L as P1 residue (albeit to a lesser extent; Chi2: 4.2).
Similarly, an enrichment for D at P2' was noted (Chi2: 8.5), indicating that both
proteasome species have a preference for negatively charged amino acids at the P2'
position. When comparing characteristics of amino acids at these positions, a preference
for hydrophobic, bulky amino acids in P1 (p < 0.0002) was observed. There is a negative
correlation between cleavage site selection and the presence of hydrophobic, bulky amino
acids in P1' (p < 0.0002).
2.5.4.5 Effect of immuno-subunit incorporation on cleavage site selection.
The data described above reveal that both proteasome species exhibit a different, but
partially overlapping (L in P1, A in P1' and D in P2') cleavage preference. However, they
do not address directly the influence of immuno-subunit incorporation on cleavage site
selection. Therefore, we compared absolute and relative amino acid frequencies around
cleavage sites used by immuno-proteasomes to those used by constitutive proteasomes.
As control, we evaluated cleavage site selection of two independent immuno-proteasome
batches, yielding no statistically significant differences (not shown). When comparing the
two proteasome species for individual amino acid usage, a strong enrichment of L (Chi2:
7.1 and to a lesser extent F, Chi2: 3.8) was detected at P1 in peptides generated by
immuno-proteasomes. The strong enrichment of L became most prominent when we
analysed in detail those cleavages exclusively generated by immuno-proteasomes, as
150
43% of these cleavages were performed after L (data not shown). Acidic amino acids
D and E in P1 exert a negative influence on cleavage site selection by immuno-
proteasomes (Chi2: 4.5 and 8.1 respectively). G in P1' is enriched in peptides generated
by immuno-proteasomes (Chi2: 7.8), pointing to a preference of immuno-proteasomes for
this small nonpolar amino acid in P1'. Analysis of amino acid frequencies at positions P2
to P6 and P2' to P6' showed a preference of immuno-proteasomes for V at P5 (Chi2: 4.2),
whereas L at P5' and P2' is disfavored by immuno-proteasomes (Chi2: 7.3 and 4.3
respectively). When testing for amino acid characteristics, we found that immuno-
proteasomes prefer bulky, hydrophobic amino acids at P1 (P < 0.003), but dislike flexible
amino acids at this position (p<0.001). Similarly, immuno-proteasomes prefer hydrophobic
amino acids in P5 (p<0.03), but disfavor flexible amino acids in this location (p<0.04). The
opposite was found in P1': hydrophobic, bulky amino acids were favored more by
constitutive proteasomes (p<0.04). Thus, comparison of peptide bonds used as cleavage
sites by immuno-proteasomes to the ones used by constitutive proteasomes revealed a
pronounced ChT-like activity of immuno-proteasomes, as is reflected by a strong
enrichment of hydrophobic amino acids in P1. The results mentioned above are
summarized in Table 2.5-3.
2.5.5 Discussion
The proteasome is the key enzyme responsible for cytosolic protein degradation and the
generation of peptides that are presented by MHC class I molecules by liberation of the
appropriate COOH- or NH2- and COOH-terminus. However, proteasomes also can
prevent MHC class I presentation by destruction of potential MHC-ligands or their inability
to select the proper C-terminal cleavage site. Cleavage site selection might change
substantially after incorporation of IFN-γ-inducible subunits, as indicated by experiments
using small fluorogenic substrates or short synthetic peptides. Therefore, detailed
knowledge on the specificity of protein degradation by either constitutive or immuno-
proteasomes is vital to the comprehension and prediction of CTL-epitope generation.
To analyse alterations of cleavage preference upon immuno-subunit incorporation, we
used an entire protein as substrate without modification of amino acids or bias to known
CTL epitopes. The quantitative identification of more than 120 peptide fragments
generated by either constitutive- or immuno-proteasomes allowed a detailed analysis of
the cleavage specificities. Our data reveal that especially the amino acids in P3 to P3'
have a strong influence on cleavage site selection as the observed frequencies of amino
acids in these locations showed the largest discrepancy with their background frequencies
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in enolase. Nonetheless, amino acids further away most likely influence cleavage site
selection as well, as was reported earlier for the effect of P at P4 on peptide bond
cleavage by yeast and constitutive proteasomes (Nussbaum et al., 1998; Shimbara et al.,
1998; Kuttler et al., 2000; Miconnet et al., 2000). The average length of fragments
produced by either set of proteasome is almost the same. The slight increase in the length
of fragments generated by immuno-proteasomes can be explained by the lack of
cleavages after acidic amino acids. As a consequence more fragments with MHC class I
ligand potential are generated.
Table 2.5-3: Cleavage motifs of constitutive and immuno-proteasomes
Preferred (+) or disliked (-) aa residues flanking cleavage sites (↓). c20S (i20S): Frequencies of aa
surrounding cleavages performed by constitutive (immuno-) 20S proteasomes as compared to the aa
frequencies in enolase. i20S/c20S: direct comparison of the aa frequencies around immuno-
proteasome cleavages to constitutive proteasome cleavages. The results shown here are based on
pmol-quantities. Letters: aa in one-letter code. Brackets: results only slightly significant. Italic: aa
characteristics: f, flexible, b: bulky, h, hydrophobic.
By comparing flanking residues around cleavage sites, we found that both proteasomes
display a partially overlapping, but different cleavage specificity (Figure 2.5-6 and Table
2.5-3). They both prefer L as P1-residue, whereas K in P3, A in P1' and D in P2' were also
favored. Nonetheless, immuno-proteasomes have a much stronger preference for L at P1,
as well as other hydrophobic amino acids in this position. These findings point to a
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pronounced ChT-like activity after immuno-subunit incorporation. In contrast, the
acidic amino acids D and E were clearly disfavored by immuno-proteasomes, whereas
these amino acids were enriched at P1 in peptides generated by constitutive
proteasomes. Some of the different characteristics regarding amino acid preferences at
the P1 position were observed previously in a small number of fragments generated from
covalently modified lysozyme using proteasomes from bovine spleen and pituitaries
(Cardozo and Kohanski, 1998).
Our observations most likely correlate with the characteristics of amino acids at the inner
surface of the proteasome. Analysis of the contribution of individual active β-subunits to
cleavage site selection in yeast 20S protesomes (Heinemeyer et al., 1997; Nussbaum et
al., 1998), revealed that the active site of β1 prefers to cleave after acidic residues, β2
after basic residues and β5 after hydrophobic residues. Structural analysis of
proteasomes has shown that the pockets around the active site threonine of β5 and β2 do
not change after immuno-subunit incorporation (Groll et al., 1997). Therefore, it is most
likely that the cleavage site-flanking amino acids that are preferred by both proteasomes
(K in P3, L in P1, A in P1' and D in P2') correlate with the characteristics of amino acids in
vicinity of the S-1 pockets of β5/ β5i  and/or β2/β2i.
The enhanced preference for hydrophobic amino acids at P1 of immunoproteasomal
cleavages does most probably not result from exchange of β5, which mediates the ChT-
like activity, for β5i (LMP7), as replacement of β5 for β5i does not alter the pocket
surrounding the active site threonine. Moreover, functional data indicate that β5i
influences the structural features of 20S proteasomes, thereby enhancing the activity of
β1i (LMP2) (Sijts et al., 2000a; Gileadi et al., 1999). The stronger preference of immuno-
proteasomes for hydrophobic amino acids at P1, however, correlates with the
characteristics at the inner surface of the proteasome when β1 (Y) is replaced for β1i.
Replacement of β1 for β1i is predicted to cause the formation of a more apolar pocket
around the active site threonine. This most likely results in the accommodation of
hydrophobic amino acids at P1, leading to an enrichment of peptides with hydrophobic
COOH-termini, and a reduction of fragments with charged COOH-termini (Groll et al.,
1997). Thus, it is conceivable that exchange of β1 for β1i causes a reduction of peptides
with charged COOH-termini (amino acids like D and E), and enhanced liberation of
peptides with hydrophobic COOH-termini.
Structural analyses of proteasomes also predict that the active S-1 pocket of β5i is more
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constricted than the pocket of β5 (Groll et al., 1997). As most hydrophobic amino acids
are rather bulky, it is conceivable that small, flexible, nonpolar amino acids, like G, in close
vicinity to hydrophobic amino acids, support accommodation of these amino acids in the
S1 pocket of β5i most efficiently. Therefore, we anticipate that the strong enrichment of G
in P1' of cleavage sites selected by immuno-proteasomes is a direct consequence of
these altered characteristics of the β5-immuno-subunit.
The observation that the P1 preference of immuno-proteasomes closely resembles the
preferences of the F-pocket of most MHC class I-molecules is thought to explain why
immuno-proteasomes are associated with more efficient processing of MHC class I-
ligands. As some CTL-epitopes are more efficiently generated by immuno-proteasomes
(Stoltze et al., 2000), it is postulated that immuno-proteasome expression is generally
associated with more efficient CTL-epitope generation. However, the correlation between
epitope production and expression of immuno-proteasomes is more subtle. Some MHC
class I-alleles harbour F-pockets that accommodate amino acids with charged polar side
chains (e.g. K and R). These MHC alleles are unlikely to "profit" from immuno-proteasome
expression, as the trypsin-like activity is not enhanced by immuno-subunit incorporation.
More importantly, current literature indicates that immuno-subunit expression does not
exert a positive effect on all CTL-epitopes (Morel et al., 2000). In view of our results,
increased CTL-epitope generation can now be explained and also predicted by several
different mechanisms. They include enhanced liberation of the proper NH2- and/or COOH-
terminus resulting from the combination hydrophobic amino acid-small amino acid at P1
and P1' (Table 2.5-4: HbcAg 141-151, LCMV pp89, Adeno E1B), enhanced generation of
transporter-associated with antigen processing (TAP)-compatible CTL epitope precursors
(Table 2.5-4: LCMV pp89, LCMV NP) or reduced PGPH-activity leaving the CTL-epitope
intact (Table 2.5-4: Influenza A NP). However, the presence of a hydrophobic amino acid
within a CTL-epitope can also result in its destruction as shown for a CTL epitope derived
from the ubiquitous self-protein RU1 (Table 2.5-4, Morel et al., 2000).
The finding that the peptide pool generated by immuno-proteasomes differs from the one
produced by constitutive proteasomes leads to important biological consequences.
Recently, it was found that dendritic cells (DC) and other professional antigen presenting
cells (APC) express immuno-proteasomes (Morel et al., 2000). In contrast, most cells
outside the lymphoid system harbour mainly constitutive proteasomes, unless they are
exposed to inflammatory stimuli. These findings indicate that the peptide pool available to
MHC molecules, and thus for presentation to the immune system, differs substantially
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between professional APC and nonlymphoid cells.  Professional APC are not only
involved in T cell priming, but are also playing a pivotal role in central and peripheral T cell
tolerization (Sauter et al., 2000; Huang et al., 2000; Steinman et al., 2000). Professional
APC not only tolerize for endogenously expressed antigens, but also for antigens acquired
from exogenous sources (cross-tolerization) (Kurts et al., 1997). Although these antigens
are derived from nonlympoid cells that only express constitutive proteasomes, tolerance
will be induced against self-peptides that are generated by cells expressing immuno-
proteasomes. During viral infection, virus-infected cells but also neighbouring cells will be
exposed to inflammatory cytokines, leading to immuno-proteasome expression. Because
tolerance has been generated to the peptide pool expressed by cells harbouring immuno-
proteasomes, self-reactive immune attack is thus reduced to a minimum.
Table 2.5-4: Correlation between observed and predicted cleavages preferentially performed
by immuno- (i20S) or constitutive (c20S) proteasomes
These considerations might also be relevant for induction of CTL-immunity against
ubiquitously expressed self proteins. If tolerance to self proteins was restricted to peptides
generated by immuno-proteasomes, nonlympoid cells expressing constitutive
proteasomes would display peptides for which no CTL tolerance has been induced. In this
respect, it is noteworthy that all CTL-epitopes derived from ubiquitous self-proteins (like
RU1, Mage-1, gp100, Melan-A; Table 2.5-4 and Morel et al., 2000) identified thusfar are
generated less efficiently by immuno-proteasomes, whereas presentation of viral epitopes
is, in general, enhanced after immuno-proteasome expression (Table 2.5-4).
155
The combination of MHC ligand motifs and constitutive-/immunoproteasomal cleavage
motifs for T cell epitope prediction will enhance progress in precise intervention of specific
immune responses. It should, for example, now be possible to identify new CTL epitopes
preferentially generated by constitutive proteasomes (like the RUI epitope). Such peptides
are attractive candidates to be used as cancer vaccines, especially if they are derived
from antigens that are, for example, overexpressed in tumors.
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3 Summary
3.1 Summary & Perspectives
In my Ph.D. research, I characterized in detail the cleavage specificities of yeast and
human proteasomes by in vitro (i.e. "in a test tube") experiments and their biochemical
and statistical analysis. In collaboration with biomathematicians, our data were used to
train computer models of the proteasome in order to apply proteasomal cleavage rules to
any aa sequence. Recently, an internet version of the resulting prediction program for
proteasomal cleavages PAProC has been instated. Thus, I have truly made a research
journey "From the test tube to the World Wide Web" during the course of my Ph.D. work.
The landmarks of the trip are summarized below.
The way for my Ph.D. thesis work was already paved by two events during my Diploma
thesis work: 1) Our lab obtained highly purified wild-type and mutant yeast 20S
proteasomes through a collaboration with the groups of Prof. Wolf (Dept. of Biochemistry,
University of Stuttgart) and Prof. Huber (MPI for Biochemistry, Martinsried). 2) I found
yeast enolase-1 to be a substrate for proteasomal degradation in vitro, without prior
covalent modification of enolase for its unfolding.
3.1.1 Summary of Results section 2.1
The cleavage specificities of the aforementioned wild-type and mutant yeast proteasomes
were initially characterized by digests of peptides containing MHC I ligands (see 2.1;
published in Dick et al., 1998). Using inhibitors differentially affecting the active sites of
20S proteasomes, we found that the so-called BrAAP-activity of the proteasome was
executed by β1/Pre3, the active site subunit generally indicated exclusively in post-acidic
cleavages. In addition, we found β2/Pup1, the subunit with T-like activity, to contribute to
cleavages after some hydrophobic and small aa. Our results confirmed the assignment of
the "classical" activities ChT-, T-like and post-acidic to the subunits β5, β2 and β1,
respectively, to be correct. In particular, β1 and β2 exclusively perform post-acidic and T-
like cleavages, respectively. The outcome of the specificity analysis is summarized in
Table 3.1-1. Moreover, our results for the first time revealed the contribution of individual
active site subunits to the generation of MHC I ligands and directly lead to the assumption
that it should be possible to "tailor" MHC I processing by active site-specific inhibitors.
Unfortunately, such strictly active site-specific inhibitors (in addition to being proteasome-
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specific) are not yet available.












R, K, H (T-like)
A, (L, M)
3.1.2 Summary of Results section 2.2
Almost simultaneous to the characterization of the different yeast 20S proteasomes, I
managed to generate nice HPLC digestion profiles of enolase using the wild-type and
mutant yeast proteasomes. Their biochemical analysis for enolase fragments took many
months to be finished. The results of this analysis was presented in part 2.2 (published in
Nussbaum et al., 1998). We saw processive degradation of enolase (i.e. no generation of
large degradation intermediates) into overlapping fragments, indicating that individual
substrate molecules are cleaved slightly differently. If however the observed processivity
is brought about by an exit size filter (see 1.3.8.2), individual substrate molecules might all
be degraded in exactly the same fashion in a first round of cleavages. Overlapping
fragments might then be generated in a second round, a stochastic process influenced by
diffusion to active sites or through the exit filter. However, the distribution of cleavage sites
along the enolase sequence suggests mutually exclusive cleavages that are difficult to
reconcile with the latter hypothesis. As the truth often lies somewhere in between, it is
possible that individual substrate molecules go through a stochastic "get chopped or get
away" process from the beginning of their proteasomal degradation. Diffusion of the
substrate aa chain to different active sites ("get chopped") would be controlled by
chance much in the same way as the egress of fragments from the 20S proteasome
cylinder ("get away"). The "affinity" of the substrate sequence towards the active sites as
well as the size of the exit filter would be regulators of the process. It is tempting to
postulate that the likelihood of cleavage increases with the time a substrate sequence
remains in close proximity to the nucleophilic threonines, the time being regulated by how
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well the substrate aa sequence fits into the active site pocket. In other words, the
flanking sequences of a potential cleavage site would determine the probability for a
cleavage. There is ample evidence for this notion, and all the different models explaining
the processivity of degradation can be brought to terms with the selection of cleavage
sites on the basis of flanking sequences.
A surprising result of the enolase digestion using wild-type and mutant yeast 20S
proteasomes with partly "toothless" active sites was the fact that the distribution of
fragment lengths did not significantly vary between the proteasomes. This finding was not
in agreement with the classical view of the molecular ruler hypothesis, according to which
the distance of active sites in proteasomes determines the fragment length (see 1.3.6).
Our results therefore represent the strongest evidence against the molecular ruler
hypothesis to date.
The main reason, however, for which we had attempted the time-consuming analysis of
so many enolase fragments was the search for the rules governing cleavage site selection
by eucaryotic proteasomes. We found that all three active site subunits contributed to the
degradation of enolase, as judged by missing cleavage sites in proteasome mutants
lacking particular activities. There seems to exist some redundancy in the system, as the
cleavages of missing activities were replaced by alternative cleavages of present
activities, resulting in similar fragment lengths. This was even true for proteasomes
lacking the activity of β5/Pre2, a mutation that is lethal in yeast. Similar to the findings in
2.1, we saw that β1 and β2 exclusively perform post-acidic and T-like cleavages,
respectively, and that they contribute to cleavages after small and hydrophobic aa, such
as A, F, G, I, L, M, N, Q, S, V, W, Y (Table 2.2-1). The most prominent P1-residues found
in digests by wt yeast proteasomes were L (selected by β5/Pre2), R (β2/Pup1) and D
(β1/Pre3). We could deduce cleavage motifs, i.e. the preferred flanking aa around
cleavage sites, for each of the three activities by combinatorial and substractive analysis
of the results obtained using the different mutant proteasomes (Table 2.2-2). Interestingly,
the cleavage motifs for β5/Pre2 and β2/Pup1 matched the inner surface of the substrate
binding pockets of these subunits (Figure 3.1-1).
Unfortunately, there was only one proteasome available in which two activities had been
silenced. This proteasome only carried β5/Pre2 as active subunit. Such 'single-activity'
proteasomes would be best to determine the cleavage preferences of the individual active
site subunits. However, they seem to be difficult to generate.
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Soon after the analysis of the experiments using yeast proteasomes I finished the
analysis of an enolase digest using human erythrocyte 20S proteasomes (see 2.2.9).
Their cleavage preferences were less pronounced than those of the wild-type yeast
proteasomes, but largely overlapped for the size of fragments (Figure 2.2-7) and the
cleavage motif (Table 2.2-3).
Figure 3.1-1: The inner surfaces of the substrate binding pockets of β5/Pre2 (A) and β2/Pup1
(B) correlate to the cleavage motifs of these subunits (see Table 2.2-2)
(A) A pocket lined by polar aa residues could accommodate polar P3-residues found in the cleavage
motif of β5/Pre2. On the P1' side, two Asp residues might be responsible for the enrichment of basic
P1' residues in the cleavage motif. (B) An acidic P3 pocket in β2/Pup1 could interact with Lys
residues at P3 of the substrate chain. The enrichment of the bend-promoting aa Gly and Pro on the
P'-side of β2/Pup1-substrates might be imposed by a steric obstacle ("C-terminal wall") that blocks
the way. P1: location of the nucleophilic Thr residue. The location of the substrate chain was fitted to
the known position of the propeptides found in the crystal structure of mutant yeast proteasomes.
3.1.3 Summary of Results sections 2.3 and 2.4
In order to turn our experimental results into a prediction tool for proteasomal cleavages,
we sought the help of people at the Department for Biomathematics of Prof. Hadeler at
the University of Tübingen. To obtain a simple model with few parameters, we constructed
a proteasome model inspecting a flanking window of several aa around the cleavage
sites. This model was then trained with our different experimental data in the fashion of an
evolutionary algorithm, aiming at the reproduction of the training data. Trial and error led
to an optimal flanking window P6-P1',P4' (P2' and P3' omitted) around the cleavage site
for the model to decide about a cleavage. Together with the aa-pair at P1/P1', especially
the residues at P5 and P4 were of great importance for the model. For all sets of
experimental data, the algorithms arrived at nearly perfect reproduction of the training
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data. A data set of randomly selected cuts was not reproduced as efficiently as actual
proteasomal cleavage data, suggesting that there were regularities/rules present in the
experimental data and that our mathematical proteasome model could detect them. In
fact, the theoretical proteasomes used basically the same kind of rules ("affinity
parameters") for cleavage site selection as the rules we had previously determined
statistically from our experimental data. The algorithm trained with human proteasome
data reached almost 90% precision in the prediction of cleavages that had not been
included in the training data (see 2.3, published in Kuttler et al., 2000).
The predictive power of the algorithms was not satisfactory for all test sequences. We
found evidence that mainly the lack of training data is to blame for that. It is also possible
that our proteasome model is not accurate enough. The current model, for example,
weighs the influence of aa residues at certain positions within the inspected window
independently of the aa at other positions. However, experimental results indicate that this
might be too simple an approach. In order to improve the performance of the prediction it
might therefore be necessary to come up with a model that considers the identity of all
other aa in the inspected window when judging the influence of a particular aa at a fixed
position. Moreover, it might be necessary to include positions P2' and P3' into the
inspected window for future sets of experimental data. These positions seem important for
cleavage site selection by human 20S proteasomes from LCL cells (see 2.5). We are
therefore continuously struggling to refine the model and to generate and gather more
training and test data. Refined models that can accommodate quantified experimental
cleavage data have already been developed for the experimental data introduced in 2.5.
We have only recently made our prediction algorithms available via World Wide Web
under the name PAProC (for Prediction Algorithm for Proteasomal Cleavages,
www.paproc.de; see 2.4; Nussbaum et al., in press), a user-friendly program that can
easily be handled by researchers unfamiliar with proteasomes. In addition we have
provided background information for users to expand their knowledge about proteasomes.
It might be risky to make PAProC available at a time when the performance of the
predictions is still suffering from the aforementioned teething troubles: Users could lose
faith in PAProC before it reaches higher predictive power. However, we specifically ask for
and hope to get feedback from users that should allow us to improve PAProC. In
particular, PAProC could turn into a platform for the collection of experimental cleavage
data. This would probably most efficiently improve the predictions. During the first four
months of its existence, PAProC has already been accessed more than 1000 times by
researchers from all over the world, although it will only be announced in a peer-reviewed
165
journal in a few months (Nussbaumet al., in press).
In collaborations with S. Brunak/C. Kesmir (Copenhagen), C. Melief/F. Ossendorp
(Leiden) and G. Holzhütter/H. Mollenkopf (Berlin) we are trying to establish more reliable
proteasomal cleavage prediction. This group of people combines the know-how of
experienced proteasome researchers and mathematical and computational skills. The
neural networks by C. Kesmir or the algorithms by G. Holzhütter might ultimately perform
better than PAProC, although first comparative results do not support this view. The
experimental data generated in the group of F. Ossendorp could complement the training
data for PAProC and other prediction tools. Eventually, all groups working on the
prediction of proteasomal cleavages want to create a link between the prediction of MHC I
ligands and proteasomal cleavages. For the above-mentioned reasons (see 1.5) such
combined prediction could be valuable in the search for CTL epitopes. The "manual"
combination of SYFPEITHI and PAProC has led to a superior prediction of candidates for
CTL epitopes from different protein sequences (see Table 2.4-1). However, this did not
hold true for all test cases. Again, the lack of training data for the PAProC algorithms
seems to be the reason for weaknesses in the predictive power.
3.1.4 Summary of Results section 2.5
The differential effects of immuno-proteasomes on the generation of CTL epitopes was
pointed out above (1.3.7.3). In order to come up with general rules for cleavages by
immuno- versus constitutive proteasomes, we compared their cleavage preferences in
digests of enolase (part 2.5, Toes et al., submitted for publication). The analysis of
enolase fragments was now performed in a strictly quantitative way. No differences were
found for the lengths of fragments produced by the two proteasome species; their sizes
ranged from 3-26 aa with an average length of 7-9 aa. However, individual fragments and
thus cleavages sites only partially overlapped. We found that immuno-proteasomes, as
compared to constitutive proteasomes, have a more pronounced preference for cleavages
after large, hydrophobic aa (L, F), but do not cleave after acidic residues any more. In
addition to this confirmation of earlier results, we could extend the knowledge on cleavage
site selection by immuno- and constitutive proteasomes to several residues flanking the
cleavage sites (see Table 2.5-3). Interestingly, the cleavage motifs we determined
properly explain many effects of immune-proteasomes on CTL epitope processing and
presentation (Table 2.5-4). Our quantified data are already being used to train refined
algorithms for the prediction of proteasomal cleavages. We are confident that the
application of quantified cleavage data for cleavage site prediction and the differentiation
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between the cleavage preferences of immuno- and constitutive proteasome will
substantially improve the predictive power of PAProC. Preliminary results show that an
algorithm trained with immuno-proteasome cleavages is better at predicting the cleavages
at the C-termini of MHC I ligands. However, it is too early to draw final conclusions about
the performance of the new algorithms.
3.2 Unmentioned and Ongoing Projects
3.2.1 Insensitivity of β-peptides to proteasomal cleavage7
Peptide-analogs are amino acid chains with unusual structural features, such as D-
instead of L-aa or more stable bonds than peptide bonds to connect the single aa. Despite
of their structural differences, peptide analogs can be biologically active. On the other
hand, they are usually resistant to enzymatic degradation and therefore stable once
brought into a target organism. Long-lived peptide-analogs with biological activity are thus
pharmacologically interesting. One group of peptide analogs are β-peptides, which are
built from aa with an additional CH2-group between the α-C-atom and the terminal
carboxy group. In a collaboration with Jürg Schreiber from the ETH Zürich, I was able to
show that neither the multicatalytic proteasome nor very vigorous proteases or protease
mixes such as Pronase and Proteinase K were able to degrade β-peptides in vitro
(Seebach et al., 1998). These results suggest that β-peptides might be long-lived in the
cytosol of cells and hence have important implications for their use as pharmacological
agents.
3.2.2 Directionality – a story with an end?
If proteins are degraded by proteasomes in a processive way (see 1.3.8), then it might be
required that the substrate enters the proteolytic chamber in a defined direction, either
starting with the  N- or with the C-terminus of the aa chain. To find the 'end' of the
substrate that is inserted/degraded first, we constructed several modified versions of
enolase. By making use of the single Cys residue approximately in the middle of the
enolase sequence (at position 247 of 436), we coupled gold-beads, agarose-beads and
rhodamine to enolase. We hoped that the bulky obstacle would inhibit full entry of enolase
                                               
7 The publication summarized here is part of the prospective Ph.D. theses of Stefan Abele and Jürg
V. Schreiber, ETH Zürich.
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into the proteasome cylinder, but still expected to see partial enolase degradation. The
left-over half of enolase and the generated fragments from the other, degraded half should
have made it possible to identify the enolase terminus degraded first. Unfortunately, none
of these experiments yielded any result as proteasome activity was in all cases completely
blocked, probably by adsorption to the beads or inhibitory effects of the chemical groups
coupled to enolase. A different try using miniature dialysis chambers to "pull out" early
degradation products was too insensitive to detect casein or enolase fragments before
single substrate molecules were completely degraded.
This project, which was originally started by Tobias P. Dick, was continued by David
Gatfield, who constructed recombinantly a Casein-derived Artificial Proteasome Substrate
(CAPROS) for radioactive labeling during his Diploma thesis project. The project is
currently carried on by Ph.D. student Stefan Tenzer who will perform the radioactive
labeling and the actual digestion experiments. If it is possible to stop the experiment after
one protein terminus has been degraded and before the other terminus has been touched,
then it should theoretically be possible to determine a degradation direction for CAPROS.
The use of a radioactively labeled protein substrate will hopefully overcome the problem of
sensitivity in the previous approaches.
3.2.3 The Gly-Ala story
When we were looking for a method to block enolase degradation in order to determine
the directionality of degradation, we remembered the observation that the Gly-Ala-repeat
region (GARR) from Epstein-Barr virus nuclear antigen 1 (EBNA1) inhibits proteasomal
degradation of proteins harboring GARRs (Levitskaya et al., 1995; Levitskaya et al., 1997;
Sharipo et al., 1998). The mechanism for this inhibition not being known, we assumed that
the GARR physically inhibited proteasomal digestion on the level of the 20S proteasome
core. (Later it was reported that a 22 aa long GARR inserted into IκBα exhibits random
coil structure, thus eliminating structural stabilization as reason for protection from
proteasomal degradation; Leonchiks et al., 1998). It therefore came as a surprise to us
when 20S proteasomes in vitro were perfectly able to degrade enolase harboring a GARR
of about 20 aa. This observation meant we could not use the GARR to determine
directionality, but at the same time it raised our interest in the mechanism by which
GARRs block proteasomal degradation. Our proteasomal cleavage algorithms predicted
GARRs to be spared from proteasomal cleavages (2.3). This hint proved right in digestion
experiments using various (roughly 30mer) peptides harboring an 8 aa GARR: Whereas
the rest of the peptide was extensively cleaved, the GARR stayed untouched.
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Interestingly, the presence of the GARR prolonged the half-life of the GARR-
containing peptide substantially, confirming a stabilizing effect for the whole polypeptide,
not just for the GARR itself, as already observed with GARR-containing proteins.
Unfortunately, we have up to now not been able to investigate the degradation of GARR-
containing enolase in cells. Despite the valiant efforts of David Gatfield during his Diploma
thesis, we continuously had problems with the immunoprecipitation of cmyc-tagged
enolase from the cells in pulse-chase experiments.
In the near future, we would like to examine the in vitro digestion of  enolase containing
longer GARRs, as it was recently reported that the length of the GARR determines protein
stability (Dantuma et al., 2000). Besides, we will test whether the related Gly-Ser-Ala-
regions from monkey viruses (Blake et al., 1999) also inhibit proteasomal cleavages in in
vitro peptide substrates. We are currently analyzing whether GARR-containing peptides
and proteins interfere with the functions of the 26S proteasome, for example by the
binding and therefore competition of the hydrophobic GARRs to ubiquitin-recognition sites
in the 19S cap.
The work with GARRs has brought other proteins with unusual aa repeat sequences to
my attention, most notably poly-glutamine (polyQ)-containing proteins implicated in the
generation of neurodegenerative diseases such as Huntington's disease and several
forms of spinocerebellar ataxias (see 2.4 for more information). We have just initiated a
collaboration with G.B. Landwehrmeyer and K.S. Lindenberg from the Department for
Neurology, Experimental Neurology, University of Ulm, Germany, in order to investigate
the role of proteasomes in the accumulation of polyQ-proteins in neurons, a possibly
critical factor in the onset of disease.
3.2.4 When does the PA28-effect kick in?
Despite earlier reports denying a role for the proteasome activator PA28 in protein
degradation (Dubiel et al., 1992), I assumed that PA28 not only participates in the
generation of peptides, but must also have a function in the degradation of proteins.
Therefore I tried to show that PA28 can accelerate the degradation of FITC-labeled bovine
β-casein by human 20S proteasomes in vitro, which was not successful: PA28-activated
proteasomes with increased activity towards short fluorogenic model substrates did not
degrade FITC-casein faster than just 20S proteasomes alone. However, I observed in
HPLC-chromatograms that the signals for (what looked like) intermediate degradation
products of casein were shifted faster to early retention times (i.e. smaller degradation
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products) in the presence of PA28. My interpretation of this result was that the
activating effect of PA28 only "kicks in" when the degradation products have reached a
certain "smallness". This hypothesis is in line with the latest results that PA28 induces the
α-rings of 20S proteasomes to open (Whitby et al., 2000; see Introduction 1.3.7.1). The
diffusion of peptides in and out of the proteolytic chamber, that is most likely regulated by
the α-ring opening, is probably most effective for small peptides. Therefore, once
degradation products have reached a threshold "tininess", their increased diffusion could
accelerate their degradation into even smaller fragments.
In order to test the hypothesis that PA28-mediated proteasome activation only affects
protein fragments of a threshold size, in future experiments substrates of different sizes
will be incubated with 20S proteasomes in the presence and absence of PA28. If a
threshold size exists, differences in the initial velocity of degradation should be detected
for the substrate of the critical size.
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aa aa residue(s) = amino acid(s)
AMC 7-amino-4-methylcoumarin
APC antigen presenting cell
BrAAP Branched amino acid peptidase
Bz Benzoyl
CAPROS Casein-derived artificial proteasome substrate
ChT chymotryptic activity
CTL cytotoxic T lymphocyte





FPLC fast performance liquid chromatography
GARR Gly-Ala-rich region
HEPES N-2-hydroxyethylpiperazin-N'-2-ethansulfonic acid




LMP low molecular weight polypeptide
MALDI matrix-assisted laser desorption ionization
MHC I/II major histocompatibility complex class I/II
MS mass spectrometry / mass spectrometric
NP nucleoprotein
Ntn N-terminal nucleophile
PAGE polyacrylamide gel electrophoresis
PAProC Prediction Algorithm for Proteasomal Cleavages
PDI protein disulfide isomerase
PGPH peptidylglutamylpeptide-hydrolysing
polyQ poly-glutamine
RP-HPLC reversed phase high performance liquid chromatography
SDS sodiumdodecylsulfate
SNAAP small neutral amino acid peptidase
Suc succinyl
T tryptic activity
TAP transporter associated with antigen processing
TCR T cell receptor
T-like Trypsin-like
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TOF time of flight
Ub ubiquitin





Abbreviations for amino acid names:
1-letter code 3-letter code Full name Selected properties
A Ala Alanine small
C Cys Cysteine small, polar
D Asp Aspartic acid negative charge
E Glu Glutamic acid negative charge
F Phe Phenylalanine bulky, hydrophobic
G Gly Glycine small
H His Histidine positive charge
I Ile Isoleucine branched-chain, hydrophobic
K Lys Lysine positive charge
L Leu Leucine branched-chain, hydrophobic
M Met Methionine hydrophobic
N Asn Asparagine polar
P Pro Proline kinked, polar
Q Gln Glutamine polar
R Arg Arginine positive charge
S Ser Serine small, polar
T Thr Threonine small, polar
V Val Valine branched-chain, hydrophobic
W Trp Tryptophan bulky, hydrophobic
Y Tyr Tyrosine bulky, hydrophobic
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